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Cervical cancer is an important cause of morbidity and mortality in developing countries. This 
thesis examines the challenges to and opportunities for comprehensive (primary and secondary) 
prevention of cervical cancer in South Africa (SA), a middle-income country. Four questions 
were explored: a) can a cytology-based based screening programme be effectively implemented 
in South Africa? ; b) what are the potential challenges to and opportunities for implementing a 
human papillomavirus (HPV) vaccination programme in South Africa? ; c) what is the 
association between human immunodeficiency virus (HIV), HPV, cervical cancer precursors and 
cervical cancer in South Africa and d) what is the prevalence of HPV and cervical cancer 
precursors, HPV types and HPV viral load  in women initiating highly active antiretroviral 
therapy (HAART)?  
 
Three provinces in SA were included in a study to design, develop and evaluate health system 
interventions for public sector cytology-based cervical screening services. A pre-and post-
intervention cross-sectional study was conducted. Service organisation and service related 
outputs improved post-intervention. The proportion of staff who ever performed a Pap smear 
increased from 56% to 86% ( p < 0.001); and 68% of staff agreed with the screening policy after, 
as opposed to 23% before the intervention (p < 0.001).  The number of Pap smears performed 
increased by 76%, with 90% of these smears done on women in the appropriate target age group. 
However, the overall Pap smear coverage targets were not met and timely treatment for women 
with high-grade squamous intraepithelial lesions (HSIL) was a problem. Efforts to improve 
referral, feedback and health information systems proved challenging. Although there were some 
improvements in client knowledge of cervical cancer and Pap smears, this did not translate into 
an increase in the number of Pap smears among women interviewed post-intervention.  
 
A qualitative study was conducted to explore key challenges to and opinions about HPV 
vaccination introduction in South Africa. A total of 50 in-depth interviews and 6 focus group 
discussions were conducted at policy, health service provider and community levels of enquiry. 
All respondents indicated support for the HPV vaccine. Policy makers and providers expressed 















cost of the vaccine was perceived as a barrier by policy makers. Providers and policymakers 
noted that the Department of Health had sufficient experience with managing vaccines, but 
recognised that the HPV vaccine would need to reach a different target age group compared to 
that usually served by the Expanded Program on Immunization. The most appropriate form of 
delivery was considered to be through schools, but concern was expressed about the capacity of 
the current school health system to deliver the vaccine. Most respondents did not anticipate that 
opposition to the HPV vaccine would be a major problem. The limited knowledge of the HPV 
vaccine, cervical cancer prevention and the current cervical cancer screening policy suggest that 
the introduction of the vaccine will need to be accompanied by a strong information, education 
and communication strategy that addresses issues of HPV vaccine side-effects and efficacy as 
well as provides ongoing education on cervical cancer.  
 
Two studies were conducted to determine the role HIV plays in the risk of cervical cancer and 
cervical cancer precursor lesions in South Africa. The first, a case control study conducted at an 
early stage in the HIV epidemic and prior to the introduction of HAART in the public sector in 
South Africa, showed no association between HIV and invasive cervical cancer (adjusted odds 
ratio 1.0, 95% confidence interval (CI) 0.7 - 1.7). An analysis of the controls was undertaken to 
determine the association between HIV and cervical cancer precursors and HPV.  Fifty percent 
of the HIV positive controls had an abnormal Pap smear. HIV positive women were nearly 5 
times more likely to have high-risk HPV (HR-HPV) present compared to HIV negative women 
(prevalence ratio (PR) 5.1, 95% CI 3.3 - 7.7). Women infected with both HIV and HR-HPV were 
at a higher risk of squamous intraepithelial lesions (SILs) than women infected with neither of 
these viruses (adjusted PR 19.8, 95% CI 11.0 - 35.7). 
 
The second study was a cross-sectional survey conducted at a public sector ART clinic in Cape 
Town. The median age of the 109 participants was 31 years and the median CD4 count was 125 
cells/µL. Sixty six percent of women had an abnormal Pap smear, the HR-HPV prevalence was 
78.9 % and the median HPV viral load was 181.1 relative light units (RLU). The most prevalent 
HR-HPV types among women with SILs were HPV types 18 (24.0%), 35 (22.0%) and types 16, 
45 and 58 all with a prevalence of 20.0%. Multivariate regression was carried out to determine 















increased risk of SILs. The adjusted PR for SILs was 5.0 (95% CI 1.2 - 20.6) for those that were 
HC2 positive and a viral load of ≤ 181.1 RLU (the median HPV viral load) and 7.6 (95% CI 1.9 - 
30.8) for those that were HC2 positive with a HPV viral load > 181.1 RLU, with HC2 negative 
women as the reference group. Smokers were 1.5 times more likely to have SILs compared to 
non-smokers (PR 1.5, 95% CI 1.1 - 2.1).  
 
The final chapter reflects on the main findings and discusses opportunities for and challenges to 
preventing cervical cancer in SA. The thesis concludes that without strong leadership, improved 
management capacity and a strengthened health system, implementation of a comprehensive 
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Chapter 1: Introduction 
Chapter 1 provides background information about the research field, outlines the aims and 
objectives of the thesis, briefly describes the research methods and provides an outline of the 




1.4. Synopsis of methods 
1.5. Thesis structure 
 
1.1 Background 
Cervical cancer continues to be an important women’s health problem (Parkin et al. 2005; Ferlay 
et al. 2010b).
 
Until recently, the only option for prevention of cervical cancer has been to screen 
and treat precursor lesions i.e. through secondary prevention. In developed countries
1
 the 
implementation of organised cervical screening programmes, most commonly by means of 
Papanicolaou (Pap) smears, has resulted in a decline in cervical cancer incidence and mortality 
(Miller et al. 2000; Peto et al. 2004; International Agency for Research on Cancer (IARC) 2005). 
By contrast, cervical cancer remains a problem in developing countries because of ineffective or 
absent screening programmes (Lazcano-Ponce et al. 1999; Sankaranarayanan, Budukh & 
Rajkumar 2001; IARC 2005).
 
There are no organised cytology-based programmes in low-income 
countries. It has been suggested that these countries should focus their efforts and resources on 
improving diagnostic and treatment services for clinically manifest cervical cancer before 
embarking on a screening programme for precursor lesions (Sankaranarayanan, Budukh & 
                                                 
1
 The World Bank classifies countries as low, middle (subdivided into lower middle and upper middle) or 
high income. The classification is based on the gross national income (GNI) per capita and is as follows: 
low income, $995 or less; lower middle income, $996 - $3,945; upper middle income, $3,946 - $12,195; 
and high income, $12,196 or more. High income countries, with the exception of Hong Kong (China), 
Israel, Kuwait, Singapore, and the United Arab Emirates are sometimes referred to as developed 
countries.  Low-income and  middle-income countries as well as Hong Kong (China), Israel, Kuwait, 


















Rajkumar 2001). Some middle-income countries have implemented cytology-based screening 
programmes in the past 30 years. However they have achieved limited success, largely due to 
programmatic challenges (Lazcano-Ponce et al. 1999; Sankaranarayanan, Budukh & Rajkumar 
2001; IARC 2005; Garland et al. 2008b; Murillo et al. 2008). It has been suggested that middle-
income countries should consider implementing an organised programme in a limited 
geographical area before expanding to cover the country (Sankaranarayanan, Budukh & 
Rajkumar 2001; Sepulveda, Prado 2005). Programmes should emphasize high coverage of older 
women rather than offer frequent smears to women in a wide age range. Competing health care 
priorities and poorly functioning health care systems have made it difficult for sub-Saharan 
African countries to implement cervical cancer screening programmes and currently no 
comprehensive cervical cancer screening programme exist in this region (IARC 2005). 
 
South Africa (SA) is a middle-income country with a relatively well-developed health 
infrastructure compared to other developing countries. Cervical cancer is the second most 
common cancer among South African women with an age-standardised incidence rate (ASIR) of 
25.5 per 100 000 women and is the leading cause of cancer mortality amongst women (age-
standardised mortality rate (ASMR) of 21 per 100 000 women) (Norman et al. 2006; National 
Health Laboratory Service 2009).
 
The impact of the gross inequities in terms of health status and 
access to health care during the apartheid era can be seen in the differences in cervical cancer 
incidence and mortality rates by race group. The South African National Department of Health 
(NDOH) has identified cervical cancer as a national health priority and in 2000 introduced a 
screening policy stating that every woman is entitled to three free Pap smears (in the public 
sector) in her lifetime at 10-year intervals, starting at the age of 30 years (Department of Health 
2000). Studies in South Africa have indicated that barriers to an effective screening programme 
exist both at community and health service level (Leiman 1987; Abrahams, Wood & Jewkes 
1997; Smith, Moodley & Hoffman 2003; Moodley et al. 2006; Moodley, Harries & Barone 
2009). This policy thus presents a considerable challenge to reproductive health programme 

















It is now well established that infection with certain types of human papillomavirus (HPV) is a 
necessary but not sufficient cause of cervical cancer (Walboomers et al. 1999; Bosch et al. 2002). 
This is of considerable public health importance and has led to new possibilities for the 
prevention of cervical cancer. There are 15 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68, 73, and 82) classified as high-risk (HR) types or oncogenic for cervical cancer. HPV16 
and HPV18 are the dominant oncogenic types worldwide, consistently detected in 70% of all 
cancers of the cervix (Munoz et al. 2003).   
 
The recent development of two prophylactic HPV vaccines (Harper et al. 2006; FUTURE II 
Study Group 2007), a bivalent vaccine that targets HPV16 and HPV18 and a quadrivalent 
vaccine that targets HPV types 16, 18, 6 and 11, offers potential for primary prevention of 
cervical cancer in SA. However implementing a HPV vaccine programme presents several 
unique challenges: for example, to obtain maximum effectiveness the vaccine needs to be 
administered prior to the onset of sexual activity. This means vaccinating young adolescents, a 
target group not usually included in public sector immunization programmes. Experience with 
introducing new health technologies has demonstrated the importance of understanding the local 
context before innovations are introduced and incorporating the perspectives of a broad range of 
stakeholders, including those of users, providers, managers, policy makers and community 
groups (Simmons et al. 1997). Studies in developed countries have examined the knowledge and 
attitudes of health providers, parents and young women, and have assessed what factors may 
play a part in uptake of the HPV vaccine (Giles, Garland 2006; Noakes, Yarwood & Salisbury 
2006; Zimet et al. 2006; Ogilvie et al. 2007). Little work has been done in developing countries, 
where these issues may be different (Harries et al. 2009).   
 
Whilst recognizing the potential impact of the vaccines on the incidence of HPV and cervical 
cancer, secondary prevention of cervical cancer remains important because, not all women will 
be vaccinated, some cervical cancers are caused by HPV types that the vaccines do not protect 
against, and the vaccines are not effective in women who already have HPV infection (Jacob, 
Bradley & Barone 2005; Franco et al. 2006). An effective cervical cancer prevention programme 
















SA is confronted by one of the worst human immunodeficiency virus (HIV) epidemics in the 
world and it is estimated that there are currently 5.4 million people with HIV or acquired 
immune deficiency syndrome (AIDS) in SA, with a greater number of women, compared to men, 
affected (Department of Health 2008). The HIV epidemic has impacted on health service 
delivery in many ways in South Africa: the workload of health service providers, particularly 
nurses has increased, health workers have been infected by HIV, and overall increased health 
resources are needed to address the burden of HIV-related illness (Benatar 2004; Shisana et al. 
2004; Schneider et al. 2006). HIV also has a direct impact on cervical cancer and its precursor 
lesions. Immune-suppression plays an important role in conferring increased risk and is 
associated with an increase in incidence and prevalence of HPV infection (Wright et al. 1994; 
Ellerbrock et al. 2000; Palefsky, Holly 2003). There may also be a direct interaction between the 
two viruses at a molecular level (Palefsky, Holly 2003). Studies have shown that women infected 
with HIV have a higher prevalence of HPV and are at a greater risk of developing cervical 
cancer and its precursor lesions compared to HIV negative women (Sun et al. 1997; Minkoff et 
al. 1998; Massad et al. 1999; Massad et al. 1999; Palefsky et al. 1999; Ahdieh et al. 2000; Duerr 
et al. 2001; Jamieson et al. 2002; Hawes et al. 2003; Schuman et al. 2003; Moodley et al. 2006; 
Rowhani-Rahbar et al. 2007). An increase in HPV viral load has been shown to be associated 
with increasing severity of cervical lesions (Lillo et al. 2005). HIV positive women are infected 
with a broader range of HPV types and are more likely to have multiple HPV types present, 
compared to HIV negative women (Clifford et al. 2006). HPV type is a strong risk factor for 
progression from persistent HPV infection to cancer (Schiffman et al. 2007). Worldwide there is 
considerable variation in regional HPV type distribution in HIV positive women (Clifford et al. 
2006). Limited information is available on the prevalence and distribution of HPV types and on 
HPV viral load among HIV positive women in South Africa (Denny et al. 2008; Moodley et al. 
2009). In developing a comprehensive cervical cancer prevention strategy for South Africa, it is 
important to determine the role HIV plays in the risk of cervical cancer and cervical cancer 
precursor lesions. 
  
Highly active antiretroviral therapy (HAART) has been shown to decrease HIV viral loads, 
increase CD4 cell counts and decrease most opportunistic infections (Hogg et al. 1998; Palella et 















HIV infected individuals (Jacobson et al. 1999; Ledergerber, Telenti & Egger 1999). HAART 
has the potential to influence the relationship between HIV and cervical cancer in two 
contrasting ways. Firstly, by prolonging life HAART lengthens exposure to HPV infection 
thereby increasing the likelihood of cervical precursors and cancer. Conversely, because 
HAART restores immune-competence, it may reduce the risk of cervical precursors and cancer 
(Palefsky 2003; Palefsky 2006). However, it has also been suggested that HPV-specific 
immunity may not recover fully after immune response is restored (Palefsky 2003; Palefsky 
2006). Studies on the impact of HAART on the natural history of cervical cancer have produced 
mixed results, with some studies showing benefit and others no effect (Heard et al. 1998; 
Orlando et al. 1999; Lillo et al. 2001; Minkoff et al. 2001; Heard et al. 2002; Moore et al. 2002; 
Ahdieh-Grant et al. 2004; Heard, Palefsky & Kazatchkine 2004; Heard, Potard & Costagliola 
2006; Omar et al. 2011). As HAART becomes increasingly available in the public sector in SA, 
the life expectancy of HIV positive women will increase.  The important question of whether the 
benefits of HAART will or will not be partially offset by an excess risk in cervical cancer 
remains to be answered. Long-term longitudinal studies of the natural history of cervical lesions 
in women initiating HAART will be critical to inform the development of locally relevant, 
rigorous screening protocols. Data on the prevalence of cervical cancer precursor lesions 
amongst HIV positive women initiating HAART will assist in estimating resources and planning 
cervical cancer prevention and treatment services. 
 
Little is known about the burden of HPV associated disease in HIV positive women in SA
 
and 
about the implications of the HIV epidemic for cervical cancer prevention programmes. 
 
This thesis sets out to examine the challenges and opportunities in preventing cervical cancer in a 
middle income, African country. It will examine four related questions: 
 Can a cytology-based based screening programme be effectively implemented in 
South Africa? 
 What are the potential challenges to and opportunities for implementing an HPV 















 What are the associations between HIV, HPV, cervical cancer precursors and 
cervical cancer in South Africa and what are the implications of the associations 
for cervical cancer prevention programmes? 
 What is the prevalence of HPV and cervical cancer precursors and the HPV types 
and HPV viral load in women initiating HAART? 
 
Issues relating to cost-effectiveness and competing health priorities are important in developing a 




The overall aim is to identify challenges in comprehensive prevention (primary and secondary 
prevention) of cervical cancer in South Africa and make recommendations for an optimal 
cervical cancer prevention strategy. 
 
1.3 Objectives 
1. To design, implement and evaluate health system interventions for public sector cytology-
based cervical screening services in South Africa. This includes: 
a. Identifying service-delivery barriers to a cytology based screening programme.   
b. Developing appropriate and replicable interventions to strengthen cervical cancer 
prevention services.  
c. Evaluating the effectiveness of these interventions. In this context effectiveness was 
defined as the extent to which the organisation and functioning of cervical cancer 
screening services; staff knowledge, attitude and practice (KAP), client KAP, service 
utilisation and Pap smear coverage improved post-intervention. 
2. To understand key opinions about, challenges to, and opportunities for, the potential 
introduction of the HPV vaccine in the public sector in South Africa. 
3. To determine the association between HIV, cervical cancer precursor lesions and cervical 















4. To determine HPV prevalence, types and  viral load and the  prevalence of  cervical 
precursor lesions among women initiating HAART. 
 
1.4 Synopsis of methods 
The studies contributing to this thesis utilise quantitative, health systems and qualitative research 
methods. This mix of methods was chosen in order to provide a more complete assessment of the 
challenges inherent in implementing a comprehensive cervical cancer preventive strategy. The 
methods used to address each of the research questions are briefly summarised below. 
 
To design, implement and evaluate health system interventions for public sector cytology-based 
screening services in South Africa. 
To address the first objective, three of nine provinces in South Africa were included in a study to 
identify health system barriers and facilitators, and to design, develop and evaluate interventions 
to address these challenges. In consultation with respective provincial health authorities, one sub-
district per province was purposively selected to represent different socio-economic, 
geographical and health system contexts in the country. The research sites represent the different 
range of challenges that are likely to be experienced in various contexts within the country viz. 
urban vs. rural, middle vs. low income populations and varying levels of health system 
infrastructure. Baseline surveys, consisting of facility audits, staff KAP surveys, client KAP 
surveys and a review of laboratory data were conducted at primary care facilities in the project 
districts in 2001. Information on aspects of service functioning and on clients’ and provider’s 
knowledge, attitudes, and practices was collected. Meetings were held with stakeholders to 
discuss baseline findings and to further identify programmatic strengths and weaknesses. Based 
on these findings a number of health system (e.g. Pap registers, data collation sheets) and 
community awareness interventions (e.g. posters and pamphlets at clinics and community sites, 
radio and newspaper slots) were developed and implemented. Surveys were undertaken once 
again in 2002/2003. Pre- and post-intervention data were compared to determine changes in 
















To understand key opinions about, challenges to, and opportunities for, the potential 
introduction of the HPV vaccine in the public sector in South Africa 
A qualitative study that explored key challenges and opinions towards HPV vaccination 
introduction in South Africa was conducted between February 2007 and March 2008. Qualitative 
methods were used as they are particularly useful in exploring a topic about which little is 
known. Experienced fieldworkers trained in qualitative research methods conducted in-depth 
interviews with 24 health care providers and 26 policy makers and key policy informants at 
national and provincial levels. Six focus group discussions were carried out with female 
community members and in total forty-three women were included in these discussions. Key 
issues explored included: views and experiences on current cervical screening policy and 
programmes; views on vaccination as a method of cervical cancer prevention; HPV vaccine 
delivery mechanisms and possible opposition to the HPV vaccine. Data were analysed using a 
thematic analysis approach in which main themes and categories were identified and analysed.  
 
To determine the association between HIV, cervical cancer precursor lesions and cervical 
cancer among South African women 
Two studies were undertaken to determine the role that HIV plays in the risk of cervical cancer 
and cervical precursor lesions. The first, a case-control study was conducted to determine the risk 
of cervical precursor lesions and cervical cancer among HIV positive women in South Africa. 
This study was conducted at an early stage of the HIV epidemic and at a time HAART was not 
available in the public sector services. Data were derived from a case-control study conducted in 
the Western Cape, between January 1998 to December 2001 that examined the association 
between hormonal contraceptives and invasive cervical cancer. In 2004 anonymous HIV testing 
was done on stored serum samples, using the enzyme-linked immunoabsorbant assay (ELISA). 
The relationship between HIV, cervical cancer precursor lesions and cervical cancer was then 
explored.  For the association between HIV and cervical cancer, HIV prevalence in the cases (n= 
486) were compared with that in the controls (n= 1365). Adjusted HIV odds ratios (OR) and 
95% confidence intervals (CI) were calculated using multiple logistic regression. For the 
association between HIV and cervical cancer precursor lesions, the analysis was restricted to the 
control group which consisted of 103 women with atypical squamous cells of undetermined 















high-grade squamous intraepithelial lesions (HSIL) and 1159 with normal cytology women. 
Women with normal cytology were used as a reference group. Adjusted prevalence ratios (PR) 
for HIV and 95% confidence intervals (CI) were calculated using log-binomial regression. 
 
To determine HPV prevalence, types and viral load and the prevalence of cervical cancer 
precursor lesions among women initiating HAART  
The second study conducted to provide information on the role of HIV in cervical cancer and 
precursor lesions of the cervix was undertaken at a later stage of the HIV epidemic in the 
Western Cape Province. A cross-sectional survey was conducted at an antiretroviral therapy 
(ART) clinic in Cape Town, South Africa, between January and May 2007, to determine the 
prevalence of high- risk HPV (HR-HPV), HPV viral load, HPV types and cervical cancer 
precursor lesions in 109 HIV positive women initiating HAART. A research nurse collected data 
on socio-demographic status and sexual and reproductive history; conducted a pelvic 
examination; took a Pap smear and collected cervical samples for HPV testing. Descriptive 
statistics (medians and proportions) were used to characterise the variables. Adjusted prevalence 
ratios and 95% confidence intervals for predictors of squamous intraepithelial lesions (SILs) 
were determined using Poisson regression with robust variance.  
 
1.5 Thesis structure 
Chapter 2 is a literature review on the prevention of cervical cancer. It explores the burden of 
cervical cancer, describes the natural history of cervical cancer as a basis for preventive 
strategies, describes methods of screening, discusses issues related to implementation of 
cytology-based screening programmes, discusses primary prevention through HPV vaccination 
and the association between HIV and cervical cancer. Chapter 3 provides information on the 
context of the problem. It describes the unique challenges that South Africa faces as a middle-
income country with a relatively well developed infrastructure, a fragmented health system and a 
huge HIV/AIDS burden. It also describes cervical cancer prevention efforts in South Africa. The 
next 4 chapters present the methods, results and discussion for each of the study objectives 
namely: implementing a cytology-based secondary screening programme in SA i.e. a secondary 















the introduction of HPV vaccination in South Africa i.e. a primary preventive strategy (chapter 
5), HIV, cervical cancer precursor lesions and cervical cancer among South African women 
(chapter 6) and HPV infection and cervical cancer precursor lesions among women initiating 
HAART (chapter 7). Chapter 8 considers the implications of the main findings and discusses the 















Chapter 2: Literature review 
The literature review provides information on the burden of cervical cancer, describes the natural 
history of cervical cancer as a basis for preventive strategies, describes methods of secondary 
prevention of cervical cancer, discusses issues related to implementation of cytology-based 
screening programmes, discusses primary prevention through HPV vaccination and the 
association between HIV and cervical cancer.  The structure of the chapter is as follows: 
 
2.1. Burden of cervical cancer 
2.1.1. Global burden of disease 
2.1.2. Burden of disease in South Africa 
2.2. Natural history of cervical cancer  
2.2.1. HPV as the causative agent 
2.2.2. Progression of HPV infection to cervical cancer 
2.2.3. Aspects of epidemiological findings pertinent to preventive strategies 
2.3. Secondary prevention  
2.3.1. Screening tests 
2.3.2. Experience with cytology-based screening programmes  
2.3.3. Summary of challenges in implementing cytology-based screening  
    programmes in middle-income countries 
2.4. Primary prevention through HPV vaccination 
2.4.1. Features of current vaccines 
2.4.2. Experience in introducing HPV vaccine in developed countries 















2.5. HIV and cervical cancer 
2.5.1. HIV and HPV infection 
2.5.2. HIV and cervical cancer precursor lesions 
2.5.3. HIV and invasive cervical cancer 
2.5.4. The impact of HAART on cervical lesions 
2.5.5. Prevention of cervical cancer in HIV positive women  
2.6. Summary 
 
2.1 Burden of cervical cancer 
2.1.1 Global burden of disease 
Cervical cancer is the third most common cancer among women worldwide, comprising 8.8% of 
all cancers in women (Ferlay et al. 2010b). In 2008 it was estimated that there were 529 000 new 
cases and 275 000 deaths from cervical cancer worldwide (Ferlay et al. 2010b). Cancer is 
responsible for 13% of all deaths worldwide (Boyle, Levin 2008; World Health Organization 
2009), with cervical cancer accounting for 8.6% of all cancer deaths (Ferlay et al. 2010a). Global 
prevalence estimates suggest that there are 1.4 million cases of clinically recognised cervical 
cancer annually (Sankaranarayanan, Budukh & Rajkumar 2001). The current available 
information however probably underestimates the true burden of disease, as for several 
developing countries good quality incidence and mortality data are not available. In developing 
countries many women do not receive medical care and are therefore not included in cancer 
registries, where these exist.  
 
Developing countries, where 85% of all cases occur, bear a disproportionate burden of the 
disease. Cervical cancer accounts for 11.4% of all cancer deaths in developing countries 
compared to 2.7% of cancer deaths in developed countries (Ferlay et al. 2010a). The cumulative 
risk for developing cervical cancer before age 74 years in developing countries is almost double 















differences in age-standardised cervical cancer incidence and mortality rates for different 
regions. All cancer incidence and mortality rates have been included in Table 2.1 to illustrate the 
comparative burden posed by cervical cancer and all cancers.  
 
The highest cervical cancer incidence rates occur in the low and medium income regions of sub-
Saharan Africa, South-Central Asia, Latin America, Melanesia and the Caribbean, where there 
are few cervical cancer prevention programmes.  The East African region has the highest ASIR 
for cervical cancer with cervical cancer accounting for nearly one third of all cancer cases. By 
contrast the Australia/New Zealand region has the highest all cancer ASIR, with cervical cancer 
accounting for less than 2% of the cancer cases. East Africa also has the highest ASMR for 
cervical cancer with cervical cancer responsible for almost a quarter of all cancer deaths. By 
contrast in the Australian/New Zealand region cervical cancer accounts for less than 2 % of 
cancer deaths.   
 
There is considerable variation in the incidence rates among countries in the various regions. For 
example, in a review of the incidence and mortality rates for cervical cancer in 21 Latin 
American countries very high rates  were reported in Haiti (ASIR 93.9 per 100 000), whilst  
much lower rates were reported in Uruguay (ASIR13.3 per 100 000) (Arrossi, Sankaranarayanan 
& Parkin 2003). Cervical cancer is the most common cancer among women in Africa, 
comprising 25.4% of all female cancers (Parkin et al. 2008). Eastern and Southern Africa have 
the highest cervical cancer incid nce rates in the African region and worldwide, while North 
















Table 2.1: Age-standardised incidence and mortality rates per 100 000 for cervical cancer 
and all cancers in 2008 (world standard population) 








Eastern Africa 34.5 125.3 25.3 95.9 
Southern Africa 26.8 161.1 14.8 108.1 
Western Africa 33.7 123.5 24.0 91.2 
Middle Africa 23.0 96.7 17.0 75.6 
Northern Africa 6.6 98.9 4.0 68.2 
Caribbean 20.9 153.5 9.4 86.2 
Central America 22.2 134.4 11.1 80.6 
South America 23.9 162.9 10.7 88.2 
Northern America 5.7 274.4 1.7 91.5 
South Central Asia 24.6 110.8 14.1 71.7 
Eastern Asia 9.6 158.1 3.9 87.3 
Western Asia 4.5 119.5 2.1 74.3 
South-Eastern Asia 15.8 141.7 8.3 89.4 
Central and Eastern Europe 14.5 184.2 6.3 94.0 
Southern Europe 8.0 212.2 2.5 81.2 
Western Europe 6.9 250.9 2.0 84.3 
Northern Europe 8.3 249.4 2.4 99.7 
Australia / New Zealand 5.0 276.4 1.4 86.0 
Melanesia 23.7 133.4 16.6 95.9 
Micro/Polynesia 13.4 184.0 4.9 79.9 















Time trends in cancer incidence and mortality need to be interpreted with caution due to changes 
in data quality and methodology of estimation over time (Parkin et al. 2005). With cervical 
cancer an additional complexity relates to changes in the proportion of deaths coded as ―uterine 
cancer not otherwise specified‖ and time trends need to be interpreted with this caveat in mind. 
In general cervical cancer incidence and mortality rates have decreased in most developed 
countries in the past 20 to 40 years (IARC 2005). Most of this decline is credited to the 
implementation of effective screening programmes.  
 
The limited data on time trends of cervical cancer in developing countries indicate that incidence 
and mortality rates have been relatively stable with some small declines which have been 
attributed to socio-demographic changes rather than to prevention efforts (Sankaranarayanan, 
Budukh & Rajkumar 2001). This assumes reliable and valid data in these countries. Cancer 
registration systems are relative uncommon in Africa and limited data is available on time trends 
for cervical cancer (Parkin et al. 2008). Data from the Kampala Cancer registry, set up in 1954, 
shows an increase in the incidence of cervical cancer between the 1960 and 1997 from 17.1 per 
100 000 to 45.8 per 100 000 (Wabinga et al. 2000). The reasons for the increase are not 
understood and have not been investigated. No increase in incidence over time has been 
documented in Harare (Zimbabwe) or Nigeria (Parkin et al. 2003; Parkin et al. 2008). In most 
Latin American countries cervical cancer mortality has remained relative unchanged since 1960 
except for declines documented in Puerto Rico and Chile (Robles, White & Peruga 1996; 
Sankaranarayanan, Budukh & Rajkumar 2001; Arrossi, Sankaranarayanan & Parkin 2003; IARC 
2005). Cervical cancer continues be an important cause of morbidity and mortality in developing 
countries. 
 
2.1.2 Burden of disease in South Africa 
South Africa does not have a national population-based cancer registry. The main source for 
cancer statistics is the National Cancer Registry (NCR). The registry was established in 1986 and 
relies on histology reports from public and private pathology laboratories nationwide. As a 
















Data on the ASIR of cervical cancer, as with many other diseases in South Africa, describes the 
distribution of the disease among the four race groups that formed the legal basis of apartheid 
regulation viz. Black (African), White (Caucasian), Coloured(mixed race) and Asian (Indian). A 
problem with the use of these categories is the implication that phenotypic differences between 
races are coterminous with genetic differences which determine predisposition to disease. This 
has been shown to be incorrect (Diamond 1994; Ellison et al. 1996; Ellison, de Wet 1997).  In 
South Africa apartheid resulted in sharp social, economic and geographic divisions between the 
races. Differences in health status reflect these socio-economic divisions. 
 
According to the most recent NCR statistics (2001), cervical cancer is the second commonest 
cancer among all South African women with an ASIR of 25.5 per 100 000 women (National 
Health Laboratory Service 2009). Overall one in thirty five women in South Africa is at risk of 
developing cervical cancer. Figure 2.1 shows the age-specific incidence rate for cervical cancer 
in 2001. The incidence rate rose steadily with age with women aged 60 to 64 years having the 
highest rate (ASIR 97.0/ 100 000 women).  
 








































































Source: (National Health Laboratory Service 2009) 
The marked difference in the ASIR for cervical cancer in the different population groups in 















cervical screening and differences in HPV infection rates. Among Black South African women 
cervical cancer is the commonest cancer with an ASIR of 30.6. 
 
Table 2.2: Age-standardised incidence rates for cervical cancer, 2001 (world standard 
population) 






Source: (National Health Laboratory Service 2009)  
 
The ASIR for the different population groups over a 10 year period are shown below (Figure 
2.2). There has been a small decline in the overall ASIR from 1992 to 2001. Over time there has 
been a modest decline in the ASIRs in the Coloured and Black population, however these rates 
remain unacceptably high, and are similar to the high rates seen in developing countries in 


















































































Source: (Sitas et al. 1997; Sitas, Madhoo & Wessie 1998; Mqoqi et al. 2003; Mqoqi et al. 2004; National 
Health Laboratory Service 2009)  
 
Trends in age standardised cervical cancer mortality rates in South Africa for the period 1949 to 
1990 showed  that the overall trend for Coloureds increased in this period, the  trend for Asians 
decreased from the mid 1970’s whilst that for Whites decreased (Bailie et al. 1996). Trends in 
the African population could not be studied because of deficiencies in mortality data for that 
population group. The authors ascribe the contrasting mortality patterns between Coloureds and 
Whites to differences in access to screening services, with Whites mostly having access to Pap 
smears in the private sector and Coloureds reliant on opportunistic Pap smear screening in the 
public sector services.  
 
Cervical cancer is the leading cause of cancer deaths amongst women in South Africa (Norman 
et al. 2006). In a burden of disease study conducted in South Africa in 2000, cervical cancer was 
ranked as the 15
th
 highest cause of loss of life among females, accounting for 50 027 premature 
years of life lost (Bradshaw et al. 2003). Table 2.3 shows the all cause mortality rates and the 















was 1.7 times higher for African compared to White South African women, whilst for cervical 
cancer the mortality rates were 5.4 times higher for African compared to White women 
(Bradshaw et al. 2006).  
 
Table 2.3: All cause and cervical cancer age-standardised mortality rates per 100 000 
population by population group 2000 (world standard population) 
 African Coloured Indian White South African 
All cause 1613 1394 1172 937 1468 
Cervical cancer 27 22 8 5 21 
Source: (Bradshaw et al. 2006; Norman et al. 2006) 
 
In summary cervical cancer remains an important cause of morbidity and mortality among 
women in South Africa, underscoring the need for a comprehensive prevention strategy. 
 
 
2.2 Natural history of cervical cancer  
2.2.1 HPV as the causative agent 
Epidemiological studies have shown strong and consistent associations between HPV infection 
and cervical cancer (Walboomers et al. 1999; Munoz 2000; Bosch et al. 2002). Studies include 
cross-sectional surveys, case-control studies, cohort studies, intervention studies, experimental 
studies and natural history investigations (Bosch et al. 2002; IARC 2005). The strength of 
association is the strongest ever observed for human cancer, with a pooled odds ratio for 
squamous cell cervical cancer associated with HPV positivity of 158.2 (95% CI 113.4 - 220.6) 
(Munoz et al. 2003). The worldwide prevalence of HR-HPV in cervical cancer specimens is 
99.7% and HPV is now recognised as a necessary cause of cervical cancer (Walboomers et al. 
1999). This is of considerable public health relevance as it not only enables identification of a 
high-risk group of women (those with persistent HR-HPV infection), but it also raises the 
















Infection with HPV is not a sufficient cause of cervical cancer and among women persistently 
infected with HPV additional cofactors increase the risk of progression to cervical cancer. These 
cofactors include exposure to tobacco smoke, a parity of greater than five,  immune-suppression 
including infection with HIV, the use of oral contraceptives for greater than five years, infection 
with Chlamydia Trachomatis and Herpes Simplex type 2 (Castellsague, Munoz 2003; IARC 
2005). Other cofactors that have been identified in studies in Africa include poor genital hygiene 
and alcohol (Parkin et al. 2003). From a public health perspective women exposed to any of 
these cofactors constitute a group at increased risk of cytological abnormalities compred to 
women in the general population. Evidence for the role of diet in cervical cancer remains 
inconclusive (Castellsague, Munoz 2003; IARC 2005).  
 
HPV is a non-enveloped, double-stranded deoxyribonucleic acid (DNA) virus that infects 
epithelial cells. Papillomaviruses are relatively stable and resistant to desiccation. Over 100 types 
of the HPV have been identified and approximately 40 of these affect the anogenital area.  
Fifteen HPV types are classified as high-risk or oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68, 73, and 82) and these are frequently associated with cervical cancer. Three 
HPV types (26, 53, and 66) are classified as probable high-risk types (Munoz et al. 2003). 
HPV16 is the dominant type associated with more than half of the cervical cancers world-wide, 
followed by HPV18 (10% - 15%), HPV45 (7%), and HPV31 (3%) (Bosch, de Sanjose 2003; 
Clifford et al. 2003; Munoz et al. 2003). Twelve HPV types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 
81, and 89) have been classified as having a low-risk of association with cervical cancer and are 
referred to as benign or non-oncogenic types (Munoz et al. 2003). Low-risk types 6 and 11 are 
most often associated with genital warts (Munoz et al. 2003; Trottier, Franco 2006). 
 
HPV is a common sexually transmitted infection. Results from a global meta-analysis on HPV 
prevalence in women with normal cytology indicate a point prevalence of 10.4% (95% CI 10.2–
10.7) with a higher prevalence in less compared to more developed countries (15.5%% vs. 
10.0%) (de Sanjose et al. 2007). HPV prevalence is highest in young women (approximately 
20% in women < 25 years) and decreases with age. In all regions except Asia a second peak in 
prevalence is seen in older women. In Africa this 2
nd
 peak occurs after the age of 54 years. 















hormonal changes resulting in reactivation of latent HPV, changes in sexual behaviour and that 
of their partners in middle age, or a result of cohort effects. 
 
There is considerable variation in HPV prevalence worldwide, with the highest HPV prevalence 
rates reported in Africa (22.1%; 95% CI 20.9 - 23.4) (de Sanjose et al. 2007).  An IARC 
population-based survey conducted in 15 613 cytologically normal women aged 15 -74 years 
from eleven countries around the world also demonstrated a variation of nearly 20 times in 
prevalence across the countries (Clifford et al. 2005). In the latter pooled analysis only one 
African country viz. Nigeria was included and these women had the highest HR-HPV and 
HPV16 prevalence. Worldwide HPV16 is the most common HPV type with an estimated point 
prevalence of 2.6% (95% CI 2.5 -2.8). Studies indicate that in Europe, and Central and South 
America HPV18 is the second most frequent type, whilst in Africa, HPV52 is the second most 
frequent type and HPV18 the third. In Asia the commonest types in order of decreasing 
frequency are types 16, 52, 58 and then 18. In Northern America, HPV18 is also the fourth most 
common type after HPV16, HPV53 and HPV52 (Bosch et al. 2008; WHO/ICO Information 
Centre on HPV and Cervical Cancer 2010). 
 
Relatively few studies have looked at HPV prevalence and type distribution in South African 
women. A study conducted among women attending public sector health services in the Western 
Cape reported a high HPV prevalence (20.4%) in women with normal cytology (Allan et al. 
2008).  In this study the commonest types seen in women with normal cytology were HPV16 
(2.0%) and HPV52 (1.9%). In women with HSIL types 16 and 35 were the commonest both with 
a prevalence of 18.9%, followed by types 52 and 31 both with a prevalence of 11.3%. Two small 
studies reported on HPV types in women with invasive cervical cancer and concurred with 
results elsewhere that HPV16 was the most prevalent type (Williamson et al. 1994; Kay et al. 
2003). The prevalence of HPV types in South Africa will be important in assessing the possible 
















2.2.2 Progression of HPV infection to cervical cancer 
An understanding of the natural history of cervical cancer is important in developing preventive 
strategies and in managing cervical cancer and its precursors. It is useful to note that several 
classifications exist for reporting cervical cancer precursor lesions (National Cancer Institute 
1989; Solomon et al. 2002). The original classification used by Papanicolau, was replaced by a 
descriptive one (using the dysplasia terminology), and later by the cervical intraepithelial 
neoplasia (CIN) classification. Since 1988, the Bethesda classification, using the terminology 
squamous intraepithelial lesion (SIL)) has been introduced. The 1988 Bethesda system also 
introduced the term atypical squamous cells of undetermined significance (ASCUS) which is an 
equivalent cytological diagnosis that denotes cellular changes that are more marked than reactive 
inflammatory changes but are not diagnostic of SILs.  In 2001 atypical squamous cells were 
divided into those that were of undetermined significance (ASC-US) and those with atypical 
squamous cells but where HSIL could not be excluded (ASC-H). The changes in nomenclature 
are summarized in Table 2.4. 
 
Table 2.4: Cytology nomenclature 
Descriptive 
classification  
CIN Classification  Bethesda 1988  Bethesda 2001  
Atypia  Atypia  ASCUS  ASC-US  
ASC-H  
Mild dysplasia  CIN grade 1  LSIL  LSIL  
Moderate dysplasia  CIN grade 2  HSIL  HSIL  
Severe dysplasia  CIN grade 3  HSIL  HSIL  
CIS  CIN grade 3  HSIL  HSIL  
CIS,  carcinoma in situ; CIN, cervical intraepithelial neoplasia; ASCUS, atypical squamous cells of undetermined 
significance; LSIL, low-grade squamous intraepithelial lesion ; HSIL, high grade  squamous intraepithelial lesion; 


















The main steps in cervical carcinogenesis include: HPV transmission and infection of the 
epithelium (Holowaty et al. 1999; Schiffman, Kjaer 2003; Moscicki et al. 2006)of the 
transformation zone of the cervix, viral persistence, progression to precursor lesions and invasion 
of the basement membrane of the epithelium (invasive cancer)  (Holowaty et al. 1999; 
Schiffman, Kjaer 2003; Moscicki et al. 2006; Schiffman et al. 2007) and are depicted in Figure 
2.3.  
 
Figure 2.3: Natural history of cervical cancer  
Normal Cervix
HPV infection with HR types
Low-Grade SIL (CIN 1)
High-Grade SIL (CIN 2/3/, CIS)
Invasive Cancer
viral persistence and progression
clearance
viral persistence and progression
clearance
clearance
CIS,  carcinoma in situ; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HR, high-risk LSIL, low-grade 
squamous intraepithelial lesion; HSIL, high grade  squamous intraepithelial lesion 
 
Adapted from (PATH 1997) 
 
 
Penetrative sexual intercourse is the primary route of HPV infection. Transmission through non-
penetrative sexual contact does occur but is rare (Winer et al. 2003; Burchell et al. 2006). HPV is 















computer simulation study to be 40% (range 5 – 100%) (Burchell et al. 2006). Winer, et al. 
(2003) followed up a group of university students and reported a cumulative 24-month incidence 
of HPV of 38.9 % (95 % CI: 29.4 - 50.3) among virgins that initiated sexual activity. Risk factors 
for HPV transmission include number of sexual partners, partner’s sexual behaviour and early 
sexual debut (Schiffman, Kjaer 2003; Burchell et al. 2006). Evidence for male circumcision as a 
risk factor for HPV infection is conflicting (Burchell et al. 2006). Condom use appears to offer 
some protection against HPV infection, however HPV can still be transmitted through contact 
with areas not protected by condoms (Burchell et al. 2006). 
 
The majority of cervical HPV infections are cleared spontaneously or suppressed within one to 
two years of exposure by cell-mediated immunity (Stanley 2006). Persistence (defined as the 
detection of the same HPV type over a time period of several months to a year) is uncommon, 
but the longer the virus persists the greater is the risk of cervical cancer developing (Schiffman, 
Kjaer 2003).  Persistence is commoner in older women (Schiffman et al. 2007). Reasons why 
some women infected with HPV develop persistent infection are not fully understood, but are 
thought to include viral type, differences in cell-mediated immune responses, individual host 
factors and possible environmental factors such as smoking and oral contraceptives (IARC 2005; 
Schiffman et al. 2007). HPV16 has been shown to persist longer than other oncogenic types 
(Franco et al. 1999). Persistent HR-HPV infection can lead to precursor lesions of the cervix. 
Women infected with multiple HPV types are also at a greater risk of cervical cancer precursor 
lesions compared to women infected with a single type, although it is not clear whether the risk 
is greater than the sum of risks posed by individual HPV types (Herrero et al. 2005). 
 
Studies have shown that the majority of LSILs regress (Ostor 1993; Holowaty et al. 1999; IARC 
2005).  A review of studies reporting on the natural history of CIN1 concluded that 57% of CIN1 
lesions regressed (Ostor 1993). Progression and regression rates were studied in a large historical 
cohort study in Canada, where Pap smear histories were recorded at a laboratory in a time when 
cervical squamous lesions were managed conservatively. In this study the majority (87.7%) of 
cases with mild dysplasia regressed to normal cytology within 10 years, with most of the 















regressed to normal cytology. Progression from mild dysplasia to severe dysplasia or worse 
occurred in 10.0% of women within 10 years, and from moderate to severe dysplasia in 32.0% of 
women within 10 years. It is not possible to study the progression of HSIL to invasive cancer, as 
this would be ethically unacceptable. Crude estimates from early studies suggest the risk of 
invasion is 30% within 5- 10 years (Kinlen, Spriggs 1978; Chang 1990).  
 
HPV type is also a strong risk factor for progression from persistent HPV infection to cancer 
(Khan et al. 2005; Schiffman et al. 2007). Identifying which HR-HPV types preferentially 
progress from precursor lesions to cancerous lesions is important in informing the development 
of type-specific HPV vaccines. A meta-analysis that compared the prevalence of HPV types in 
HSIL (the immediate precursor lesion to cervical cancer) and invasive cancer concluded that 
HPV16, 18 and 45 were most likely to progress to invasive cervical cancer compared to other 
types (Clifford et al. 2003). A similar study conducted in Taiwan showed that HPV16 followed 
by HPV33 and 18 was most likely to progress from subclinical infection to invasive cervical 
cancer (Ding et al. 2008). The oncogenic potency of types 16 and 18 was confirmed in a study 
that followed up 20 810 women and reported the risk of developing CIN3 or cancer 10 years 
after HPV infection was 17.2% for HPV 16 and 13.6% for HPV 18, whilst the risk for women 
who had other HR-HPV types present was 3% (Khan et al. 2005; Schiffman et al. 2007). 
Although there is variation in the HPV types in women with normal cytology across regions, 
similarities in HPV type-specific distribution in invasive cervical cancer across the regions 
worldwide have been recorded (Clifford et al. 2003). 
 
Progression from HPV infection to invasive cancer is slow, usually taking decades. The peak 
prevalence of transient HPV infections occurs in young women (teens to early 20s) after sexual 
debut.  The peak in precancerous lesions occurs approximately 10 years later and the peak 
















2.2.3 Aspects of epidemiological findings pertinent to preventive strategies 
Knowledge of the natural history and epidemiology of cervical cancer provide important 
information for the development of cervical cancer preventive strategies. The identification of 
HPV as a necessary cause of cervical cancer raised the possibility of primary prevention by 
vaccination. HPV infection is common with worldwide variation in prevalence and types. Fifteen 
high-risk HPV types have been identified.  Vaccines against cervical cancer must provide 
protection against types that have demonstrated the greatest oncogenic potential, with the ideal 
being a polyvalent vaccine. Prophylactic vaccines will need to be administered prior to sexual 
debut. The impact of the vaccine at a country level will depend on prevalent HPV types and 
vaccine coverage. HPV-type specific data are therefore important in estimating the potential 
impact of an HPV vaccine strategy. Condoms offer some protection against HPV and should be 
promoted, however, consistent condom use is a challenge and condom use is unlikely to impact 
significantly on cervical cancer rates.   
 
Criteria have been developed to assist when trying to determine whether or not screening is a 
suitable prevention strategy for a given disease (Wilson, Junger 1968). Cervical cancer meets all 
of the disease characteristics described: it is a common disease with serious consequences if left 
untreated; the natural history is well understood and it has a long latent period allowing time to 
detect and treat precancerous stages. 
  
 
In summary natural history data provide guidance on when best to initiate screening. Cervical 
cancer most often develops in women after the age of 40 years. The immediate precursor lesion, 
HSILS, peak in women in their mid-30s. To achieve the maximum benefit from screening, 
countries with limited resources should aim to identify and treat women with HSILs by directing 
screening efforts at women in their thirties. As cervical cancer develops slowly screening can 
take place relatively infrequently and still have a significant impact on morbidity and mortality. 
HPV infection is common in young women and most infections clear spontaneously, hence 
screening by HPV testing should target older women who are more likely to have persistent HPV 
infection. As most LSILs (57% - 88%) regress spontaneously (Ostor 1993; Holowaty et al. 















Programmes should focus on active treatment of HSILs as a significant proportion of these 
lesions (estimated 30%) progress to invasive cancer (Kinlen, Spriggs 1978; Chang 1990). 
 
2.3 Secondary prevention 
2.3.1 Screening tests 
Conventional cytology 
The first cytology test was developed by George Papaniculaou in the 1920s. Conventional 
cytology testing involves the collection of cervical cells from the transformation zone of the 
cervix using a spatula or brush, slide preparation and staining, and then microscopic examination 
of the cells.  The accuracy of the test has been reviewed in several cross-sectional studies that 
have compared the Pap smear results to a reference standard of histology or colposcopy (Fahey, 
Irwig & Macaskill 1995; Nanda et al. 2000; IARC 2005; Sankaranarayanan et al. 2005). 
Histology results report the absence or presence of CIN of different degrees (CIN1, CIN2 or 
CIN3) or invasive cervical cancer. Pap smear results are categorized as abnormal (positive) or 
normal (negative) at various thresholds (ASC-US, LSIL or HSIL).  The reference standards 
(histology or colposcopy) are not perfect diagnostic tests and are themselves subject to 
inaccuracy, which can lead to an underes imate of sensitivity and specificity. If studies do not 
verify normal Pap smear results with the reference standard this can lead to a biased study 
sample. This verification bias can result in elevated estimates of sensitivity and lower estimates 
of specificity.  
 
Nanda et al. (2000) reviewed 12 studies conducted in women undergoing Pap tests for screening 
and in which verification was done on all, or a random sample of patients with negative Pap 
smear results. For a Pap smear threshold of LSIL, the sensitivity in detecting CIN2 or worse 
lesions ranged from 44% to 99% and specificity from 91% to 98% (Nanda et al. 2000). In four 
studies conducted in South Africa sensitivity  in detecting CIN2 or worse lesions ranged from 
53% to 78% and specificity from 88% to 97% (Denny et al. 2000; Wright et al. 2000; Denny et 
al. 2002; Cronje et al. 2003).  The study by Cronje et al. (2003) was the only study in which all 
















Both sampling and reading/detection errors are thought to contribute to the low-moderate 
sensitivity of Pap smears. Training and quality control measures (such as workload limits, 
proficiency testing, review of abnormal smears by a pathologist and cytology-histology 
correlations) are important in reducing these errors.  
  
Liquid-based cytology 
The liquid-based cytology (LBC) technique involves transferring cells collected on a sampling 
device to a fluid preservation medium and then processing the suspension in the laboratory. The 
cells remain well preserved in the suspension at room temperature for several weeks. Excess 
blood and mucus can be removed from the suspension and a small aliquot of suspension is then 
deposited in a thin layer onto a slide. The advantages of LBC include fewer unsatisfactory test 
results, the slides are quicker and easier to screen than conventional slides and remaining cell 
suspension is suitable for additional tests such HPV test (IARC 2005; Sankaranarayanan et al. 
2005; Cuzick et al. 2008). LBC is however more expensive that conventional cytology. A recent 
meta-analysis of studies comparing conventional and liquid cytology showed that LBC is neither 
more sensitive nor more specific than conventi nal cytology in detecting HSIL (Arbyn et al. 




It is established that cervical cancer is caused by persistent HR-HPV types. The direct detection 
of HPV in cervical specimens thus could be used as a screening tool. HPV cannot be reliably 
cultured in the laboratory. HPV testing relies on molecular techniques that detect HPV DNA in 
cervical samples collected by a cone shaped brush. The two HPV DNA tests that have been 
validated in large studies are the hybrid capture second-generation (HC2) and polymerase chain 
reaction (PCR) based methods.  
 
HC2 uses a signal amplification technique and is based on hybridizing long synthetic RNA 
probes in solution. One RNA probe (A) detects five low risk HPV types namely 6, 11, 42, 43 and 















56, 58, 59 and 68. The HPV DNA-RNA hybrids are captured by antibodies and detected by a 
series of reactions that produce a luminescent product that can be measured. The recommended 
cut-off value for test positive results is 1 relative light unit and is equivalent to 1pg of HPV DNA 
per 1 ml of buffer solution. The intensity of emitted light is proportional to the amount of DNA 
present in the specimen, so it is also able to provide a semi-quantitative measure of HPV viral 
load (Iftner, Villa 2003; IARC 2005; Sankaranarayanan et al. 2005). Studies have documented an 
increase in HPV viral load with increasing severity of cervical lesions (Heard et al. 2000; Sun et 
al. 2001; Sun et al. 2002; Dalstein et al. 2003; Levi et al. 2004; Wu et al. 2006). HPV viral load 
could therefore be useful in differentiating women at a higher risk of SIL. HC2 testing requires 
equipment ranging from basic laboratory supplies to advanced equipment such a luminometer 
integrated with a personal computer. These requirements make the use of HC2 costly. The HC2 
is unable to provide information on specific individual HPV types.  
 
The PCR-based method produces highly concentrated samples of a specific DNA genetic 
sequence through target amplification. Analysis of the amplified product can be done in different 
ways such as gel electrophoresis, dot blot or line assays. The strength of the PCR method lies in 
its capacity to detect very small amounts of HPV DNA. Strict laboratory procedures are critical 
to reduce contamination. Distinction of 40 types can be achieved using type-specific probes. 
Quantification of HPV viral load is possible, and the Real-Time PCR assay is considered to be 
one of the most accurate assays to quantify HPV viral load. However, the equipment and costs 
involved make PCR HPV tests inappropriate for large scale screening programmes.   
 
A number of cross-sectional studies have evaluated the accuracy of HC2 as a screening test 
(IARC 2005; Sankaranarayanan et al. 2005). The sensitivity of HC2 in detecting CIN 2 or worse 
lesions varied from 66-100% and the specificity from 61% - 96% (IARC 2005; 
Sankaranarayanan et al. 2005). In a number of the studies Pap smear accuracy was also evaluated 
and, in general, the HPV test had a higher sensitivity and lower specificity than the Pap smear. 
Generally the accuracy was lower in studies that used self-sampling specimens by clients, 
compared to clinician sampling studies. The HC2 test has been evaluated in two studies in SA. In 
a study by Denny et al (2000) the sensitivity of the HC2 to detect CIN2 or worse lesions was 















specificity 85%. Studies have shown that screening strategies that incorporated HPV testing were 
cost-effective alternatives to cytology-based screening programmes in developing countries 
(Goldie et al. 2005; Vijayaraghavan et al. 2009).  HPV testing by HC2 is an approved technique 
for cervical screening and triage of unequivocal cervical abnormalities in many developed 
countries.  
 
The effect of a single round of screening by HPV testing, cytology testing, or visual inspection of 
the cervix with acetic acid (VIA) on the cervical cancer incidence and mortality rate was recently 
assessed in a randomised controlled trial in India (Sankaranarayanan et al. 2009). Clusters of 
villages were randomly assigned to undergo screening by HPV testing (34 126 women), cytology 
testing (32 058 women), VIA (34 074 women) or to receive standard care (31 488, control 
group). In India standard of care is no screening.  Women who had positive results on screening 
underwent colposcopy and directed biopsies, and those with cervical precancerous lesions or 
cancer received appropriate treatment. Women were between 30 and 59 years old and were 
followed up for 8 years. The study found that a single round of HPV testing was associated with 
a significant decline in the rate of advanced cervical cancers and associated deaths, as compared 
with the unscreened control group. In the HPV-testing group, cervical cancer was diagnosed in 
127 subjects as compared with 118 subjects in the control group, hazard ratio for the detection of 
advanced cancer (stage II or higher) in the HPV-testing group was 0.5 (95% CI 0.32 - 0.69). 
There were 34 deaths from cervical cancer in the HPV-testing group, as compared with 64 in the 
control group, hazard ratio, 0.5 (95% CI 0.33 - 0.83). No significant reductions in the numbers of 
advanced cancers or deaths were observed in the cytology-testing group (54 deaths, hazard ratio 
0.9, 95% CI 0.62 - 1.27) or in the VIA group (56 deaths, hazard ratio 0.9, 95% CI 0.66 - 1.25), as 
compared with the control group (Sankaranarayanan et al. 2009).  
 
The use of HC2 in developing countries has been hampered by the cost of the test, laboratory 
requirements and logistics involved.  To overcome some of these problems a new test, the 
careHPV, has been developed for use in developing countries.  The test uses signal amplification 
and can detect 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). 
It does not require electricity or running water and can be performed by technical staff in two 















in China. The accuracy of the test in detecting CIN2 or worse lesions was as follows: sensitivity 
of 90% (95% CI 83.0-97.0%) and a specificity of 84% (82.7 – 85.7%). Further studies are 
needed to test reproducibility in populations with different HPV prevalence (Qiao et al. 2008).   
 
Visual inspection with acetic acid (VIA) 
VIA involves examination of the cervix with the naked eye under a bright light source, one 
minute after acetic acid (3-5% dilution) has been applied to the cervix using a cotton swab or 
spray. This method is also referred to as ―direct visual inspection‖ (DVI). The presence of aceto-
white areas in the transformation zone of the cervix indicates a positive result. Aceto-whitening 
is not specific to cervical cancer and may also occur in immature squamous metaplasia and 
inflamed cervical epithelium. A number of studies have evaluated the test characteristics of VIA 
and have reported a sensitivity of between 67% to 79% and a specificity between 49% and 86% 
in detecting CIN2 or worse lesions (IARC 2005; Sankaranarayanan et al. 2005; Arbyn et al. 
2008b). In part this wide variation can be explained by the subjective nature of VIA. Three 
studies have evaluated the accuracy of VIA in the South African setting and results are similar to 
those reported elsewhere with sensitivity ranging between 67% and79% and specificity between 
49% and 85% (Denny et al. 2000; Denny et al. 2002; Cronje et al. 2003). The main advantages 
of VIA are that it is cheap, quick and requires a low level of infrastructure and results are 
available immediately, all important issues in low-resource settings. However the test is 
subjective and provider supervision and quality assurance mechanisms are necessary to ensure 
reliable results. Limited information is available on how VIA will perform as a routine screening 
test in real health service settings.  
 
VIA also offers the possibility of immediate treatment, referred to as the ―see and treat‖ 
approach. In this approach women who are VIA positive are treated immediately with 
cryotherapy, without confirmatory tests such as colposcopy and histology. A concern with this 
approach is the possibility of high rates of overtreatment.  The safety and efficacy of the 
approach was assessed in a randomized controlled trial in South Africa where 6555 women aged 
35 to 65 years were screened using the HC2 test and VIA (Denny et al. 2005). Women were 
subsequently randomized to one of three groups: a group that received cryotherapy if the HC2 















evaluation group (control group). At 6 months all women had a colposcopy assessment and 
women with biopsy confirmed CIN2 or worse lesions were treated. The prevalence of CIN2 or 
worse lesions at 6 months was lower in both see-and-treat groups compared to the control group 
(prevalence of 0.8% in the HC2 group, 2.2% in the VIA group and 3.6% in the control/delayed 
evaluation group). The see-and-treat approach using HC2 thus resulted in a 77%  lower 
prevalence in CIN2 or worse lesions at 6 months, and the VIA a 37%  lower prevalence when 
compared to the control group. However given the known low specificity, particularly of VIA, of 
the tests in detecting CIN2 or worse lesions it is likely that a fair proportion of women were 
unnecessarily treated with cryotherapy. The results of the VIA group in this study are in 
disagreement with those reported by the study in India where no reduction in advanced cervical 
cancer or cervical cancer mortality was observed after VIA (Sankaranarayanan et al. 2009), 
which could be due to a higher rate of treatment in the South African study. 
 
Visual inspection with Lugol’s iodine (VILI) 
In this visual inspection method, Lugol’s iodine is applied to the cervix and then examined for 
mustard-yellow areas. A pooled analysis of eleven studies that concurrently evaluated five 
cervical cancer screening tests including VILI and VIA showed that VILI had a higher pooled 
sensitivity than VIA  in detecting CIN 2 or worse  lesions (91% compared to 79%) with a similar 
pooled specificity (85%) (Arbyn et al. 2008b).  There was wide inter-study variation of both VIA 
and VILI accuracy parameters, reflecting the subjective nature of these tests and the need for 
training and supervision.  
 















Table 2.5: Range of sensitivity and specificity values for different screening methods in 
detecting CIN2 or worse lesions 
Screening method Sensitivity Specificity 
Conventional cytology 44% - 99% 91% - 98% 
Liquid based cytology 57%* 97%* 
HPV testing using hybrid capture 2 66% - 100% 61% - 96% 
HPV testing using careHPV 90% 84% 
Visual inspection with acetic acid 67% - 79% 49% - 86% 




Combined screening methods 
As no current screening method has sufficient sensitivity and specificity to detect HSIL or worse 
lesions, combinations of tests are being investigated. Combinations can be applied in a single 
stage, such as LBC and HPV testing, or in sequential stages. Evidence suggests that screening 
women with both cytology and HPV tests increases sensitivity for detection of prevalent CIN3 or 
cancer (IARC 2005; Bulkmans et al. 2007). HPV testing followed by triage with cytology for 
HPV test positives has been suggested as a rational approach for older women because of the 
higher sensitivity of HPV testing and the higher specificity of cytology (IARC 2005; Cuzick et 
al. 2006). For lower resource settings possible future combinations could include a rapid HPV 
test followed by VIA for HPV test positives (Cuzick et al. 2006; Cuzick et al. 2008).  
 
Emerging technologies 
Newer technologies with better sensitivity and specificity than existing tests are being 
investigated as screening tools. Technologies include: HPV typing, HPV mRNA, HPV viral 
load, HPV integration, methylation markers and cell proliferation markers (Cuzick et al. 2006). 
















2.3.2 Experience with cytology-based cervical screening programmes 
Cytology-based screening programmes are the mainstay of cervical screening programmes in 
developed countries. In most developed countries women have their first Pap smear soon after 
initiating sexual activity and subsequently once every one to five years, with a move toward less 
frequent screening intervals (three to five years).  
 
Observational case-control and cohort studies have demonstrated the effectiveness of cytology 
screening in reducing the incidence and mortality of cervical cancer (IARC 2005). Cohort studies 
conducted in Canada, Finland, Iceland, Denmark, Norway and Sweden all showed a protective 
effect of cytology-based screening programmes. Relative risk estimates for invasive cancer 
ranged from 0.17 in the Canadian study to 0.77 in the Norwegian study (IARC 2005).  Studies 
relating trends in incidence and mortality to cervical screening have also provided ecological 
evidence of the effectiveness of cytology based screening programmes. Mortality rates in the 
Nordic countries have declined since the introduction of organised cervical screening 
programmes in the 1960’s.  The greatest reduction was seen in Iceland (80% between 1965 and 
1982), which had the widest target age range. Decline in mortality was related to population 
coverage, with greater declines seen in those Nordic countries that had higher coverage rates 
(Laara, Day & Hakama 1987). A review of mortality trends in the UK showed that since the 
introduction of the national screening programme the previous rising trend of cervical cancer 
mortality was reversed (Peto et al. 2004). Declines in cervical cancer incidence and mortality 
have also been seen in Europe, USA, Japan and Oceania and have been related to the 
introduction of cervical screening programmes (Sankaranarayanan, Budukh & Rajkumar 2001; 
IARC 2005). Organised screening programmes have shown a greater effect than opportunistic 
screening (Sankaranarayanan, Budukh & Rajkumar 2001; IARC 2005).  
 
In most low-income countries, screening for cervical cancer is non-existent (Chirenje et al. 2001; 
Sankaranarayanan, Budukh & Rajkumar 2001; IARC 2005). Sub-Saharan Africa and India 
account for a substantial proportion of the global cervical cancer burden. However, South Africa 
is the only sub-Saharan African country that has a cervical screening policy and there is no 
national organised cervical screening programme in India. Many low-income countries do not 















and it has been suggested that low-income countries should rather focus on improving their 
capacity to diagnose and treat cervical cancer (Chirenje et al. 2001; Sankaranarayanan, Budukh 
& Rajkumar 2001). Screening technologies such as VIA and rapid HPV tests are being explored 
as alternatives for low-resources countries. 
 
Cytology-based screening programmes have been introduced in some middle-income countries 
with mixed results. The Chilean programme is an example of a successful cytology-based 
screening programme in Latin America and offers instructive lessons for other middle-income 
countries. Annual Pap smear screening was introduced in the 1970’s. However screening tended 
to focus on young women and the programme was poorly organised and managed (Sepulveda, 
Prado 2005; Salas 2006). The programme was re-organised in 1987 with the aim of screening 
80% of women aged 25 to 64 years every 3 years. Screening was first implemented in a 
demonstration area and later expanded to the entire country. Key strategies included co-
ordination at national, regional and community levels with a focus on increasing management 
capacity, monitoring Pap smear quality, implementing a quality assurance programme at 
cytology laboratories and timely diagnosis and treatment of abnormal Pap smears (Salas 2006). 
Pap smear coverage increased from 40% in 1990 to 66% in 1996 and 98% of women with 
abnormal Pap smears were followed-up.  The ASMR rate decreased from 12.8% in 1980 to 6.8 
per 100 000 women in 2001 (Sepulveda, Prado 2005; Salas 2006).  
 
Puerto Rico established a cervical screening programme in the1960s, offering Pap smears to 
women 15 years and older. A survey conducted in 2002 showed that 72% of women over the age 
of 18 years had had a Pap smear in the preceding 3 years (Murillo et al. 2008). A decrease in 
cervical cancer incidence and mortality rates over the last 30 years has been documented 
(Sankaranarayanan, Budukh & Rajkumar 2001; Arrossi, Sankaranarayanan & Parkin 2003). The 
ASIR decreased from 38 per 100 000 women during 1950 - 1954 to 19.9 per 100 000 women in 
1990. During the same period the cervical cancer mortality rate decreased from 19.2 per 100 000 
women to 5.2 per 100 000 women.  
 
Since the 1970’s Costa-Rica has had opportunistic screening mainly through family planning 















older are offered Pap smears every 2 years (Murillo et al. 2008). Coverage has varied across 
regions in the country. A national survey in 2000 showed that the Pap smear coverage among 
women aged 18-44 years was low (37%). The incidence rate of cervical cancer in 2000 was 18.2 
per 100 000 women and there had only been a 9% decline in incidence since the implementation 
of the national screening programme (Murillo et al. 2008).  Mortality rates have remained 
unchanged (Sankaranarayanan, Budukh & Rajkumar 2001; Arrossi, Sankaranarayanan & Parkin 
2003). Colombia has had a cervical screening programme since the 1970s. In the 1990s the 
programme focussed on screening women aged 25-69 years every 3 years. Although the 
mortality rates have remained unchanged, a decrease in incidence rate has been seen in Cali, 
Colombia (Aristizabal et al. 1984; Sankaranarayanan, Budukh & Rajkumar 2001). 
 
Cytology based programmes have also been implemented in Cuba and Mexico. Cuba offers 
women 20 years and older Pap smears every 2 years and Mexico screens women aged 25-65 
years annually.  However there has been no reduction in cervical cancer incidence and/or 
mortality rates in either of these countries (Sankaranarayanan, Budukh & Rajkumar 2001; 
Arrossi, Sankaranarayanan & Parkin 2003).  An evaluation of the programme in Mexico showed 
that there was low screening coverage (40% over a 3 year period), the quality of the cytology 
services was sub-optimal, there was poor co-ordination of the programme and the country had 
insufficient resources to conduct annual Pap smears (Hernandez-Avila et al. 1998; 
Sankaranarayanan, Budukh & Rajkumar 2001; Flores et al. 2003). In Cuba cytology quality and 
follow-up of clients with abnormal Pap smears, both important aspects of a screening 
programme, is reported to be good, however, coverage is low (54% in 1993/1994). A review of 
cervical cancer screening programmes in Latin America and the Caribbean identified a number 
of issues that need to be addressed to improve the impact of cytology-based programmes. These 
include follow-up of screened positives, quality of Pap smears, participation rates, monitoring 
and evaluation systems (Murillo et al. 2008). 
 
Malaysia, a middle-income country with a significant burden of cervical cancer, has offered free 
Pap smears to women aged 20-65 years every 3 years since 1995. Barriers to programme 
implementation in Malaysia include, poor co-ordination, long waiting times for Pap smears, 















coverage rate remains low at 47%. A pilot project that addresses these challenges has been 
initiated in two districts in Malaysia and the impact of this are expected in 2010/2011. 
 
The key elements of a successful cytology-based screening programme include: a policy on the 
target age and frequency of smears, trained staff (smear takers, cytotechnologist, pathologists, 
colposcopists and programme managers), a good laboratory infrastructure with quality assurance 
mechanisms, transport systems to get smears to the laboratory, a system for communicating the 
results to women, a mechanism to ensure all women with abnormal smears are followed-up and 
treated, high population coverage and a system to monitor and evaluate the performance of the 
programme. 
 
2.3.3 Summary of challenges in implementing cytology-based screening programmes in 
middle-income countries 
Key challenges to implementation of cytology-based screening programmes in middle-income 
countries have been identified and include: competing health priorities, lack of organisation, poor 
coverage, poor access to services particularly for rural women, limited cytology laboratory 
capacity and quality, poorly developed health infrastructure, limited human and financial 
resources, inadequate staff training, loss to follow-up of women with abnormal smears and 
inadequate monitoring and evaluation systems (Chirenje et al. 2001; Sankaranarayanan, Budukh 
& Rajkumar 2001; World Health Organization 2002; Murillo et al. 2008; Othman, Rebolj 2009). 
Cognisant of the resource and organisational constraints in developing countries, experts have 
suggested prioritising high coverage among older women, ensuring that those with detected 
abnormalities return for follow-up and treatment and reducing screening frequency (World 
Health Organization 2002; IARC 2005). Models developed by IARC suggest that screening 
women of an appropriate age once in a lifetime may reduce the incidence of cervical cancer by 
30%  and screening women once every 10 years from age 30 on  can theoretically reduce disease 
rates by 64% (IARC Working Group on Cervical Cancer Screening 1986). There has been some 
criticism of these IARC models as they are based on high coverage and optimal follow-up and 
treatment, conditions not very likely in developing countries. However a re-evaluation of the 















highest priority group for screening are those aged 35 or over, and that screening every 5 years 
will achieve a major impact (World Health Organization 2002). 
 
Research on ways to improve programme efficiency is recognised as a high priority (World 
Health Organization 2002). It has been recommended that middle-income countries with 
inefficient cytology-based screening programmes should reorganise their programmes based on 
experiences and lessons learnt elsewhere, whilst those without any cervical screening 
programmes should consider implementation in a limited geographical regions before expanding 
nationally (Sankaranarayanan, Budukh & Rajkumar 2001; Murillo et al. 2008). Experience from 
other middle-income countries suggests that the following elements of a cytology based-
screening programme need particular attention:  consistent cytology reporting systems, 
standardised management guidelines, referral and feedback systems for clients with 




2.4 Primary prevention through HPV vaccination 
2.4.1 Features of current vaccines 
The recognition that HR-HPV is a necessary cause of cervical cancer paved the way for the 
development of HPV vaccines against cervical cancer. Currently two vaccines are available: a 
quadrivalent vaccine, containing virus-like particles (VLP) related to HPV types 6,11, 16 and 18 
and a bivalent vaccine containing VLPs related to HPV types 16 and 18 (Harper et al. 2006; 
FUTURE II Study Group 2007). Both vaccines offer protection against the two HPV types 
responsible for the majority of cervical cancer lesions, with the quadrivalent vaccine offering 
additional protection against two types associated with genital warts. The vaccines are prepared 
from empty protein shells and produced by recombinant technology (Schiller et al. 2008). They 
do not contain any live biological material and so are non-infectious. Both vaccines are designed 
to be prophylactic, not therapeutic. The vaccines must be refrigerated and are given as a series of 
three 0.5 ml intramuscular injections. The key characteristics of both vaccines are described in 
















Table 2.6: Key characteristics of HPV vaccines 
 Quadrivalent vaccine Bivalent vaccine 
Manufacturer and trade name Merck (Gardasil®) GlaxoSmithKline 
(Cervarix™) 
Virus-like particles (VLPs) 
of types  
6, 11, 16, 18  16, 18 
Substrate  Yeast (S. Cerevisiae)  Baculovirus expression 
system 
Adjuvant 225μg aluminium 
hydroxyphosphate sulphate 
500 μg aluminium hydroxide, 
50 μg 3-deacylated 
monophosphoryl lipid A  
Injection schedule 0, 2, 6 months 0, 1, 6 months 
Source: (World Health Organization 2007) 
 
The efficacy of the vaccines has been tested in randomized controlled trials that have been 
conducted in Europe, North America, Latin America and in the Asia-Pacific region (Harper et al. 
2006; FUTURE II Study Group 2007). None of the trials have been conducted in Africa. Phase II 
efficacy trials have focused on HPV infection endpoint and the phase III studies on disease 
endpoints. These trials include a number of different types of analysis: the according-to- protocol 
(ATP) analysis includes only the ideal participants who adhere to all aspects of the protocol, the 
intention-to-treat (ITT) includes all participants who participate in the trial where participation is 
defined as receiving at least the first vaccine dose and the modified- intention- to-treat (MITT) 
analysis excludes participants who violate some aspects of the trial protocol. 
  
The efficacy of the bivalent vaccine in preventing HPV infection was assessed in a randomised 
controlled trial that included 776 women with a median age of 23 years who were followed up 
for 4.5 years (Harper et al. 2006). In the ATP analysis the incidence rate of HPV16/18 was 0.2 
per 100 person-years in the vaccinated group compared to 5.6 per 100 person years in the 
placebo group, with a vaccine efficacy of 96.9% (95% CI 81.3% - 99.9%) in preventing incident 















In an interim analysis of a phase III double-blind, randomised controlled trial of the bivalent 
vaccine,18 644 women aged 15 - 25 years were followed up for a mean of 14.8 months since the 
first vaccine dose to determine vaccine efficacy in preventing CIN lesions (Paavonen et al. 
2007). A modified- intention- to- treat (MITT) analysis showed that in total 23 women 
developed CIN 2 or worse lesions with HPV16 or 18 detected in the lesion; 2 in the vaccinated 
group and 21 in the placebo group (incidence rate of 0.02 and 0.22 per 100 person-years in the 
placebo and vaccinated group respectively). For the endpoint CIN2 or worse the vaccine efficacy 
was 90.4% (CI 53% - 99%). 
 
The efficacy of the quadrivalent vaccine in preventing incident HPV infection was assessed in a 
randomised controlled trial where 277 women received the quadrivalent vaccine (median age 
20.2 years) and 275 women received a placebo (median age 20.0 years). After 30 months the 
incidence rate of HPV infection with types 6, 11, 16 or 18 (types covered by the vaccine) was 0.7 
per 100 women-years in the vaccine group and 6.5 per 100 women years in the placebo group 
(ATP analysis). Vaccine efficacy was 89% (95% CI 70% - 97%) (Villa et al. 2005). 
 
A combined analysis of the four phase III randomized controlled trials of the quadrivalent 
vaccine included 20 583 women aged 16 -26 years who were followed up for a mean of 3 years 
after their first vaccine dose (FUTURE II Study Group 2007). A total of 86 CIN2 or worse 
lesions with HPV17 or 18 present in the lesion were detected; 1 in the vaccinated group 
(incidence rate < 0.1 per 100 person-years) and 85 in the placebo group (incidence rate 0.4 per 
100 person-years. In women who were HPV16/18 naive ATP vaccine efficacy for the endpoint 
CIN 2/3 was 99% (95% CI 93% -100%). In the ITT analysis, which included women who were 
HPV16/18 naive or HPV16/18-infected at day 1, efficacy was 44% (95% CI 31% -55%).  
 
Both vaccines induced high serum antibody levels in almost all vaccinated individuals at levels 
10 to 104 times higher than those seen in natural infections (Harper et al. 2004; Harper et al. 

















The endpoint of CIN 2 or worse has been widely accepted as a proxy for cervical cancer that can 
be studied ethically. In children or young adolescents however, it is not practical to study this 
endpoint, since cervical specimens would be required, and the endpoint is rare in young people. 
Bridging studies are therefore conducted, in which the antibody responses of young people are 
compared with those of women for whom data on the clinical endpoint CIN2/3 is available. 
Bridging studies have shown that the antibody titres were approximately two-fold (Schiller et al. 
2008) higher in boys and girls compared to women (Block et al. 2006; Pedersen et al. 2007; 
Schiller et al. 2008).The potential benefit of vaccinating males include direct protection against 
HPV-related warts and indirect protection for women from cervical cancer by reducing 
transmission of HPV. 
 
Both vaccines have shown cross-protection against HPV types not specifically included in the 
vaccine. The bivalent
 
vaccine has shown protection against incident HPV45 and 31 (Paavonen et 
al. 2007), types seen commonly in Africa (Clifford et al. 2006). Unpublished reports indicate that 
the quadrivalent vaccine is able to produce antibodies to HPV45 and 31 (Smith et al. 2006).  
Further studies are needed to assess whether administration of the vaccine will reduce CIN 
caused by HPV types not found in the vaccine. 
 
In the HPV vaccine trials adverse events at the injection site (pain, erythema and oedema) 
occurred more frequently in vaccine recipients than controls, but the incidence of serious adverse 
events was not significantly higher among vaccine recipients in any of the trials (Cutts et al. 
2007; World Health Organization 2007; Schiller et al. 2008).  
 
In high income countries cohort models have been used to estimate cost-effectiveness of HPV 
vaccines and found that, in a setting of existing cervical cancer screening, the addition of an HPV 
vaccine has the potential to be a cost-effective use of health care resources, using cost per life 
year gained and cost per quality adjusted life year gained as effectiveness measures (Kulasingam, 
Myers 2003; Sanders, Taira 2003; Brisson et al. 2007; Jit, Choi & Edmunds 2008).  A recent 
study in South Africa showed that adding the HPV vaccine to the current cervical cancer 
screening strategy in the country is cost-effective (Sinanovic et al. 2009). In low- and middle-















at the current market price of US $120 per dose (Goldie et al. 2007; Goldie et al. 2008; 
Tangcharoensathien, Limwattananon & Chaugwon 2008; Sinanovic et al. 2009). 
 
The magnitude of benefit from HPV vaccination in a country will depend on the burden of HPV 
disease attributable to the types contained in the vaccine, vaccine efficacy, duration of protection 
and vaccine coverage. Theoretical models have estimates of the likely impact given different 
scenarios. For example, with a vaccine efficacy of 95% and 80% coverage a vaccine containing 
HPV 16 and 18 will theoretically reduce cervical cancer incidence by 54% (Bosch 2003). Results 
of dynamic simulation models that considered the benefits of herd immunity, suggest that, if high 
coverage of females can be achieved, little additional reduction in cervical cancer is gained by 
vaccinating males (Garnett et al. 2006; Kim, Goldie 2009).  
 
Although protection against HPV16/18 infection and CIN lesions has been demonstrated in the 
randomised controlled trials discussed above, the question of long term protection remains and 
will only be answered in years to come when results from ongoing long-term studies become 
available. Several other questions on the effectiveness of the vaccine remain. These include: 
questions on the need for a booster vaccine, cross-protection, the minimum number of doses 
needed, efficacy with different dosing schedules, the minimum age of vaccination, efficacy if 
combined with other vaccines, vaccine efficacy in males and efficacy in immune-compromised 
individuals. Studies either underway or in the preparatory stage include a trial of two versus three 
doses, studies in HIV positive individuals, efficacy studies in young men and older women and 
the development of polyvalent vaccines. At a population level HPV vaccines will reduce not 
eliminate cervical cancer and screening programmes will need to continue. 
 
2.4.2 Experience in introducing HPV vaccine in developed countries 
Over the past few years a number of studies have been conducted on HPV vaccine acceptability 
issues, focussing on knowledge and attitudes towards cervical cancer, HPV and HPV vaccination 
in relation to uptake and potential opposition to the vaccine (Pitts, Clarke 2002; Giles, Garland 
2006; Moreira et al. 2006; Noakes, Yarwood & Salisbury 2006; Zimet et al. 2006; Mosavel, El-
Shaarawi 2007; Ogilvie et al. 2007; Rosenthal et al. 2007; Vanslyke et al. 2008; Zimet, Shew & 















primarily in developed countries, found that most parents and potential recipients had limited 
knowledge about cervical cancer, HPV and the importance of regular screening measures. 
However, despite poor levels of knowledge, health care providers were willing to recommend 
HPV vaccination and parents were interested in having their children vaccinated. Most studies 
concluded that information and knowledge about HPV, cervical cancer and the importance of 
regular screening need to be improved so as to promote informed decision making with regards 
to HPV vaccination (Mosavel, El-Shaarawi 2007; Vanslyke et al. 2008).  
 
The vaccines are currently licensed for use in more than 100 countries. Some developed 
countries have introduced HPV vaccination programmes in the public sector. A national 
programme vaccinating schoolgirls aged 12- to 13 years began in the United Kingdom in 
September 2008.  An evaluation of vaccine coverage and acceptability has shown encouraging 
results (Brabin et al. 2008). Vaccine uptake was 70.6% for the first dose and 68.5% for the 
second dose. Results for uptake of the 3
rd
 dose have not been published as yet. Generally 
acceptability was good and no serious adverse events were reported. Eight percent of the parents 
refused vaccination with the main reason being insufficient information about the vaccine and its 
long term safety. Vaccine uptake was significantly lower in schools with a higher proportion of 
ethnic minority girls. Challenges in delivery included integrating the programme into the school 
academic calendar and arranging for alternate appointments for girls that missed their original 
scheduled appointments. A national school based vaccination programme was also introduced in 
Australia in April 2008 for girls aged 11 to 12 (Garland et al. 2008a; Shefer et al. 2008). After 
the first year of the school-based programme, compliance through dose 3 was estimated to be 
80%. Some provinces in Canada have introduced publicly funded school-based HPV 
immunisation programmes (Shefer et al. 2008).  The United States does not have a national 
programme, but the Advisory Committee on Immunization Practices advises that all adolescent 
females receive 3 doses of the HPV vaccine. Since 2006, CDC has conducted a population- 
based survey, the National Immunization Survey-Teen (NIS-Teen), to estimate vaccination 
coverage among adolescents aged 13 -17 years. In 2009 27% of adolescent girls had received 3 
















Experience from these countries indicate that important issues to address include establishing 
national guidelines and recommendations, providing information about the HPV vaccine to the 
public, identifying delivery options, establishing an infrastructure for vaccine delivery and a 
system to monitor vaccine implementation. Even in high-resource countries there are challenges 
to a school-based vaccine delivery such as synchronisation of vaccination schedule with the 
school calendar, obtaining parental consent and vaccinating those that have missed a dose. 
 
2.4.3 Issues for introduction in developing countries  
Developing countries bear the burden of cervical cancer and women in developing countries 
have the greatest need for primary prevention through HPV vaccination. Although the HPV 
vaccine has been licensed for use in many developing countries, no government sponsored HPV 
vaccination programmes exist in these countries. Experience with intr duction of other vaccines 
such as the Hepatitis B vaccine indicate  that people in developing countries wait decades before 
a new vaccine is available in the public sector (Kane, Brooks 2002).  Currently HPV vaccines are 
available in the private sector and as part of research projects in developing countries.  In 2006 
projects were initiated in India, Peru, Vietnam and Uganda by PATH, an international non-profit 
organisation, to explore strategies for HPV vaccine delivery in middle and low income countries. 
Formative research showed that although knowledge of the HPV vaccine and of cervical cancer 
was low, the vaccine was acceptable to communities (PATH 2009). Project evaluation results are 
anticipated in 2010/2011 (PATH 2009). The sustainability of such pilot projects is likely to be a 
huge challenge once the research period or period of vaccination donations comes to an end. 
 
A major barrier to introduction in developing countries is the high cost of the vaccine. Unless 
HPV vaccines are made available at a significantly reduced price, it is extremely unlikely that 
they will become available to women in middle and low income countries. The Global Alliance 
for Vaccines and Immunization (GAVI) was established in 1999 and provides financial 
assistance to the 75 poorest developing countries for development of infrastructure and 
introduction of new vaccines (Kaddar, Lydon & Levine 2004). GAVI has indicated that it will 
make HPV vaccine provision a priority.  However middle-income countries, such as South 
Africa are not eligible for GAVI support and will need to find alternative ways to fund an HPV 















considered. In making the decision of whether to introduce the HPV vaccine countries also need 
to consider the issue of competing health priorities including introduction of other vaccines such 
as the rotavirus and pneumococcal vaccines (Andrus et al. 2008). 
 
Rumours and myths have negatively impacted on delivery of other vaccines such as tetanus 
vaccine in Mexico, Philippines and Uganda, and the polio vaccines in Nigeria and India 
(Aylward, Heymann 2005; Kane et al. 2006). HPV vaccine is associated with a sexually 
transmitted infection and targets primarily females and could be seen as a conspiracy to sterilise 
young women (Kane et al. 2006). Acceptability may also be questioned by those who feel the 
HPV vaccine will promote sexual promiscuity (Zimet, Shew & Kahn 2008).  
 
Delivery of vaccines to adolescents is a challenge (Biddlecom, Bankole & Patterson 2006; Kane 
et al. 2006). In developing countries vaccines are usually delivered through the Expanded 
Programme on Immunization (EPI) (World Health Organization 2005). It is estimated that EPI 
has high coverage and that 75% of children worldwide receive basic immunisation (Kane et al. 
2006). However there is wide variation in coverage in developing countries, particularly in 
Africa. The EPI primarily targets infants and success with immunizing adolescents for example 
with tetanus vaccine has been mixed (Kane et al. 2006). There are few adolescent health 
programmes in developing countries, but where these exist they could potentially serve as 
another entry point for HPV vaccines (Pollack et al. 2007). Sexual and reproductive health 
programmes are responsible for cervical cancer screening and will need to be involved in HPV 
immunisation as part of comprehensive strategies to prevent cervical cancer. School-based 
delivery strategies have been used in developed countries. However in many developing 
countries poor school enrolment rates are likely to limit the success of this strategy (Hewett, 
Lloyd 2005; Biddlecom, Bankole & Patterson 2006). It has been suggested that in such countries 
annual door-to door immunisation campaigns may be more successful (Pollack et al. 2007). 
Several challenges exist to the introduction of the HPV vaccine and limited formative research is 
available to guide vaccine introduction in developing countries (Harries et al. 2009). 
 
In summary, two prophylactic HPV vaccines are currently available and offer potential for 















HIV positive individuals and cross-protection against other HPV types are currently unanswered 
and are particularly relevant in the South African setting. The high cost of the vaccine is a major 
barrier to its introduction in developing countries. Formative research to guide introduction of 
the vaccine in developing countries is lacking. 
 
 
2.5 HIV and cervical cancer 
2.5.1 HIV and HPV infection 
Women infected with HIV have a higher prevalence of HPV and are at a greater risk of 
developing cervical SILs compared to HIV negative women (Wright et al. 1994; Sun et al. 1997; 
La Ruche et al. 1998; Minkoff et al. 1998; Massad et al. 1999; Palefsky et al. 1999; Ellerbrock et 
al. 2000; Duerr et al. 2001; Jamieson et al. 2002; Hawes et al. 2003; Schuman et al. 2003; Harris 
et al. 2005; Rowhani-Rahbar et al. 2007; Massad et al. 2008). The increase in HPV prevalence 
could be due to reactivation of latent infection or new incident infections (Strickler et al. 2005). 
Several mechanisms may explain the association between HIV and HPV-related disease 
(Palefsky 2006). HIV decreases cell-mediated immunity which plays a critical role in the control 
of HPV infection. HIV diminishes local immune response at the tissue level and this might result 
in increased HPV infection. In addition there might be a direct interaction between the 2 viruses, 
with HIV interacting with HPV at a molecular level, leading to an increased expression of the 
HPV E6 and E7 oncogenes (Pal fsky 2006).  
 
A meta-analysis of 20 studies from North America, Europe, Africa, Asia and South/Central 
America found that the highest HPV prevalence was in HIV positive women from Africa 
(Clifford et al. 2006).  The highest HPV prevalence worldwide has been reported in Zambia. 
Among 145 HIV-infected women attending HIV/AIDS treatment at a tertiary level care facility, 
the prevalence of HPV was 97.2% for any HPV and 90.3% for HR-HPV (Sahasrabuddhe et al. 
2007). Women in this study were severely immunocompromised (median CD4 count 165/uL). 
HR-HPV was detected in 68% of HIV-infected women recruited from a tertiary colposcopy 















associated with a high HPV prevalence include a high HIV viral load and a low CD4 count 
(Minkoff et al. 1998; Palefsky et al. 1999; Jamieson et al. 2002; Hawes et al. 2003).   
 
A number of studies in developed countries have shown an increase in the prevalence of HPV 
infection in HIV positive compared to HIV negative women. The Women’s Interagency HIV 
study (WIHS) is a prospective cohort study of 2056 HIV-positive and 569 HIV-negative women 
at six sites around the United States that was set up to characterise the natural history and 
pathogenesis of HIV infection and its complications in HIV-positive women when compared 
with a group of age and risk-matched HIV-negative control subjects (Palefsky et al. 1999). The 
prevalence for any HPV infection was 63% among HIV positive women compared to 30% 
among HIV negative women, and that for HR-HPV 13.6% and 3.0% respectively. Another 
multisite prospective study in the United States, the HIV Epidemiology Research (HER) Study, 
was established to define the effects of HIV on the health of women and has reported similar 
results. HIV positive women participating in the HER study had a higher prevalence of any HPV 
compared to HIV negative women (63.7% vs. 27.4%), and a high prevalence of HR-HPV 
(19.1% vs. 7.7%) (Jamieson et al. 2002). In a study conducted among HIV positive and HIV 
negative women living in the New York City area HPV DNA was detected in 56% of HIV 
positive women and 31% of HIV-negative women (Sun et al. 1997).  In Brooklyn the prevalence 
for any HPV was 73% among HIV positive women compared to 43% among HIV negative 
women (Minkoff et al. 1998). Ahdieh et al (2000) reported an HPV prevalence of 69.6% among 
HIV positive women and 26.2% among HIV negative women, with a HR-HPV prevalence of 
23.4% and 8.3% respectively. As can be seen findings from the studies above are remarkably 
consistent. In HIV positive women the relative risk for high risk HPV is greater than that for all 
HPV. 
 
Fewer studies comparing the HPV prevalence in HIV positive and HIV negative women have 
been conducted in developing countries, but results are similar to that seen in developed 
countries. La Ruche et al. (1998) reported an HPV prevalence of 59.5% among HIV positive 
women compared to 24.1% in HIV negative women in Abidjan. Ina study in Dakar the 















HIV-2 and 25.3% in HIV negative women, with a HR-HPV prevalence of 53.6%, 41.2% and 15 
% respectively (Hawes et al. 2003). 
 
Similar to HIV negative women, considerable variation in regional HPV type distribution has 
been reported in HIV positive women (Clifford et al. 2005; Clifford et al. 2006). Among HIV 
positive women with normal cytology HPV16 is the most common HR-HPV type seen, with 
types 31 and 35 also high is Africa. HPV16 is the commonest type seen in all HIV positive 
women with HSIL, but HPV16 was proportionately less prevalent in HIV positive women with 
HSIL compared to HIV negative women with HSIL (Clifford et al. 2006). A shift towards HPV 
types other than HPV16 in HIV positive women with HSIL when compared to HPV negative 
women with HSIL has been documented. These types include the HR-HPV types 18, 51, 52 and 
58 and low-risk types 11, 53 and 61. Studies have documented a higher rate of multiple 
concurrent HPV types in HIV positive compared to HIV negative women, not only with HR 
types but also with types with little potential to cause cytological abnormalities in immune-
competent women (Ellerbrock et al. 2000; Duerr et al. 2001; Clifford et al. 2006; Rowhani-
Rahbar et al. 2007). It is not clear to what extent the low-risk types are benign infections in the 
presence of another type or whether they have the potential to induce HSIL in immune-
compromised women. In a study in Cape Town the commonest HPV types seen in HIV positive 
women with HSIL were HPV 16 (26%) , 52 (22%) and 53 (20%) (Denny et al. 2008) ), whereas 
in a study in Johannesburg the commonest HPV types in women with HSIL were HPV 16 
(42%), 56 (22%) and 66 (17%) (Firnhaber et al. 2010).  HPV16 and /or HPV18 were present in 
44% of women with HSIL in the Cape Town study and 42% of women in the Johannesburg 
study. Limited information is available on HPV types in HIV positive women with ICC (Clifford 
et al. 2006). In Zambia among 28 women with cervical cancer the commonest HPV types seen in 
descending order were HPV52 (46.4%), HPV58 (35.7%), HPV16 (35.7%), HPV35 (28.6%) and 
HPV31 (25.0%) (Sahasrabuddhe et al. 2007).  
 
Studies have shown that HPV viral load may predict the risk of cervical abnormalities in HIV 
positive women (Heard et al. 2000; Lillo et al. 2005; Lillo, Uberti-Foppa 2006). High HPV viral 
load has been associated with histological severity and lesions size (Lillo, Uberti-Foppa 2006). 
















Persistent HPV infection is a prerequisite for cervical abnormalities. HIV positive women have 
been shown to have a higher rate of persistent HPV infections compared to HIV negative 
women. Sun et al (1997) reported persistent HPV infections (defined in the study as the detection 
of the same type of HPV at two or more examinations during a period of 3 to 12 months) in 24% 
of HIV positive women compared to 4% of HIV negative women.  Koshiol et al. (2006) also 
reported an association between HIV positivity and duration of HPV infection and found that the 
time to clearance was longest for HPV16  
 
Further information on the prevalence of HPV in different stages of the HIV epidemic in South 
Africa will help in estimating the impact of the HIV epidemic on cervical cancer and its 
precursors. 
 
2.5.2 HIV and cervical cancer precursor lesions 
HIV positive women are at a significantly higher risk of cervical abnormalities compared to HIV 
negative women. In the WIH study the prevalence of cervical abnormalities was 38.3% among 
HIV positive women compared to 16.2% among HIV negative women (Massad et al. 1999). HIV 
positive women were at a significantly higher risk of LSIL (OR 8.9, 95% CI 4.8 -16.4) and for 
HSIL (OR 2.7, 95% CI 1.1 - 6.3) compared to HIV negative women. The prevalence of 
abnormalities among HIV positive women in this cohort has remained above 25% since the start 
of the study in 1994, with the majority of lesions being low-grade (Massad et al. 2008). In a 
European cohort study on the natural history of HIV infection 24.2% of HIV positive women had 
an abnormal Pap smear at baseline (Delmas et al. 2000).  In the HER study SILs (both LSIL and 
HSIL) were detected in 18.8% of HIV positive women and 5.3% of HIV negative women 
(prevalence ratio 3.9, 95% CI 2.4 - 6.2) (Duerr et al. 2001). 
 
A number of studies have reported on the prevalence of abnormalities in HIV positive women in 
Africa and have detected high rates of cervical abnormalities. The prevalence of cervical 
abnormalities among HIV positive sex workers in Zaire was 27% (Laga et al. 1992) and 26% 
among sex workers in Kenya (Kreiss et al. 1992). A cervical abnormality prevalence of 26 % 















2002). One of the highest rates of cervical abnormalities recorded in any population was reported 
in severely immune-compromised women attending a tertiary hospital in Zambia (93.3%) 
(Parham et al. 2006). In South Africa the prevalence of cervical abnormality in HIV positive 
women was 55% in a study conducted in Cape Town and 50% in a study in Johannesburg 
(Denny et al. 2008; Firnhaber et al. 2010).  
 
The only study in Africa comparing the prevalence of cervical abnormalities in HIV positive and 
HIV negative women was conducted in Senegal among women with HIV-1 infection attending 
an outpatient infectious-disease clinic (Hawes et al. 2003). The prevalence of cervical 
abnormalities was 37% in HIV positive women compared to a prevalence of 16% among HIV 
negative women. Women with HIV-1 were at a significantly higher risk of HSIL compared to 
HIV negative women with an adjusted odds ratio of 3.7 (95% CI 1.9 - 7.4).  
 
A number of studies have shown that among women with HIV, higher HIV plasma RNA loads 
and lower CD4 counts are associated with increasing degree of cervical abnormality (Massad et 
al. 1999; Hawes et al. 2003; Harris et al. 2005; Denny et al. 2008). Rates of abnormality in 
women with CD4 cell counts > 500cells/uL are similar to rates seen in HIV negative women. 
HIV positive women have higher progression and lower regression rates of cervical lesions 
compared to HIV negative women (Strickler et al. 2005). These rates need to be considered in 
developing cervical cancer screening policies for HIV positive women.  
 
2.5.3 HIV and invasive cervical cancer 
Studies have produced inconsistent results on the association between HIV and ICC (Sitas et al. 
1997; La Ruche et al. 1998; Sitas et al. 2000; Gichangi et al. 2003; Massad et al. 2004; 
Mbulaiteye et al. 2006; Massad et al. 2008; Stein et al. 2008; Adjorlolo-Johnson et al. 2010). In a 
cross-sectional study conducted in Abidjan 2 198 women attending outpatient gynaecology 
clinics women were screened for cervical lesions and HIV infection (La Ruche et al. 1998). A 
significant association was seen between HIV infection and HSIL (OR 5.8, 95% CI 3.6 to 9.6) 
but no association was seen between invasive cervical cancer and HIV. Of the 18 women with 
invasive cervical cancer, 14 were HIV negative and 2 HIV-1 positive and 2 HIV-2 positive.  A 















1995 found no association between invasive cervical cancer and HIV (OR 0.6, 95% CI 0.2 - 1.9 
(Sitas et al. 1997). However, data from an ongoing case-control study in a similar setting that 
commenced in 1995 showed an increased risk of cervical cancer, OR 1.6, 95% CI 1.1 - 2.3 
among HIV positive women for the period 1992 to 1999 (Sitas et al. 2000). The most recently 
analysed data from this study, for the period 1995 to 2004, also reported an increased risk of 
cervical cancer in HIV positive women (OR of 1.6, 95% CI 1.3 - 2.0) (Stein et al. 2008). A 
similar increased risk of invasive cervical cancer among HIV positive women was reported in a 
case-control study conducted in Kenya (OR 2.0, 95% CI 1.1 - 3.5) (Gichangi et al. 2003) and in 
Uganda (OR 2.4 95% CI 1.1 - 4.4 ) (Mbulaiteye et al. 2006). In the WIH study, 462 HIV 
negative and 1661 HIV positive women were followed up between 1994 and 2001 and no 
association between HIV and ICC was documented (Massad et al. 2004). No cases of ICC were 
observed in HIV negative women and 1 case of ICC was observed am ng HIV positive women 
(IR 1.2 /10 000 women-years). The low ICC rates in the WIH study could be a result of the 
intensive screening programme in which all study participants are screened with Pap smears 
every 6 months.  The disparate results on the association between HIV and invasive cervical 
cancer in the studies described above may be due to variations in the competing causes of 
mortality, stage of the HIV epidemic at the time the study was conducted and efficacy of cervical 
cancer screening programmes in different settings. A recent study conducted among HPV 
positive women in Côte d’Ivoire reported an association between HIV infection and cervical 
cancer (OR 3.4, 95% CI 1.1 - 10.8) (Adjorlolo-Johnson et al. 2010). 
 
Two studies conducted in South Africa have shown that mean age of HIV positive women with 
ICC is 10 to 15 years lower than that of HIV negative women (Lomalisa, Smith & Guidozzi 
2000; Moodley, Moodley & Kleinschmidt 2001).  
 
2.5.4 The impact of HAART on cervical lesions 
HAART decreases HIV viral loads, increases CD4 cell counts and decreases most opportunistic 
infections (Hogg et al. 1998; Palella et al. 1998).  Since the introduction of HAART there has 
been a decline in certain malignancies in HIV infected individuals (Jacobson et al. 1999; 
Ledergerber, Telenti & Egger 1999). HAART has the potential to influence the relationship 















lengthens exposure to HPV infection thereby increasing the likelihood of cervical SILs and 
cervical cancer. Conversely, because HAART restores immune-competence, it may reduce the 
risk of cervical SILs and cancer. However, it has also been suggested, that once a particular level 
of cervical disease is reached immune re-constitution may be of limited value (Palefsky 2003; 
Palefsky 2006). Non-immune factors such as chromosomal instability and genetic changes 
caused by HPV DNA integration with the host cell genome are thought to be important in 
progression of disease at this stage. 
 
Studies on the impact of HAART of cervical SILS are complicated. It is unethical to randomize 
women to HAART. Most studies have compared women on HAART to those not on HAART or 
compared women before and after HAART initiation. However HAART is only initiated once 
the CD4 cell count falls below a certain level (usually < 350/uL in developed countries), so 
women on HAART usually have more advanced disease a priori. Studies on the impact of ARVs 
on the natural history of cervical SILs have produced mixed results, with some studies showing 
benefit (Heard et al. 1998; Minkoff et al. 2001; Heard et al. 2002; Ahdieh-Grant et al. 2004) and 
others no or limited effect (Orlando et al. 1999; Lillo et al. 2001; Moore et al. 2002; Heard, 
Palefsky & Kazatchkine 2004; Heard, Potard & Costagliola 2006). Recent results from a 
prospective cohort of HIV positive women in Soweto, South Africa, showed that HAART was 
associated with 28% decrease in risk of progression from a normal/ LSIL Pap to HSIL (adjusted 
hazards ratio 0.72, 95% CI 0.52 - 0.99). However HAART had no impact on regression (Omar et 
al. 2011).  HAART has not resulted in the clearance of cervical HPV (Heard, Palefsky & 
Kazatchkine 2004). In studies showing increased regression rates or decreased progression rates 
among HAART users, the benefit has been modest and the majority of women initiating HAART 
did not regress to normal (Ahdieh-Grant et al. 2004; Heard, Palefsky & Kazatchkine 2004; 
Heard, Potard & Costagliola 2006; Omar et al. 2011). A review of cancer incidence data from 23 
prospective studies in North America, Europe and Australia has shown that since the 
introduction of HAART there has been no reduction in the incidence of cervical cancer 
(International Collaboration on HIV and Cancer 2000). However, the attributable effect due to a 















in relation to the population of women at large. The implications of all of these findings are that 
women on HAART will still need rigorous screening and close-follow-up. 
 
2.5.5 Prevention of cervical cancer in HIV positive women  
The efficacy and safety of the current HPV vaccines in HIV infected individuals is as yet 
unknown. The current bivalent and quadrivalent vaccines are prophylactic, hence they are likely 
to have limited benefit in HIV positive women as many will already be infected with HPV. Both 
HIV and HPV are sexually transmitted and a successful HPV vaccination programme before 
sexual debut is likely to help in preventing cervical lesions in women infected with both HIV and 
HPV. 
 
There are no data specifically on the efficacy of screening in HIV positive women. A number of 
studies have assessed the accuracy of cytology in HIV positive women. Some studies have found 
that the accuracy of cytology was no different in HIV positive and negative women (Boardman 
et al. 1994; Korn et al. 1994). Others have reported a higher false negative rate in HIV positive 
women compared to HIV negative women (Maiman et al. 1991; Fink et al. 1994; Goodman et al. 
2000). For example Goodman, et al.(2000),  in a cross-sectional study, reported a false negative 
rate of 37%  in the HIV positive compared to a rate of 21% in the HIV negative group. Where 
colposcopy services are not readily available, more frequent cytology screening has been 
suggested for HIV positive women, although with little supporting evidence (IARC 2005). The 
CDC and US Public Health service recommended that HIV positive women be screened for SILs 
more frequently than HIV negative women (Centers for Disease Control (CDC) 1997). 
Following the initial diagnosis of HIV infection, it is recommended that women have 2 Pap 
smears 6 months apart, if both these are negative then annual Pap smears are recommended. 
These recommendations are not feasible in developing countries, where both HIV and cervical 
cancer are common, and resources are limited.  
 
A study in Zimbabwe evaluated accuracy of the HC2 test in detecting HSIL in a population at 
high risk for HIV. The sensitivity and specificity of the HPV test for HSIL were, respectively, 















61.5% (95% CI 31.6% -86.1%) and 74.5% (95% CI 68.0% - 80.3%), respectively, in HIV 
negative women (Womack et al. 2000).  Denny, et al. evaluated the performance of VIA in 
detecting SILs lesions and reported no difference in sensitivity, but  a lower specificity among 
HIV positive women compared with HIV negative women (Denny et al. 2002). The low 
specificity observed in the studies above limit the use of VIA and HC2 as a screening test for 
HSIL in HIV positive women.  
 
In summary research has shown that HIV positive women have a higher incidence and 
prevalence of HPV and are infected with a broader range of HPV types than HIV negative 
women. Further studies are needed to better understand the impact of HAART on the natural 
history of cervical cancer. In South Africa there is limited information on HPV related cervical 
disease in HIV positive women.  Data on the risk of HPV-related cervical disease, HPV 
prevalence, types and viral load will assist in planning comprehensive cervical cancer preventive 
strategies, by permitting estimation of the likely impact of current and future HPV vaccines and 




This review shows that cervical cancer is an important public health problem in developing 
countries. In South Africa, it remains an important cause of morbidity and mortality, 
underscoring the need for a comprehensive prevention strategy. The natural history of cervical 
cancer is known and provides a scientific basis for decisions regarding preventive strategies. 
Epidemiological evidence suggests that in resource-constrained countries, such as South Africa, 
screening programs be directed at women in their thirties with the aim of identifying and treating 
women with HSILs. Secondary prevention through organised cytology-based screening 
programs has reduced cervical cancer incidence and mortality in developed countries. This 
success has not been replicated in developing countries. Research on ways to improve cytology-















priority. Research is also lacking on how other screening tests, such as HPV testing and VIA, 
will perform as routine screening tests in real health service settings in developing countries.  
 
HPV vaccines offer great potential for primary prevention of cervical cancer. However, several 
challenges exist to the introduction of the HPV vaccine and limited formative research is 
available to guide vaccine introduction in developing countries. The prevalence of HPV types in 
South Africa will be important in assessing the possible magnitude of benefit from vaccines. 
 
Research, conducted mostly in developed countries, has shown that HIV positive women are at a 
higher risk of HPV infection and cervical cancer precursor lesions, but has produced inconsistent 
results on the association between HIV and ICC.  In developing a comprehensive cervical cancer 
prevention strategy, it will be important to determine the role that HIV plays in the risk of 
cervical cancer precursor lesions and cervical cancer.  
 
















Chapter 3: The South African context 
Chapter 3 provides information on the context of cervical cancer prevention efforts in South 
Africa. The structure of the chapter is as follows: 
3.1. Health and health care in South Africa 
3.1.1. The health system during apartheid 
3.1.2. Key changes in health care policy since 1994 
3.1.3. Current health system challenges 
3.2. History and experience of cervical cancer prevention efforts in South Africa 
3.2.1. Access to cervical cancer screening services 
3.2.2. Community knowledge, attitudes and practice 
3.2.3. Development of the current national cervical cancer screening policy 
3.2.4. HPV vaccines in South Africa 
3.3. Summary 
 
3.1 Health and health care in South Africa 
South Africa is a middle income country spending 8.6% of its gross domestic product on health 
(World Bank 2009). This health expenditure is similar to high income countries and higher than 
most other middle and low income countries (Table 3.1). Compared to other African countries, 
SA has a relatively well developed health infrastructure. However there is a disconnect between 
the investments in health and the health status of its people (Table 3.1). South Africa’s 
oppressive history has had a profound impact on health and health care delivery in the country. 
In addition South Africa has been severely affected by the HIV/AIDS epidemic - it has the 
world’s largest population of people living with HIV (UNAIDS/WHO 2009). Since the advent of 
democracy in 1994 there have been a number of bold health policy initiatives and reforms, 















Table 3.1: Health expenditure and health status in South Africa and selected high, middle 
and low income countries (2007) 
Country % of total gross 
domestic product spent 
on health 
Life expectancy at 
birth in years 
Infant mortality 





8.4 80 5 
Australia 8.9 81 5 
The 
Netherlands 
8.9 80 4 
Upper middle income 
South Africa 8.6 51 47 
Chile 6.2 79 7 
Botswana 5.7 53 44 
Lower middle income 
India 4.1 63 54 
Nigeria 6.6 48 91 
Vietnam  7.1 74 20 
Low income  
Tanzania 5.3 55 73 
Nepal 5.1 66 43 
Haiti 5.3 61 67 

















3.1.1 The health system during apartheid 
During apartheid Black South Africans were denied social, economic, political and health rights. 
Poverty, squatter settlements, the migrant labour system and the subordinate position of women 
created an environment favorable for the efficient transmission of sexually transmitted infections 
(STIs) (Kark 1949), including HPV. Apart from the favorable environment for HPV 
transmission, health services for Black South Africans were underdeveloped, including 
preventative services such as cervical screening. A notable feature of health services in South 
Africa has been fragmentation. Prior to the apartheid era health facilities were racially segregated 
and curative and preventative care were separated. In the 1940’s there was a realization that these 
divisions needed to be addressed and that a broader perspective on health was needed. The 
Gluckman Commission was appointed, by order of the governor-general, to review health 
service provision in the country (Gluckman 1970). The Commission was influenced by local and 
international developments in the field of social and preventive medicine. In 1945 the 
commission recommended the establishment of a unitary health service (Gluckman 1970). 
However, when the National Party took over in 1948 these recommendations were ignored and 
instead fragmentation was further entrenched. Ten ―homelands‖ were created for Black South 
Africans. By the mid-1980s the South African public sector health system consisted of 14 
different authorities: 10 Bantustan health departments, 3 ―own affairs‖ health departments for 
Whites, Coloureds and Indians and the National Department of Health. This resulted in 
duplication of services and wastage of resources. Each of these authorities also had different 
health policies and guidelines, with a general lack of overarching policy direction. Multiple 
incompatible health information systems were set up by the different health authorities and none 
provided health planning information (Bradshaw, Mbobo 1995). The emphasis in the health 
sector was on curative, tertiary urban health care. In 1992/93 only 11% of health expenditure was 
on primary health care, whilst 44% was spent on tertiary hospitals (McIntyre et al. 1995). Access 
to health services was significantly worse for those living in rural compared to urban areas. 
 
During the apartheid years private health care expanded.  Private sector health services were paid 
for largely through medical insurance schemes. Until the late 1970’s membership to these 















transfer the health care of White South Africans from the public to the private sector (Republic 
of South Africa 1967). By 1992/1993 the private health sector accounted for almost 58% of the 
total health expenditure, but served only 23% of the population (McIntyre et al. 1995). Although 
Pap smears were available in the private sector, in essence, only a minority of mostly White 
South African women had access to these services. While the country had state-of the-art high 
technology health facilities in the private sector, by 1994 based on international standards the 
country had an estimated shortfall of 600 to 1000 health clinics (McIntyre et al. 1995).  
 
During the apartheid years women’s health services consisted mainly of maternal health services 
and there was an emphasis on contraceptive services aimed at limiting population growth 
amongst the Black population (Cooper et al. 2004). There was no comprehensive reproductive 
health or cervical screening policy. In the 1990’s international conventions, such as the 1994 
International Conference on Population and Development (ICPD) in Cairo and the 1995 Fourth 
World Conference on Women in Beijing, expounded on the links between women’s reproductive 
health, women’s rights and socio-economic development, and emphasised the need for a 
broadened definition of reproductive health (United Nations 1994; United Nations 1996). At the 
same time in South Africa civil society organisations active in gender and women’s health began 
lobbying for the creation of locally appropriate reproductive health policies. 
 
3.1.2 Key changes in health care policy since 1994 
In 1994, the newly elected democratic government inherited a deeply fragmented inequitable 
health system. The vision of the new government was a unified national health system, 
integrating the public and private sectors. In 1994/1995 the fourteen health authorities were 
consolidated into one national and nine provincial departments of health.  In the South African 
Constitution (Republic of South Africa 1996), health was enshrined as a right and the 
government was mandated to provide access to health care services, including reproductive 
health care. In response to the constitutional mandates the Department of Health (DOH) 
increased access to services by eliminating user fees for public primary health care and all fees 















programme was set up in 1994, and by 1998, 485 new clinics were built and 248 existing clinics 
were upgraded to improve access to primary health care (Pillay 2001).  
 
In 1997 the DOH published a White Paper for the Transformation of the Health System in South 
Africa, which proposed a primary health care (PHC) approach, the development of a district 
health system (DHS) and the reduction of inequities (Department of Health 1997). Primary 
health care is seen as key in the plan to transform health services. A comprehensive integrated 
package of essential PHC services was developed in 2000 (Department of Health 2001). This 
package of services is meant to be provided to the entire population and to form the foundation 
of a unified health system. Lessons from other countries that have adopted a comprehensive 
primary health care approach suggest that key to success is a strong district health system (Rohde 
et al 2008). The development of the DHS, however, has been delayed by finalisation over local 
government boundaries and confusion over governance responsibilities.  
 
The new government embarked on a number of policy initiatives to regulate practices in the 
private sector. A moratorium was place on the building of private hospitals. The Medical 
Insurance Schemes Act of 1998 prescribes minimum benefits and prohibited risk rating 
(Republic of South Africa 1998). However, the resources located in the private sector have not 
been made available to the broader population (McIntyre, Gilson 2002). The new government 
had hoped to address this public-private inequity through implementing a National Health 
Insurance (NHI) scheme, but there have been intense debates about a NHI scheme. In 2009 a 
ministerial advisory committee was appointed to advise government on the development of policy 
and the implementation of a NHI scheme. Detailed proposals are expected in 2010/2011. 
 
The National Health Act, finally passed in 2003, provides the overall legal framework for the 
health system in South Africa (Republic of South Africa 2003). According to the Act the national 
DOH has the responsibility of policy formulation, whilst the provincial departments of health are 
responsible for implementation of national health policy, norms and standards. The Act (61 of 
2003) also formally established the DHS and District Health Councils (DHC). The DHS is meant 
to be the most decentralised structure of health governance and management. Both the district 















government is responsible for preventative and promotive services. Provision is made for 
provincial government to delegate health services to local government if they wish.  Three tiers 
of hospitals exist: tertiary, regional and district. The primary health care system includes the 
district hospitals, community health centres and nurse-driven clinics. 
 
A concerted effort has been made to redress past neglect of the health needs of poor women. The 
essential PHC package includes reproductive services and states that these services are to be 
provided in an integrated comprehensive manner (Department of Health 2000). Since 1994 many 
laws and policies affecting women’s health have been passed and show a concern for the health 
needs of women beyond their role as mothers (see Table 3.2). However there has been no 
















Table 3.2 Law and policies affecting women’s health 
Year            Policies and laws passed 
1994  Free public health services for pregnant women and children under the age of 6 
years introduced 
1995  Government ratifies the United Nations Convention on the Elimination of all 
forms of Discrimination Against Women  
1996  South African Constitution adopted 
 Choice on Termination of Pregnancy (CTOP) Act passed which provides the 
framework for legal abortion services 
1997  Maternal deaths made a notifiable condition 
 Patients Rights Charter launched 
1998  Population Policy introduced shifting focus away from population control 
 Domestic Violence Act passed prohibiting physical, sexual and emotional 
violence against women 
 Sterlisation Act passed. Only the consent of the woman requesting sterilisation is 
required 
2000  National Cervical Cancer Screening Guidelines introduced, stating that every 
woman is entitled to three free Pap smears (in the public sector) in her lifetime at 
10-year intervals, starting at age 30 
2001  National Contraceptive Policy Guidelines introduced, providing guidance for the 
provision of contraception 
2002  Government approves provision of HIV post-exposure prophylaxis for rape 
survivors 
 Prevention of mother to child  transmission (PMTCT) programme introduced 
country-wide 
2003  ART use in public sector approved 
2007  Sexual Offences and Related Matters Act passed, establishing a broader 
definition of rape 
2008  CTOP Amendment Act passed, further increasing access to abortion services 















3.1.3 Current health system challenges 
The implementation of the policy and programme initiatives described above has been sub-
optimal. The delays and difficulties in implementing the basic building block of the new health 
system viz. the DHS, have resulted in uncertainty in health service governance and in confusion 
regarding through which organisational structures to route programme implementation. Between 
1995 and 2005 health expenditure in the public sector has remained relatively stagnant 
(McIntyre, van den Heever 2007), making implementation of new programmes and policies 
challenging. In addition the health sector faces a crisis in terms of declining numbers of health 
personnel, particularly in the most disadvantaged rural areas (Wadee, Khan 2007; Daviaud, 
Chopra 2008). There has been a decrease in staffing capacity including professional nurses, who 
form the backbone of the cervical cancer screening programme. Reasons for the decline in health 
personnel include: a decreased in the production of nurses which is related to the lack of a human 
resource plan and the closing of nursing colleges as part of a cost-containment drive, provision of 
early retrenchment packages to nurses, emigration of health care providers and AIDS related 
illness ampng health care providers. The professional nurse-to–population ratio has decreased 
from 149 per 100 000 in 1998 to 116 per 100 000 in 2008 (Day, Gray 1998; Day, Gray 2008). In 
facilities with shortages of lower cadre health workers professional nurses often have to perform 
tasks meant for lower skilled workers, resulting in inefficient use of human resources (Daviaud, 
Chopra 2008). Maldistribution of nurses, poor skills mix at clinic level, increasing demands on 
primary care nurses and inadequate attention to nurses’ knowledge, skills and attitudes have all 
been identified as problems that hamper the implementation of health programmes (Kawonga, 
Fonn 2008; Coovadia et al. 2009). Leadership and management skills to successfully implement 
policies and programmes have been lacking (Coovadia et al. 2009). 
 
South Africa faces a quadruple burden of HIV/AIDS, communicable diseases, non-
communicable diseases and injury-related disorders (Bradshaw et al. 2003). Despite socio-
economic development in South Africa, the distribution of wealth and income in South Africa 
remains unequal (May 2000). The Gini coefficient for South Africa has increased from 0.56 in 
1995 to 0.73 in 2005 (a value of one reflects complete inequality while a value of zero reflects 
complete equality), making South Africa an extremely unequal society (World Bank 2009). 
















In the past 18 years the HIV epidemic has grown exponentially, with antenatal surveillance data 
showing an increase in HIV prevalence among women attending public sector antenatal care 
services from 0.7% in 1990 to 29.3 % in 2008 (Department of Health 2009). There are currently 
more than 5 million people with HIV/AIDS in South Africa, with women more severely affected 
than men. HIV/AIDS has increased the demand for medical care dramatically, with the public 
sector carrying the heaviest load. Between 1995 and 2000 HIV related hospital admissions 
increased 7-fold (Shisana et al. 2003). Apart from the increased resources needed to address the 
epidemic and the increased workload, health care workers are also infected by HIV. It is 
estimated that 17.5% of health workers in primary health care settings are infected with HIV, 
with younger workers (aged 18 to 35 years) more severely affected.  HIV-related absenteeism, 
nurse attrition and burnout amongst non-infected staff all impact on health service delivery 
(Shisana et al. 2004).  
 
 
3.2 History and experience of cervical cancer prevention efforts in South Africa 
3.2.1 Access to cervical cancer screening services 
Cytological screening has been available in South Africa for more than 40 years. However, in the 
public sector, screening was conducted for most of this time in an ad hoc manner and focussed 
on women attending family planning clinics. Women who did not attend family planning 
services had little or no access to Pap smear screening. The ad hoc cervical cancer screening 
resulted in over-intense frequent screening of a small proportion of the population, the exclusion 
of most women at high risk and very low population coverage. A study among rural women 
workers in the Western Cape showed that women attending family planning services were being 
'overscreened' with annual Pap smears, while women not on contraceptives were being excluded 
from cervical cytological screening (London 1993).  
 
Women attending family planning services tend to be younger women, who typically experience 















Province in 1989 showed that at that time almost one third of Pap smears were being done in 
women aged 15 to 24 years (Cronje et al. 1989). Similarly a review of Pap smears done between 
1988 and 1992 at the Groote Schuur Hospital Cytopathology Laboratory in Cape Town showed 
that there was an overemphasis on screening young women, whilst those in the age groups at 
which precancerous lesions are more likely to occur were considerably less likely to be screened 
(Bailie 1994a; Bailie, Barron & Learmonth 1995). The peak incidence of screening was in 
women aged 20 to 29 years, however, the highest proportion of smears showing CIN3 were in 
women aged 30 to 39 years.  A study conducted in one district in the Western Cape Province 
reported that only 37% of Pap smears taken in the public sector clinics in 1998 were in women 
older than 30 years (Smith, Moodley & Hoffman 2003). Although cervical screening is now 
meant to be available at all primary health care facilities, missed opportunities have been 
documented. For example only 2.3% of eligible patients attending a primary health care clinic in 
Worcester in the Western Cape Province were asked about a cervical smear (Mphatsoe, Pather 
2008).  
 
3.2.2 Community knowledge, attitudes and practice 
Little has been done in South Africa to raise awareness of the need for cervical screening either 
in the health services or at a community level. The importance of public education was 
demonstrated in the ―Project Screen Soweto‖ study (Leiman 1987). In the early 1980s, ―Project 
Screen Soweto‖ failed to recruit the planned 90 000 clients per year and the project was 
terminated after five years. The study authors suggested that one of the reasons for the failure 
was that the project lacked an appropriate awareness campaign and no consumer demand for 
screening had been created.  
 
A number of studies in South Africa have shown that women have limited knowledge of cervical 
cancer and Pap smears, and few have had Pap smears. A community-based survey in an urban 
area in Cape Town showed that only 37.2% of the participants had had a Pap smear (Bailie, Pick 
& Cooper 1996). The main reason for not having had a Pap smear was that the participant had 
not heard of it. Only 27.3% of women attending the gynaecological outpatient department at 















the authors reported poor communication about Pap smears by health care providers (Wellensiek 
et al. 2002). A study conducted in the Eastern Cape Province showed that 63.6% of women had 
heard about a Pap smear and knowledge was associated with older age, higher education level 
and higher parity (Lartey, Joubert & Cronje 2003). However, only 35.3% of all respondents had 
ever had a Pap smear. Among those that had heard of a Pap smear, the main reasons for not 
having one was that it is was not suggested by a health care provider and women feeling that it 
was unnecessary (40.4% and 37.8% of respondents respectively). More extreme findings were 
reported in a cross-sectional study conducted in a rural area in KwaZulu Natal in 2005 (Hoque, 
Hoque & Kader 2008). This study reported that 49% of women had heard of a Pap smear, 
however only 18% had ever had Pap smear. Among those who did not have a Pap smear, the 
majority said that it was because they were not ill, 12 % said it had not been suggested by a 
health care provider, and 6% cited bad attitudes of the health care provider as their reason for not 
asking for a Pap smear. Cervical screening is clearly not seen as a priority by health care 
providers, and there has been limited discussion on the importance of Pap smears with clinic 
attendees.  
 
Fonn, et al. demonstrated a receptiveness and responsiveness among women to attend health 
services to have a Pap smear once they are informed of the importance of cervical screening 
(Fonn et al. 2002). As part of a multicentre survey to determine prevalence of cervical 
abnormalities among South African women, a call was made to women in ten geographically 
defined areas in all provinces to attend the local health service for a Pap smear. Encouragingly 
70% of women attended health services specifically for a Pap smear, mostly as a result of 
information provided by clinic staff and the limited advertising that was part of the project. Of 
the 20 603 women who participated in the study 80% had never had a Pap smear previously 
(Fonn et al. 2002).  
 
3.2.3 Development of the current national cervical cancer screening policy 
Over the past four decades there have been a number of calls to introduce a cervical cancer 
screening programme in South Africa. In 1962 an editorial in the South African Medical Journal 
discussed the use of Pap smears and a plea was made to the government to ―cut red tape‖ so that 















mid 1970’s the Department of Health advocated that Pap smears only be done when the cervix 
appeared abnormal (Bloch 1979). Clinicians reacted strongly and called for this policy to be 
revoked (Bloch 1979; Grant 1982). Although Pap smears were theoretically available in the 
public sector, mostly at family planning and antennal clinics, little screening occurred. In 1990 
the South African Society of Obstetricians and Gynaecologists (SASOG), sent a proposal to the 
then Department of National Health and Population Development (DNHPD) recommending that 
a Pap smear screening programme be implemented in the country in which ―every woman in 
South Africa should have three free Pap smears at the ages of 25, 35 and 45 years‖ (Bloch et al. 
1994). Some academic debate on the ages at which the smears should take place followed, but 
the recommendation was ignored by the DNHPD (Bailie 1994b; Bloch et al. 1994; Fonn 1994).  
In 1991 the Women’s Health Project (WHP) was established at the University of Witwatersrand 
with the aim of developing policy proposals, conducting policy related research and lobbying for 
improvements in women’s health in South Africa. In preparation for a Women’s Health 
Conference that was held in December 1994, the WHP hosted a workshop on cervical cancer 
screening earlier that year (Klugman, Stevens & Arends 1995). At the workshop, attended by 
health service managers and providers, non-governmental organisations, community-based 
organisations, clinicians, researchers and academics, recommendations for a cervical cancer 
screening strategy were developed. It was recommended that a cervical cancer screening 
programme that targets older women be set up in South Africa and that women be offered three 
free Pap smears, at ten year intervals (Klugman, Stevens & Arends 1995). These 
recommendations served as the basis for the development of the current national cervical cancer 
screening guidelines. Post-apartheid in the late 1990’s, the NDOH identified cancer of the cervix 
as a national health priority. In 2000, the National Cancer Control Programme developed policy 
guidelines for the country stating that every woman is entitled to three free Pap smears (in the 
public sector) in her lifetime at 10-year intervals, starting at age 30 (Department of Health 2000). 
The policy aimed to screen 70% of women aged 30 years and older within 10 years. It was based 
on the best available epidemiological data of how to achieve the greatest reduction in cervical 
cancer, taking into account resource constraints and conforms to WHO recommendations for 
screening in resource-limited countries (World Health Organization 2002). The ultimate aim of 
the South African screening policy is to reduce cervical disease by detecting and treating pre-
















The South African cervical cancer screening programme is based on cytological examination of 
cervical specimens. Women are screened with conventional Pap smears usually done by 
professional nurses in primary care centres. Estimates showed that there were sufficient 
professional nurses in the public sector to screen all eligible women (Fonn 2003). However these 
estimates did not take into account the impact of the HIV testing and treatment interventions on 
health services and attrition of nurses in the public sector (Kawonga, Fonn 2008) both of which 
have placed massive additional burdens on nursing staff. 
  
Compared to other developing countries, South Africa has a relatively well developed cytology 
infrastructure. Pap smear slides are sent to the National Health Laboratory Service (NHLS), 
where they are read by cytotechnologists. The NHLS was established in 2001, amalgamating the 
various state laboratories and the South African Institute of Medical Research to form a single 
public health laboratory service in South Africa. It comprises approximately 260 laboratories 
countrywide. Local guidelines state that cytotechnologists can read a maximum of 48 Pap smears 
per day. Reviews of laboratory capacity indicate that there is a shortage of cytotechnologists 
(Fonn 2003; Michelow, Dubb 2003).  
 
Pap smear results are sent from the laboratory back to the clinics, and clients are informed either 
by the laboratory or by clinic staff if further follow-up is required. Clients with HSILs or 
persistent LSILs are referred for a colposcopic assessment. Colposcopy services are based at 
secondary and tertiary level hospitals.  
 
The DOH cervical cancer screening guidelines (DOH, 2000) does not make reference to HIV. 
Cervical cancer screening practices for HIV positive women vary widely in the public sector 
(Niederfahrenhorst 2008; Batra, Kuhn & Denny 2010). A study conducted at three HIV clinics 
based at primary health care facilities in the Western Cape reported that only 13.2% of HIV 















conducted at three ARV clinics in the same province reported that 59.1% of women had at least 
one Pap smear (Niederfahrenhorst 2008). In 2010 the HIV/AIDs directorate of the National 
Department of Health released clinical guidelines for the management of HIV positive adults 
which advocates Pap smears every 3 years in HIV positive women (National Department of 
Health 2010). The extent to which health care providers are aware of, and implement, this policy 
is unknown.  
 
3.2.3 HPV vaccines in South Africa 
The recent development of two prophylactic HPV vaccines (Harper et al. 2006; FUTURE II 
Study Group 2007), a bivalent vaccine that targets HPV16 and HPV18 and a quadrivalent 
vaccine that targets HPV types 16, 18, 6 and 11, offers potential for primary prevention of 
cervical cancer in SA. Both vaccines have been licensed for use in South Africa since March 
2008. However they are not yet available in the public health sector. Key opinions about the 




The above sections have detailed the context of health care in South Africa. Compared to other 
middle-income countries, South Africa has a relatively well-developed infrastructure. Post-
apartheid health sector transformation has been characterised by bold policy initiatives and a 
number of policies have been developed to address women’s health needs. However ther has 
been a gap between policy making and policy implementation. Moving from a fragmented, 
curative centred health system to a unified health system based on the comprehensive primary 
health care approach has proven to be challenging. The HIV/AIDS epidmic in South Africa has 
added another level of complexity. Cervical cancer has been recognized as a priority. The 















Chapter 4: Implementing a cytology-based cervical cancer screening 
programme in South Africa  
This chapter presents the methods, results and discussion for the first study objective i.e. to 
design, implement and evaluate health system interventions for public sector cytology-based 
cervical screening services in South Africa. Specific objectives were to improve the organisation 
and functioning of cervical cancer screening services; improve staff knowledge, attitude and 
practice (KAP), improve client KAP, increase service utilisation and Pap smear coverage. The 
chapter is structured as follows: 
4.1. Methods 
4.1.1. Study setting 
4.1.2. Study design 
4.1.3. Data analysis 
4.2. Description of interventions 
4.2.1. Re-organisation of cervical screening services 
4.2.2. Staff training 
4.2.3. Cytology services 
4.2.4. Referral process for clients with cervical abnormalities 
4.2.5. Record keeping and data collation 
4.2.6. Community awareness 
4.2.7. Study products 
4.3. Results  
4.3.1. Organisation of services 
4.3.2. Staff knowledge, attitudes and practices 
4.3.3. Cytology services 
4.3.4. Referral and feedback 
4.3.5. Record keeping and data collation 
4.3.6. Client knowledge, attitudes and practices 
4.3.7. Number of Pap smears and Pap smear coverage 




















4.1.1 Study setting 
This study was conducted between January 2001 and May 2003. Three of the nine provinces in 
South Africa were included in a study to design, develop and evaluate health system 
interventions for public sector cytology-based cervical screening services. In consultation with 
respective provincial health authorities, one sub-district site per province was purposively 
selected to represent different socio-economic, geographical and health system contexts in the 
country. The sites represented the different range of challenges that are likely to be experienced 
in various contexts within the country viz. urban vs. rural, varying levels of unemployment and 
varying levels of health system infrastructure. Table 4.1 summarises the socio-demographic and 
geographic characteristics of the three study sites. 
  
The clinics in Site 1 had been performing Pap smears for many years. Pap smears were and still 
are sent to public cytology laboratory (Laboratory A). Colposcopy services are provided by a 
tertiary hospital in Cape Town. Appointments for clients with an abnormal Pap smear that need 
to be seen at the colposcopy clinic are made by the cytology laboratory. The laboratory mails a 
letter with the colposcopy date directly to the client. A study conducted in 1998 showed that the 
majority of smears were being done on younger women (Smith, Moodley & Hoffman 2003). 
 
Clinics in Site 2 had also been performing Pap smears for many years. Pap smears were sent to a 
public sector laboratory (Laboratory B) until April 2002, thereafter, as part of the provincial 
restructuring plan, Pap smears were sent to another public sector laboratory (Laboratory C). 
Cytology results are sent back to the clinics. Clinic staff refer clients with abnormal Pap smears 
to a secondary level hospital, where, during the pre-intervention phase of this study, clients had a 
non-colposcopy-guided punch biopsy and those with a positive histology result were referred to 
the colposocpy clinic at a tertiary hospital in Johannesburg.  
 















Table 4.1: Socio-demographic characteristics and locations of study sites 
 Site 1 Site 2 Site 3 
Geographical 
location 
A sub-district located in the 
City of Cape Town 
Metropolitan Municipality 
(CCTMM), Western Cape 
Province  
Urban  area 30 kilometers 
from Cape Town 
A sub-district located in 
the Ehurkhuleni 
Municipality (EM) in 
Gauteng Province 
Urban area 45 kilometres 
from Johannesburg 
A rural area in 
Waterberg district in 
Limpopo Province  
Situated 250 kilometres 









72% of population have 
attained some high 
school education (i.e. 
grade 8  or higher) 
 
Unemployment rate of 
30% 
 
Housing: 94% formal, 6 
% informal 
 
2001 per capita 
expenditure on primary 
health care for CCTMM: 
R500 
Mostly Black (75%) 
population, with a 
minority Coloured and 
White population 
 
74% of population 
have attained  some 
high school education 
 
 
Unemployment rate of 
40% 
 




2001 per capita 
expenditure on primary 







48% of population 
have attained  some 
high school education 
 
 
Unemployment rate of 
30% 
 
Housing: 80.5 formal, 
6.6% informal, 12.9% 
traditional 
 
2001 per capita 
expenditure on 
primary health care 
for Waterberg: R190 
Catchment 
population 
280 000 230 000 202 000* 
No. of clinics 
included in study 
All 9 primary care clinics in 
the sub- district were 
included 
All 7 primary care clinics 
in the sub-district were 
included 
5 of 10 clinics in the 
district were included 
* In this Site, 5 clinics serving a population of 202 000 were included in the study. Distances between the 
clinics are far greater in Site 3 than in the other study sites. 















4.1.2 Study design 
A pre-and post-intervention cross-sectional study design was used. A number of health system 
and community awareness interventions were developed and implemented. Pre-and post-
intervention surveys were conducted and included: facility audits; staff KAP surveys, client KAP 
surveys and a review of laboratory and clinic records. The dates of the pre-and post-intervention 
surveys and of the implementation activities are outlined in Table 4.2 below. Activities in Site 3 
started approximately 6 months after those in Sites 1 and 2. 
 
Table 4.2: Study timeline 
Activity Date 
Pre-intervention assessments 
Health facility audit April - May 2001 
Staff KAP survey April - May 2001 
Clinic and laboratory record review May -  July 2001 
Client KAP survey April  2002 - July 2002 
Intervention implementation 
Staff training August 2001 – April 2002 
Re-organisation of services December 2001 
Introduction of Pap register May 2002 
Introduction of data collation sheets May 2002 
Introduction of referral and feedback forms July 2002 
Implementation of cytology request and report forms July 2002 
Community launches May 2002 - September 2002 
Post-intervention assessment 
Health facility audit November 2002 - March 2003 
Staff KAP survey November 2002 - January 2003 
Client KAP survey November 2002 - March 2003 
Clinic and laboratory record review March 2003 
















Trained interviewers conducted both pre- and post- intervention facility audits to obtain 
information on the organisation of cervical cancer screening services.  Interviews were 
conducted with facility managers at the 21 clinics included in the study, using a structured 
questionnaire. Interviewers also conducted a walk-though inspection and completed a facility 
check-list (Appendix A). Data were obtained on the organisation of Pap smear services, staffing, 
management and referral of clients with abnormal Pap smears, cytology reporting and 
turnaround times (refers to the time from taking a Pap smear to the time the Pap smear result is 
received at the clinic), record keeping, availability of Pap smear equipment and the availability 
of information, education and communication (IEC) materials.  
 
A pre- and post-intervention cross-sectional KAP survey was conducted among professional 
nurses to determine their knowledge and attitude to the screening policy, knowledge of cervical 
cancer, cervical cancer screening practices and management of clients with cervical 
abnormalities. The number of staff interviewed is shown in Table 4.3 below. The main reasons 
for staff not participating in the survey was that they were either ill, on leave or were on night 
duty.  In Site 1 a trained interviewer administered a structured questionnaire (Appendix B). In 
Sites 2 and 3, due to staff time constraint, questionnaires were self-administered. The pre-
intervention survey took place in the first year of the study (April- May 2001) and the post-
intervention survey 6 months after the interventions had been implemented (November 2002 - 
January 2003). In Site 3 the post-intervention survey took place over the end- of-year vacation 
period and more staff were on leave in the post- compared to the pre-intervention survey. 
  
 
Table 4.3: Number and percentage of staff interviewed 
 Site 1 Site 2 Site 3 Total 
Pre-intervention 51/62 (82.3%) 29/34 (85.3%) 31/32 (96.9%) 111/128 (87.5%) 
Post-intervention 40/49 (81.6%) 28/32 (87.5%) 22/33 (66.7%) 90/114 (78.9%) 
















A pre- and post- intervention cross-sectional survey was conducted among clinic attendees to 
assess client knowledge and attitudes concerning Pap smears and cervical cancer, and to 
determine Pap smear screening history. Sample size calculations were based on an expected 
increase of at least 6% in the proportion of women attending the health services who ever had a 
Pap smear after the interventions had been implemented. The required sample size with a 
significance level of alpha = 0.05 and power of 80% was 1024 for the three sites in both the pre- 
and post-intervention survey groups. Women were recruited from the general waiting area of the 
clinic. All women 25 years and older attending the clinic for any reason were eligible for 
enrollment. Systematic sampling was used and every 5
th
 woman in the waiting area of the clinic 
was selected to participate in the study. Trained interviewers collected data using a structured 
questionnaire (Appendix C).  The pre-intervention survey took place between April and July 
2002 and the post-intervention survey 6 months after the interventions had been implemented. A 
total of 1 121 and 1 118 women were interviewed before and after the intervention, respectively 
(Table 4.4) 
 
Table 4.4:  Number of clients interviewed per site 
 Site 1 Site 2 Site 3 Total 
Pre-intervention 445 341 335 1 121 
Post-intervention 449 341 328 1 118 
 
 
To evaluate screening and treatment services clinic records and cytology laboratory data were 
reviewed. Laboratory data were examined for the period January 2001 to December 2002, 
yielding information by clinic on the number of clients screened, their ages, the endocervical 
component of the Pap smears, and the occurrence of abnormalities. Pap smear coverage was 
calculated by dividing the number of new (not repeat) Pap smears performed on women in the 
target age by the total number of women of that age in the catchment area. Catchment population 
data was obtained from the relevant health authorities. 
 
Clinic Pap smear registers, which were one of the interventions introduced at each clinic, were 















the numbers of new or repeat smears done, the age of women screened, turnaround times and 
action taken for abnormal Pap smears. To answer questions about timely treatment for women 
with HSIL, Pap smear register data for women screened between July 1 and October 31, 2002 
(post-intervention period), were reviewed.  It was expected that clients with HSIL would be seen 
at the colposcopy clinic within 6 months. Client attendance at colposcopy clinics and hospitals 
through to the end of April 2003 (i.e. up to six months after being diagnosed with HSIL) was 
checked using colposcopy clinic records. Colposcopy and biopsy findings and treatment were 
recorded. No information on treatment and follow-up of client with HSILs was available from 
clinic records prior to the study. 
 
Research staff kept notes on service functioning during site visits and at meetings with providers 
and managers throughout the course of the study. Information on the extent to which intervention 
tools were being utilised was collected. 
 
Ethical approval was granted by the University of Cape Town, Faculty of Health Sciences 
Research Ethics Committee and the University of Witwatersrand Human Research Ethics 
Committee. Written informed consent was obtained from all study participants.   
  
 
4.1.3 Data analysis 
A health systems approach was used to assess the performance of the cervical cancer screening 
programme pre-and post-intervention. A performance evaluation typically involves measurement 
of indicators of provision (are the services available, accessible and of adequate quality), 
utilisation and coverage (Habicht, Victora & Vaughan 1999). Indicators that were used to assess 
the cervical cancer screening programme are shown in Table 4.5. The indicators selected were 
adapted from the list of performance indicators recommended by IARC (IARC 2005).This list 
was limited by data available from cytology laboratories, hospital registries. 
 
Data analysis was conducted using the statistical programme STATA 10.1 (STATA Corporation, 
College Station, Texas). Descriptive statistics (medians and proportions) were used to 















squared and Fisher’s Exact test in the case of small numbers and, medians were compared using 








 Number of clinics providing cervical screening services 
 Number of clinics adequately equipped 
 Number of clinics with client information (posters, pamphlets etc.) 
 Number of clinics using a Pap register 
 Number of clinics using appropriate referral, recall, and feedback systems 
Staff knowledge, attitudes, and practices 
 Knowledge of cervical cancer and screening policy 
 Attitudes to cervical cancer screening policy 
 Proportion of staff trained and able to perform Pap smears 
 Proportion of staff performing Pap smears  
 Proportion of Pap smears that have adequate endocervical component 
 Proportion of women with abnormal smears that are appropriately managed 
Cytology services 
 Number of laboratories using consistent and appropriate management 
recommendations 
 Average turnaround times for results 
Client knowledge, attitudes, and practices 
 Knowledge of cervical cancer and Pap smears 
 Sources of information  
 Attitudes toward screening  
 Proportion of clients that ever had a Pap smear 
Utilisation of services 
 Number of women attending  health services that ever had a Pap smear 
 Number of women with HSILs treated within 6 months 
Coverage 
 Pap smear coverage calculated as total number of new smears done in a year 






















4.2 Description of interventions 
Intervention development was informed by the results of the pre-intervention surveys. Common 
problems identified pre-intervention are outlined in Table 4.6. 
 
 
Table 4.6: Common problems identified in the pre-intervention surveys 
Area of service Issues 
Programme 
organisation 
 No Pap smear targets 
 Inadequate record keeping and client follow-up 
 Inadequate communication between clinics, laboratories and treatment 
facilities 
 Lack of equipment and client education materials 
Client 
recruitment 
 Low levels of community knowledge about Pap smears  
 Low Pap smear coverage  
 Missed opportunities for screening in clinics 
 Lack of information, education and communication materials 
Providers  Providers’ resistance to the national policy 
 Providers’ knowledge gaps (e.g. policy, natural history of cervical 
cancer, screening objectives, and management of clients) 
 
Cytology 
 Long turnaround times 
 No standardised terminology for cytology results 
 No standardised recommendations for client management, and use of 
outdated protocols, resulting in inappropriate management and/or staff 
confusion 
Colposcopy  Poor referral and feedback systems 
Health 
information 
 No data to assess client management 
 No data collection or collation 
 
 
In developing and implementing the interventions the research team adopted a participatory, 
capacity building approach. This approach seeks to empower providers though active 
participation in research and development activities, in problem identification and in developing 
solutions in relation to particular questions (Macaulay et al. 1999).  At the start of the study a 
steering committee, consisting of key role-players, was set up nationally and in each study 















task groups were also set up to guide the development of specific interventions. The 
interventions consisted of: re-organisation of cervical screening services; staff training; re-design 
of cytology request and report forms; improving the referral process for clients with cervical 
abnormalities; improving record keeping and data collation and a community awareness 
programme. Facility and programme managers were encouraged to coordinate the following 
components: 
 Screening services—prepare health facilities for screening services, ensure that 
appropriate equipment is available, and ensure that staff are trained to perform Pap 
smears 
 Cytology services—monitor and address turnaround times 
 Client management at the primary care level—implement standardised management 
guidelines for clients with abnormal Pap smears and establish mechanisms for informing 
clients of results and for tracking clients who need re-screening or referral for further 
management 
 Colposcopy and treatment services—ensure women’s access to colposcopy and treatment 
services where necessary, and establish mechanisms for referral to and feedback from 
these services 
 Client recruitment— establish an IEC programme to inform and educate men and women 
in the community about cervical cancer, as well as women utilising health facilities for 
other health concerns 
 Monitoring and evaluation—ensure that mechanisms are in place to collect and analyse 
key cervical screening data and to use indicators to further strengthen and inform the 
screening programme 
 
4.2.1 Re-organisation of cervical screening services 
A key element in planning is setting goals for the programme, specifically in terms of the target 
group, the proportion of the target group that should be screened (the coverage goal), and the 
screening interval. The goal for the national cervical screening programme is to achieve 70% 
coverage of women 30 years or older within the first 10 years of implementation. At the start of a 
cervical screening programme, managers need to estimate the number of women 30 years or 















subsequent 10 years. During the 10 years, managers will need to regularly monitor progress 
towards achieving this goal of 70% coverage of the target population. An annual screening goal 
is required to monitor progress. A tool was developed that enabled managers and providers to 
determine annual and monthly screening targets for each sub-district and clinic (Figure 4. 1). 
 
 Figure 4.1: Estimating screening goals for a cervical screening programme  
A. Total population in the catchment area (public sector users) 
A = 80% of catchment population (Assume 80% of people in catchment area use public sector facilities) 
 
B. Number of females 
B = 51% of A (Assume 51% of catchment population are female) 
 
C. Number of females 30 years or older 
 C = 38% of B (if data not available assume 38% of women are ≥ 30 years) 
 
D. Number of new Pap smears the district/region must do per year 
to achieve 70% coverage of the target group in 10 years 
D = 70% of C, then divided by 10 (70% average is the national goal) 
 
E. Number of new Pap smears the district/region will need to do per month 
E = D divided by 12 (It is more practical to work with monthly targets. E is the monthly target) 
 
 
In order to reach a cervical screening coverage of 70% in 10 years in women 30 years and older 
(step D in Figure 1 above), managers in all three study sites decided to screen 7% of the target 
population per year. This translated into a coverage goal of 7% of women aged 30 years and 
older per annum for the next 10 years.  
 
Research staff assisted facility managers in organizing services to meet these targets. Changes 
included increasing the number of rooms that could be used for screening, as well as increasing 
the number of days and hours on which screening would be provided and, where possible, 
establishing fast-track queues for clients returning for results. The latter is a separate queue for 
















An equipment and supplies audit form was drawn up to assist in determining equipment needs 
for the increased workload. The audit form compared the quantities of equipment available 
against the quantities required to cater for the anticipated workload. Where there was a shortfall, 
the manager took action to acquire addition equipment.  
 
4.2.2 Staff training 
The research team provided training for all clinic staff. Training for doctors and nurses was 
conducted in two phases. The first phase was directed at all doctors and nurses working in the 
clinics and focused on the epidemiology and natural history of cervical cancer, the rationale for 
the South African national screening policy and on the health system interventions that had been 
developed. In the first phase of training a total of 152 staff were trained in Site one; 29 in Site 
two and 31 in Site three. The second phase of training was directed at staff responsible for taking 
Pap smears and/or managing cervical screening services. This phase focused on Pap smear 
technique (theory and practical) and management of clients with abnormalities. The training 
approach differed slightly in each site, because of differences in staff availability, numbers to be 
trained, and local preferences for direct or ―training of trainers‖-type training. In the second 
phase of training 40 nurses were trained in Site one; in Site two 7 master trainers trained 21 
nurses and; in Site three 8 master trainers, trained 15 nurses. Staff training took longer than 
expected, not because large numbers of staff were to be trained but because training had to be 
phased so as not to disrupt services.  
 
Research staff also provided an orientation session for all other clinic support staff (receptionists, 
administrators, radiographers etc.), so they would be better able to support cervical cancer 
screening services. This two-hour training focused on what the cervical screening policy was 
trying to achieve as well as on how the support staff could become advocates for the women 
being screened e.g. by informing clients that Pap smear services were available at the clinic. A 
total of 93 support staff were trained: 64 in Site one; 16 in Site two and 13 in Site three. 
 
Materials developed for all training sessions were made available to the local, provincial and 















4.2.3 Cytology services 
The pre-intervention surveys identified the need for uniform cytology reporting and appropriate 
standardised guidelines for the management of abnormal cervical cytology within the South 
African context. To address this, a national consultative meeting was held with representatives 
from: the National, Provincial and Local Departments of Health, the South African Society of 
Clinical Cytology, the South African Institute for Medical Research, the National Health 
Laboratory Services and pathologists, clinicians and nurses. Based on this meeting and various 
discussions, the research team designed new cytology request and report forms. The forms 
clearly state the cytology results and have standard recommendations for client management, 
based on the New Bethesda System (NBS) (Solomon 2002), and adapted for the South African 
screening policy. Laboratory B and C began to use these forms to report cytology results. Staff at 
Laboratory A were reluctant to change the reporting format and management guidelines, but 
agreed to use the request and reporting forms for a six-week trial period in 2002 while 
simultaneously using their existing format. 
 
Research staff worked closely with staff at the three laboratories to encourage improved 
communication between the laboratories and primary care facilities and colposcopy services. The 
study did not have any specific intervention, such as increasing cytology staffing, which would 
have shortened the turnaround times for results. Laminated posters were developed for clinic 
staff, depicting the standard client management guidelines to be followed based on the cytology 
result. 
 
4.2.4 Referral process for clients with cervical abnormalities 
Interventions that were directed at improving the referral of clients with cervical abnormalities 
included: a module on management and referral of clients with cervical abnormalities which was 
a part of staff training, standardised recommendations on the cytology report form and a 
laminated poster for clinic staff describing standard client management and referral guidelines as 
an easy-to-use algorithm. In an attempt to improve communication between referral centres and 
primary care services, the research team facilitated discussions between staff at both levels, and 















4.2.5 Record keeping and data collation 
The pre-intervention survey indicated that none of the sites had a system for collecting, analysing 
and collating data to monitor and evaluate a cervical screening programme. A health information 
task team was set up at each site to indentify information needed by managers to monitor and 
evaluate the cervical cancer screening programme and mechanisms to collect the information. A 
paper-based clinic Pap register was developed to record data about each Pap smear performed. 
The register collects information on client contact details, the date the smear was taken, the Pap 
smear results and actions taken.  Data collation sheets were also developed to assist with 
production of monthly, quarterly and annual summary statistics that allowed for monitoring of 
services. These sheets summarize Pap register data and provide information on: the number of 
Pap smears per month, proportion of Pap smears in the target age group, proportion of Pap 
smears with an endocervical component, proportion of repeat Pap smears, and management of 
abnormal Pap smears. Programme and facility managers, as part of their managerial duties were 
responsible for data collation. Facility managers were also tasked to check on various aspects of 
the cervical cancer screening programme during facility supervisory visits. These included: the 
management of abnormal Pap smears, cytology turn-around times, feedback from colposcopy 
clinics and turnaround times for cytology results. 
 
4.2.6 Community awareness 
In each study site a task team was set up to develop and implement an IEC campaign to provide 
information and education in cervical cancer screening to potential clients in clinics as well as in 
the community. The teams included representatives from the health services, community 
organisations and non-governmental organiaations. A cervical cancer awareness campaign was 
launched in the three sites once the screening services at the health services had been established 
or strengthened (community launch in Site 1 in May 2002; Site 2 in June 2002; Site 3 in 
September 2002).  The launch took place at a community venue in each site and consisted of 
talks by experts as well as opportunities for community members to ask questions. The purpose 
of the campaign was to raise awareness about the screening services, publicise the availability of 
















The Site 1 IEC task team spearheaded development of a pamphlet and a series of three posters; 
these were then translated into local languages appropriate for Sites 1 and 3 (Afrikaans, English, 
Xhosa, SiPedi and SeTswana). The pamphlets and posters included information on: what 
cervical cancer and Pap smears are; who is at risk of acquiring cervical cancer, how cervical 
cancer can be prevented (through Pap smears), recommended age and frequency of cervical 
cancer screening and the need to return for results and further management if necessary. Site 2 
did not utilise these materials because IEC materials had already been developed by the local 
provincial health department. The posters and pamphlets were distributed via health facilities, 
non-governmental organisations, and community-based organisations and were displayed at 
health facilities, shops, taxi ranks, and other public places in the study sites. 
 
Local newspapers published articles and press releases developed by the IEC task team about 
cervical cancer and screening during, and soon after the launch. In each site one or more radio 
spots discussed cervical cancer and screening during and soon after the launch. Additionally, in 
Site 2, recorded messages were broadcast throughout the community a few days before the 
launch, using a public address system and a roving banner publicising cervical cancer 
prevention. 
 
In all three sites community health committees and community-based organisations indentified 
possible peer educators. These included existing health motivators, community leaders, and 
church elders. The research team trained a total of 50 peer educators: 20 in Site 1, 11 in Site 2 
and 19 in Site 3. Once trained, the peer educators distributed pamphlets and gave talks on 
cervical cancer within their communities. 
 
During the staff training health providers were encouraged to recruit eligible clients who were 
attending the health services for other health matters, to avoid missed opportunities for cervical 
cancer screening. 
 
4.2.7 Study products 
Based on lessons learned in training staff and in managing the implementation and evaluation 















(Cervical Health Implementation Project (CHIP) 2004b) and Volume II is a guide for trainers 
(CHIP 2004a). Besides providing overall guidance for programme managers, Volume I contains 
suggested client management protocols, client referral and feed-back letters, client tracking 
systems, tools for estimating target populations, audit forms for equipment and supplies, 




4.3.1 Organisation of services 
The tools to calculate Pap smear targets and assess equipment had been used by all clinics. 
Following the interventions there was an improvement in the availability of services (Table 4.7). 
There was an increase in the number of clinics offering Pap screening services (from 16 to 21 
clinics) and offering Pap smear services on demand i.e. without an appointment (from 7 to 16). 
Prior to the interventions none of the clinics offered a fast track system for clients to receive 
results and post-intervention 19 clinics offered this service. Overall the percentage of staff 
trained to do Pap smears increased significantly from 58.5% to 85.8% (p < 0.001), with the 
greatest increase occurring in Site 3 (13.8% to 77.4%). There was a significant increase in the 
number of staff doing Pap smears at all three sites, with an overall increase from 38.5% to 61.1%  
(p <0.001) 
 
Pre-intervention data showed that equipment availability varied between sites and clinics. In 
Sites 1 and 2, district health authorities helped to equip the clinics. In Site 1, the Provincial 
Department of Health designated special funds in 2002 for cervical screening equipment. In Site 
3, however, the situation improved only marginally during the study, despite clinic requests to 
district and provincial health authorities for equipment. At the post-intervention evaluation, in 
Site 3 one clinic still had only one speculum, most clinics only had one lamp for the whole 
facility. 
  
The availability of IEC materials improved post-intervention, with the majority of clinics having 
a poster announcing the availability of Pap smears. Pre-intervention only one of the 21 clinics 















available in any of the clinics. Post-intervention in Site 1 Pap smear posters were displayed in 
seven of the nine clinics, other posters announcing the general availability of Pap smears in five 
clinics, and smaller signs indicating screening times were present in eight of the nine clinics. Site 
2 had decided to use existing materials developed by the provincial health department. However 
the post-intervention assessment found posters in only two of the seven clinics and pamphlets in 
only four clinics. Staff reported that they had run out of stock and that further supplies were not 
available from the Department of Health. Six of the seven clinics in Site 2, however, had a notice 
informing clients that Pap smears were available. In Site 3 all five clinics displayed the cervical 
cancer posters and four of the five clinics had pamphlets; staff at the other clinic had run out of 
pamphlets and these had not been reordered.  
 
Peer educators reported concerted recruitment efforts after training. In the six months after 
training, peer educators, with little external support, reported providing information about 
cervical cancer, mostly in clinic waiting rooms and at community gatherings. Over a 6-month 
period peer educators reported making contact with 1 363 people in Site 1; 1 560 people in site 2 

















Table 4.7: Service availability 
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4.3.2 Staff knowledge attitude and practices 
In total 111 and 90 professional nurses took part in the pre- and post-interventions staff 
KAP surveys, respectively. For the most part these were the same, though fewer staff 
during the follow-up. Across the three sites, in both pre-and post-surveys the majority of 
staff interviewed were female professional nurses older than 35 years. In Sites 1 and 2, 
more than 90% of respondents had been qualified as a nurse for more than five years, 
which contrasted sharply with the comparatively less experienced staff in Site 3, where 
only 45% reported that they had qualified more than five years before. 
 
Table 4.8 shows an increase in staff knowledge of and improved attitudes toward the 
cervical screening policy after the interventions. Pre-intervention, the number of staff 
who knew there was a national cervical screening policy differed significantly by site. 
Staff at Site 1 were significantly more likely to be aware of the national screening policy 
compared to staff at Site 2 (90% vs. 66%, p = 0.007) and compared to staff at Site 3 (90% 
vs. 55%, p < 0.001). Pre-intervention there were no significant differences in terms of 
policy awareness between staff in Sites 2 and 3 (p = 0.399). In the post-intervention 
survey there were no significant differences in the proportion of staff aware of the policy 
between the three sites. Staff at all three study sites showed greater awareness of the 
policy in the follow-up survey and there was a significant overall increase between the 
two surveys in the proportion of staff who agreed with the policy (from 23% to 68%, p < 
0.001). Of those who disagreed with the policy, the main reason offered at both surveys 

















Table 4.8: Staff knowledge of and attitudes toward screening policy and Pap smear practices 
 
















































































































Data are n (%) 





















In the pre-intervention survey, overall, just over half of the participants had ever 
performed a Pap smear with significantly more staff in Site 1 performing Pap smears 
compared to staff in Site 2 (84% vs. 52%, p < 0.001) and staff in Site 3 (84% vs. 13%, p 
< 0.001). Staff at all three sites felt that more Pap smears could be done at the facilities. 
Pre-intervention in Sites 1 and 2 participants cited that the main obstacle to performing 
Pap smears was insufficient staff, whereas in Site 3 the main obstacle was a lack of 
equipment. Overall the proportion of staff who ever performed a Pap smear increased 
significantly in the post-intervention survey (56% to 86%, p < 0.001). Although the 
proportion of staff that ever performed a Pap smear in Site 3 increased post-intervention, 
this was still significantly lower compared to the post-intervention proportion of staff that 
ever performed a Pap smear in Site 1 (p < 0.001) and Site 2 ( p = 0.016). In the post-
intervention survey participants in all 3 sites mentioned staff shortages as the main 
obstacle for not performing more Pap smears. 
 
Nurses’ lack of understanding of how to manage clients with abnormal cytology results 
was recognised as a problem in the pre-intervention survey and in discussions with nurses 
during training.  At pre-intervention 35% of the participants in Site 1, 10% in Site 2 and 
none in Site 3 were aware of the correct management for a HSIL. As part of the 
intervention the recommended management approach for a client with a HSIL result was 
a clear ―refer for colposcopy.‖ In the post-intervention survey, nurses who had done Pap 
smears in the previous three months were asked to describe the management of clients 
with HSIL. Of the 58 nurses who responded, only 40 (69%) correctly stated the 
appropriate management for HSIL (63% in Site 1, 87% in Site 2, and 45% in Site 3).  
 
4.3.3 Cytology services 
Clinic staff at all three sites and laboratory staff at Laboratories B and C reported being 
satisfied with the new cytology request and report forms. Staff in Laboratory A used the 
request and report forms during a six week trial period and reported that the forms were 
easy to use. However the laboratory management indicated that it would not be possible 
to adopt the new forms until further discussions were held with the newly-formed NHLS, 
















Despite discussions with laboratory staff and encouragement of clinic staff to follow up 
with laboratories when results were not returned quickly enough, problems with long 
turnaround times persisted. In Site 1 in the pre-intervention survey, health managers 
reported that they waited 3.1 weeks, on average, to receive laboratory results. At the time 
of the post-intervention assessment this had increased to 5.6 weeks. Examination of Pap 
register data in Site 1 revealed that 5% of laboratory reports had not been received after 
four months, and that for those received, the average turnaround time was five weeks. 
Severe laboratory staff shortages were given as the reason for these increased delays. 
 
In Site 2 in the pre-intervention survey health managers estimated that smear results were 
available at the clinic in six weeks. When Site 2 began sending slides to Laboratory C, 
turnaround times were reduced to an estimated two weeks, primarily because Laboratory 
C had an established transport courier system that collected specimens from and 
delivered results to facilities. A review of the Pap registers in Site 2 clinics, however, 
revealed that the turnaround time in late 2002 was nine days, however, 9% of results had 
still not been received by clinics after four months. 
 
Health managers in Site 3 reported that turnaround times remained long, and that results 
were returned to the clinics in eight weeks. A review of Pap register data showed that 
almost one-fifth of results had had not been received by Site 3 clinics up to four months 
later, and of those received, the mean turnaround time was 6.3 weeks. 
 
Over the study period three different laboratories read cytology smears. The proportion of 
smears read in Laboratory A serving Site 1, that had endocervical cells varied each month 
between 65% and 88% (Figure 4.2). In Laboratory B which served Site 2 until March 
2002, 99% of smears (range per month, 96 -100% per month) had endocervical cells 
present. When Site 2 clinics began sending slides to Laboratory C (from April 2002), the 
percentage of smears with sufficient endocervical cells decreased to between 45% and 
86% per month. Laboratory B also served Site 3 and the percentage of smears with an 
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Note: Site 2 switched from Laboratory B to Laboratory C in April 2002. Site 3 used 




4.3.4 Referral and feedback 
The system for referring Site 1 clients to the colposcopy clinic at the tertiary hospital did 
not change over the course of the study, with the laboratory continuing to contact clients 
by letter about colposcopy appointments. The only change made was that laboratory staff 
recorded the date of the colposcopy appointment on the cytology report that was returned 
to the clinic. At one clinic, one of the professional nurses reported phoning colposcopy 
clients to reassure them, and at another, the staff reported sending an additional letter to 
clients to provide more information. Staff at other clinics in Site 1 reported that clients 
often came to them seeking clarification about the colposcopy appointment letter they 
















During the post-intervention assessment, none of the health facility managers or staff 
providing screening services in Site 1 reported ever having seen the feedback letters. 
However research staff did find feedback letters in client folders. The clinic administrator 
had filed them without communicating their contents to any of the nursing staff.  
 
In Site 2 staff reported using the standard referral letters for clients that needed further 
assessments at secondary and tertiary levels. To reduce unnecessary visits, research staff 
tried to persuade the provincial authorities to modify the referral pattern, so that clients 
would go straight to the provincial tertiary level hospital for a colposcopy assessment as 
the secondary level hospitals did not have colposcopy machines. However, this did not 
happen as provincial authorities felt they needed to address referral patterns for the 
province as a whole. Non-colposcopy-directed biopsies were discontinued at the 
secondary level hospital. Clients with abnormal Pap smears were assessed by a 
gynaecologist at the secondary level hospital and referred to a tertiary hospital. By the 
end of the study the originating clinics still did not receive feedback from the secondary 
or tertiary level hospitals. 
  
Although an agreement was reached during the study in Site 3 about referring cancer 
patients or those with HSIL directly to the regional hospital, staff mostly continued to 
refer clients to the district hospital, from where they were again referred to the regional 
hospital, causing a needless intermediary visit. Staff reported that they never received 
feedback from the referral hospitals.  
 
4.3.5 Record keeping and data collation 
Pre-intervention there was a lack of tools for data collection and collation. Post-
intervention there was a positive response to the introduction of the Pap registers. Pap 
smear registers were filled in correctly in all three sites and were being used by staff to 
track clients with abnormal Pap smears. However the data collation sheets were not being 
consistently used by all facility managers. Facility managers reported discussing cervical 
screening statistics at clinic meetings, however there were no reports or minutes of 
















4.3.6 Client knowledge, attitudes and practices 
The women interviewed in both surveys were most commonly in the health centre that 
day for general medical consultations or to accompany someone. Only 16 (1.4%) of the 
pre-intervention group and 22 (2.0%) of the post-intervention group were at the health 
service specifically for a Pap smear. The overall socio-demographic profile of women in 
the pre-and post-intervention surveys were similar (Table 4.9). The overall median age 
for women in the pre- and post-intervention group was 36 years (interquartile range 30 - 
45) and 35 years (interquartile range 29 - 44) respectively. In the pre-intervention group 
women in Site 2 were slightly older (median age 38 years, interquartile range 32 - 47)) 
compared to women in Site 1 (median age 36 years interquartile range 30 - 46) 
(Wilcoxon p-value = 0.015) and women in Site 3 (median age 34 years interquartile range 
29 - 41) (Wilcoxon p-value < 0.001). In the post-intervention survey there was no 
significant difference in the mean age between sites (p = 0.063). The overall education 
levels of women in the pre- and post-intervention surveys were similar. The majority of 
women in the pre- and post-interventions surveys were unemployed. The highest 
employment level was in Site 1 and the lowest in Site 3 in both the pre- and post-






















Table 4.9: Socio-demographic profile of clients 
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Changes in clients’ knowledge about cervical cancer are provided in Table 4.10. Overall 
although the proportion of women that had had heard of cervical cancer had increased 
post-intervention (50% to 54 %), this difference was not statistically significant (p = 
0.079). Similarly the proportion of women that had heard of Pap smears increased from 
52 to 56%, but this increase was not statistically significant (p = 0.065). Significantly 
more women in the post-intervention survey had knowledge about the cervical cancer 
screening policy. In both the pre- and post-intervention surveys clients in Site 1 had 
significantly higher knowledge of cervical cancer, Pap smears and the policy compared to 
clients in Sites 2 and 3.  In Site 1 knowledge levels increased significantly across all 
knowledge measures post-intervention, except for the proportion of clients that had ever 
heard of a Pap smear which was already high in the pre-intervention survey. In Site 2 the 
proportion of women who had ever heard of cervical cancer and the proportion that knew 
that cervical cancer can be prevented decreased significantly post-intervention (p  < 0.001 
for both measures). There was no significant increase in any of the knowledge measures 
in the post- compared to pre--intervention survey in Site 2.Women in Site 3 had very low 
levels of knowledge of Pap smears, cervical cancer and the cervical cancer screening 
policy in the pre-intervention survey and although there were significant increases in 
knowledge levels post-intervention, levels were still low.  
 
The proportion of women that ever had a Pap smear remained constant at 38% during the 
pre-and post-intervention surveys. Pre- and post-intervention, reported use of Pap smears 
was 78% vs. 74% in Site 1 (p = 0.134), 18% vs. 20% in Site 2 (p = 0.433), and 5% vs. 
8% in Site 3 (p = 0.141). Among women that had not previously had a Pap smear, two-
thirds of the women in Sites 2 and 3 and one-third of the women in Site 3, in both the pre- 
and post-intervention surveys said the reason for not having had a Pap smear was that 
they had never heard of a Pap smear. Once the interviewers had described and explained 
















Table 4.10: Clients’ knowledge about cervical cancer prevention 
























































Knows that national policy calls for first Pap smear 


















Knows that national policy states calls for Pap smear 





































































In both surveys women were asked if they had received information on Pap smears or 
cervical cancer in the preceding six months, from a variety of sources. Results are shown 
in Table 4.11. In the post-intervention survey a higher proportion of women reported 
having heard or seen cervical cancer information from all sources of information. 
Although these differences were significant, the majority of women interviewed in both 
the pre- and post-intervention surveys had not seen a poster or pamphlet; heard or read; or 
had discussions about cervical cancer and Pap smears. In the post-intervention survey 
posters, pamphlets and the radio were the most common source of information in Site 1, 
whereas the radio and health worker group talks were the most common in Sites 2 and 3. 
Although the proportion of individual discussions with health workers increased post- 






























Table 4.11: Source of information and discussions about Pap smears or cervical cancer in preceding six months 

























































































































































4.3.7 Number of Pap smears performed and Pap smear coverage 
In the three sites overall, the total number of Pap smears (new and repeat) performed 
increased from 1 964 in 2001 to 3 466 in 2002, with the majority of the increase 
occurring in the post-intervention period (from July 2002). In the pre-intervention 
phase 84% of Pap smears in Site 1 and 70% of the Pap smears in Site 2 were in the 
appropriate target age. In the post- intervention phase this increased to 94% in Site 1 
and 84% in Site 2. In Site 3 no Pap smears were being done in the pre-intervention 
phase and 88% of Pap smears in the post-intervention phase were in the appropriate 
target age. The number of Pap smears done per month for each site for 2001 and 2002 
is shown in Figure 4.3.  
 
   Figure 4.3: Number of Pap smears per month 
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In 2001, staff in the nine clinics in Site 1 performed 1 594 Pap smears, an average of 
132 per month. In the post-intervention period (July to December 2002) the average 
number of Pap smears performed per month increased to 246 per month, an 86% 
increase. Of these 76% were new (not repeat) smears. Clinics in Site 2 did 370 Pap 
smears in 2001, an average of 31 per month. In the post-intervention period this 
increased to an average of 91 per month, a 194% increase. Of these smears 90% 
















clinics of Site 3 prior to this study. For the period August to December 2002 staff 
performed 133 Pap smears, 96% of which were new (not repeat) smears. 
  
All three sites had set a target of screening 7% of the eligible women in their 
catchment populations per annum. Pre-intervention Pap smear coverage for the period 
January to December 2001 was calculated by dividing the number of new Pap smears 
done in that period by the target catchment population. In Sites 1 and 2 all 
interventions were only implemented by June 2002 and in Site 3 by July 2002. To 
calculate an annual post- intervention Pap smear coverage for a 1-year period, we 
assumed that sites would continue to perform the same average number of Paps 
performed per month as they did in the period July to December 2002 for Sites 1 and 
2 and August to December for Site 3, for a 1-year period. Pap smear coverage per site 
is shown in Table 4.12.  
  
 
Table 4.12: Pap smear coverage  
 
 Site 1 Site 2 Site 3 
No. of new 
Paps  
Coverage No. of new 
Paps 
Coverage No. of new 
Paps 
Coverage 
Pre-intervention 1 211 2.3% 333 0.9% 0 0% 
Post-
intervention* 
2 240 4.2% 962 2.1% 256 0.8% 




4.3.8 Referral of clients with HSILs 
Across the three sites, 28 women had a result of HSIL in the post-intervention period 
between July and October 2002 and all were referred for colposcopy (Table 4.13). 
Only 14 women with HSIL had a colposcopy assessment and/or biopsy within 6 




















Table 4.13: Referral and management of clients with HSILs 
 Site 1 Site 2 Site 3 Total 
Number of smears done in a 4-month 
period 
1 090 396 60 1 546 










Number of clients referred for further 
management 
19 6 3 28 
Number that attended colposcopy 
services within 6 months of Pap smear 
12 0 2 14 
Number in which the diagnosis of 
HSIL was confirmed by histology 





This study identified a number of challenges to public sector cytology-based cervical 
cancer screening in South Africa. It also demonstrated that significant improvements 
can be made through a multifaceted intervention. The three sites in this study were 
purposively selected. The infrastructural and socio-demographic situations differed 
between the sites but are likely to be representative of the main types of health 
settings in South Africa.  
 
The pre- and post- intervention study design is common in health system research as it 
corresponds to program evaluation activities. A limitation of the design is that without 
a control group it is difficult to be certain that changes can be attributed to the 
interventions. Due to research resource constraints in this study, it was not possible to 
include a control group. However, as there were no other cervical cancer screening 
















attributed to the research interventions. A limitation of the study is that the 
interventions took place over a fairly short period and evaluations took place soon 
after the interventions were introduced, results need to be viewed with this in mind. 
Although the study officially lasted two years, initial progress was slow, especially in 
Site 3, where services were being established for the first time. Training staff and 
developing IEC materials took longer than expected, so there was not enough time 
remaining in the study to support the services for as long as expected or desired. 
Funding constraints meant that follow-up staff and client surveys took place less than 
six months after all the interventions were implemented. Providers’ knowledge, 
attitudes, and practices were assessed a very short time after training and intensive 
support; this might have yielded more positive results than if the survey had been 
conducted later. The relatively lower response rate among providers in Site 3 was due 
to the post-intervention interviews being conducted during the end-of-year vacation 
period. This could have introduced bias if leave allocation was related to level of 
experience and knowledge of staff. 
 
Measures of community knowledge were based on surveys of clinic attendees. It is 
unlikely that the systematic sampling of clinic attendees could have introduced any 
bias, as queues in the waiting area were not ordered according to any pattern. 
However the women interviewed are likely to represent a sample of the population 
who are more likely to attend modern health facilities and possibly more likely to 
avail themselves to cervical screening. A more representative community-based 
sample might in fact show even poorer results in terms of improved cervical cancer 
KAP.  
 
Rather than setting up distinct data-gathering systems specifically for this research 
study, systems based in the health services were used. Although this made the data 
more visible to clinic staff, and offered the potential for data to be used for health 
service quality improvement, it also meant there was less control on data quality. The 
use of routine data systems illustrates the difference between efficacy (results under 
ideal conditions) and effectiveness (real conditions) of health system interventions.  
 
In managing a health systems research study, there is always a fine balance between 
















little and achieving negligible results. In this case, the intervention and the site support 
did not last very long and health service managers and providers were instrumental in 
developing the interventions. However the services were supported fairly intensively 
by the research staff over this short period, probably much more than would be 
expected in reality.  
 
As a result of the interventions cervical screening services became more available and 
many more women were screened. However, clinic staff were not proactive in 
recruiting clients for Pap smears. This was shown by the client survey which found 
that most women, once they were informed of Pap smears, were interested in having 
one, suggesting further potential for increasing coverage among general clinic 
attendees.  
 
As a result of the training more staff were able to perform Pap smears, and knowledge 
of and attitudes toward the cervical screening policy improved. The post-intervention 
assessments showed an increase in the proportion of women screened in the national 
screening policy recommended target age group.  However, knowledge gaps 
remained, especially with regard to the management of clients with abnormal Pap 
smears and post- intervention only 69% of staff who had performed Pap smears in the 
preceding 3 months correctly stated the appropriate management for HSIL. Although, 
in the short 4-month follow-up of clients with HSILs, we noted that all HSIL clients 
were appropriately referred by clinic staff for colposcopy, staff did not confirm client 
attendance at the colposcopy clinic.  
 
The presence of endocervical cells in the Pap smear indicates that the specimen has 
been collected from the transformation zone of the cervix (Solomon et al. 2002). It is 
often used to assess staff competence in taking good Pap smears and it is generally 
accepted that 80% of Pap smears taken should have an endocervical component 
present (Herbert, Johnson & Patnick 1995).  However, detection of endocervical cells 
is also dependent of the skill of the by cyto-technician in reading Pap smear slides 
(Roberson et al. 2002). In our study we noted a dramatic change in reported 
endocervical component when Site 2 changed the laboratory used in April 2002. This 
together with the considerable difference in the presence of endocervical cells 
















individual client implications. In this study we were unable to disentangle whether the 
lack of endocervical cells reported was due to a poorly taken Pap smear or from a 
poorly interpreted Pap smear. Further research into the accuracy of endocervical 
reporting is required so that appropriate corrective action can be taken. 
 
Also of concern was that only 44% of women referred for colposcopy after a cytology 
HSIL result were found to have high-grade disease. This was a very small sample and 
further research is needed on laboratory quality assurance and diagnostic thresholds.  
 
The turnaround time for clinics to receive Pap smear results from the laboratories 
continued to be long. To a large extent, this is a function of continued cytology staff 
shortages and limited recruitment to the field (Michelow, Dubb 2003). Poorly 
functioning administrative and transportation systems also contribute to this problem. 
The NHLS and respective provincial authorities need to examine these issues as a 
matter of urgency. Without investment in the training of new cytology laboratory staff 
and attention to strengthening systems for sorting and transporting specimens, an 
accelerated client recruitment drive would cause serious problems for the laboratories. 
 
 
Clients’ awareness of Pap smears and cervical cancer was very low pre-intervention, 
especially in Sites 2 and 3. Reasons for the decrease in client knowledge in Site 2 (i.e. 
the proportion of clients that had ever heard of cervical cancer and the proportion of 
clients that knew cervical cancer could be prevented) are not clear, but could be 
related to the fact that Site 2 had decided to use pre-existing IEC materials, rather than 
those developed by the study. Further, Site 2 also reported a shortfall in supply of 
provincial IEC materials. Overall the time and resources needed for the IEC campaign 
were high and the results were minimal. Although more women reported receiving 
information via the radio, posters and pamphlets post-intervention, this did not 
translate into an increase in the number of Pap smears among women interviewed, 
which remained constant at 38%. The proportion of women who had a Pap smear 
differed across the three sites both at baseline and post-intervention, with the highest 
proportion reported in Site 1 and the lowest in Site 3.These differences could be 
related to differences in the health care infrastructure and per capita expenditure 
















in implementing a cervical cancer screening program. The addition of an intervention 
to an already under-resourced area with poorly functioning health systems may not 
lead to the desired improvement in screening coverage unless pre-existing 
infrastructure weaknesses are addressed. 
 
The proportion of clients who reported receiving Pap smear information from 
discussions with the health provider during the post-intervention survey was very low 
(7%). Perhaps it was unrealistic to expect a larger change as the post-intervention 
survey was conducted after a relatively short intervention period. However, this does 
represent a considerable missed opportunity. Studies elsewhere have shown the 
importance of provider interactions in affecting health behaviour (Mandelblatt, 
Yabroff 2000; Miedema, Tatemichi 2003; Ogedegbe et al. 2005). Coverage could 
have been significantly increased if clinic staff approached women attending health 
facilities for any reason, discussed cervical cancer screening and offered them a Pap 
smear.  
 
Post-intervention staff at all three sites cited staff shortages as one of the barriers to 
doing more Pap smears. During the study period the number of professional nurses 
decreased from 130 to 113, and increasing demands were being placed on a shrinking 
workforce. The shortage of primary care nurses in the public sector health services 
has been recognised nationally (Day, Gray 1998; Day, Gray 2008; Kawonga, Fonn 
2008; Coovadia et al. 2009). Unless this crisis is addressed the successful 
implementation of a national cervical screening programme will be severely 
hampered. 
 
It is critical that women with HSILs are identified, referred and treated, as the 
majority of these lesions progress to invasive cervical cancer (Kinlen, Spriggs 1978; 
Chang 1990). Programmes need to focus every effort on ensuring that the women 
identified with HSILs attend colposcopy appointments. Although all women with 
HSIL seen over a four-month period were informed of the need to attend a referral 
facility, there still was considerable loss to follow-up in this population. Despite 
efforts to improve inter-facility linkages and establish feedback systems so that clinics 
know which of their clients fail to attend referral visits, these continued to 
















HSIL that were referred to colposcopy to confirm attendance. Poorly managed clinic 
administrative systems also meant that feedback letters from the colposcopy centre 
were being filed without staff having reviewed the contents. At the district and 
provincial levels, it was difficult to affect changes to referral and feed-back letters, 
reporting systems, and forms.   
 
Establishing well-functioning information systems are essential for successful 
programme monitoring and evaluation. At the clinic level the Pap smear registers 
were being used by staff to collect data on clients. However the data were not being 
optimally used to track clients with abnormal Pap smears. Data collation and use of 
data for programme monitoring by facility and programme managers also continued 
to be sub-optimal. This reflects a wider problem of limited information management 
capacity within the health system and is not restricted to cervical cancer prevention 
services (Coovadia et al. 2009). Managers had not detected or acted upon: the failure 
of clinics to meet monthly Pap smear targets, problems with follow-up of clients with 
abnormalities and poor feedback from colposcopy services.  
 
The South African cervical cancer screening policy requires that women with normal 
cytology results return for a repeat smear in 10 year intervals. Loss to follow-up will 
compromise the potential benefit of the cervical cancer screening strategy. Systems to 
track women and ensure they return for repeat Pap smears will need to be developed. 
 
A positive outcome of the study was that the interventions and manuals developed are 
being used by the National Department of Health to set-up and provide cervical 
screening services. The cytology request and reporting forms have subsequently been 
adapted and adopted by the NHLS. However cervical cancer screening programmes 
will not be effective in reducing cervical cancer mortality unless there is a high 
coverage of the target population (World Health Organization 1986; IARC 2005). 
Although the number of women screened post-intervention increased, none of the 
sites was able to meet their annual target coverage (7%). Perhaps the target was 
unreasonably high within the short time period that interventions were being 
implemented. The annualised coverage in the first year post- intervention was 4.2% at 
















women screened to reach an average coverage of more than 7% each year; in order to 
meet the national goal of 70% coverage within 10 years. 
 
Evidence suggests that implementing and re-organizing health programs is complex 
and requires multifaceted interventions and ongoing support (Grol & Grimshaw 2003 
2003; Grol & Wensing 2004). Developing systems to ensure access to high quality 
cytology-based services is a known challenge (Lazcano-Ponce et al. 1999; 
Sankaranarayanan, Budukh & Rajkumar 2001; IARC 2005). Our end results show 
that with health system interventions, cervical cancer screening service related outputs 
can be substantially improved. However cervical cancer screening coverage and 
follow-up of clients with HSIL was sub-optimal and, despite an IEC campaign, client 
KAP did not improve.  In our experience co-ordinating and linking the different 
service facilities, embracing shared goals, developing common protocols, defining 
areas of responsibility, and defining management goals and activities proved to be 
challenging tasks. This was due in part to competing health demands, but it was also 
due to bureaucratic inertia that impede all efforts to change the way things have 
always been done and to poor stewardship, leadership and management. These 
problems have been described elsewhere (Coovadia et al. 2009) and are not unique to 
the cervical cancer prevention programme. Although it has been suggested that 
alternate screening technologies, such as visual inspection with acetic acid or HPV 
testing be explored particularly in low-income countries, for any cervical cancer 
strategy to be successful in South Africa the more fundamental challenge is one of 
















Chapter 5: Preparing for HPV vaccination in South Africa 
 
This chapter presents the methods, results and discussion for the study objective: To 
understand key opinions about, challenges to, and opportunities for the introduction of 
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5.1.1 Study design  
A qualitative study was conducted in the Western Cape Province between February 
2007 and March 2008, to explore key opinions about, potential challenges to and 
opportunities for, HPV vaccination introduction in South Africa. Qualitative research 
has its origins in the social sciences but is increasingly being used in health service 
research (Mays, Pope 1995). It focuses on understanding how beliefs and perceptions 
influence behaviour, and is particularly useful in exploring a topic about which little is 
known (Pope, Mays 1995). In conducting this study an ecological conceptual 
perspective was utilised. This perspective recognises that individual health behaviors 
are influenced at different levels within a complex environment (Green, Kreuter 2005; 
McLaren, Hawe 2005). The ecological model provides a framework to collect both 
content-specific and contextual information. It allows for the integration of multiple 
levels and contexts in understanding complex health issues. Our enquiry was directed 
at three levels of influence: community, health service provider (institutional level) 
and policy (Table 5.1).  
 
The community level of enquiry included discussions with women who had children 
eligible for the HPV vaccine as they would be key in making decisions as to whether 
their child would or would not receive the vaccine. In addition these women would be 
aware of organisations and individuals likely to influence health making decisions in 
the community. At the provider level individuals who were involved in the following 
services were interviewed: reproductive, maternal, child or school health. The policy 
level of enquiry included policymakers as well as individuals likely to influence the 
policy-making process: managers and directors working in sexual and reproductive 
health, and women’s and child health at the provincial and national level; managers in 
the education directorates at provincial and national level; and academics and 
researchers in the fields of sexual and reproductive health, virology, infectious 
















Table 5.1: Levels of enquiry, study respondents and data collection methods 
Level of enquiry Respondents Data collection 
method 




Primary care nurses 
School health nurses 





Policy level Provincial  policy makers - Departments 
of Health and Education 
National policy makers - Departments of 







5.1.2 Study setting 
Three sites in the Western Cape Province were selected for the community and health 
service provider level of enquiry. The sites were selected to represent different urban 
and rural settings in the Province. Site A is a rural area located in the Breede Valley, a 
wine and fruit growing area 120 kilometers from Cape Town, and has a population of 
143 520 (67% Coloured, 20% Black and 13% White). Site A has an unemployment 
rate of 20% and 59% of the population have attained a Grade 8 or higher level of 
education (Statistics South Africa 2003). Site B, an urban area formally designated for 
Coloured South Africans, is located approximately 30 kilometers from Cape Town 
and has a population of 305 343 (84% Coloured, 15% Black).  It has an 
unemployment rate of 30% and 72% of the population have attained Grade 8 or 
higher level of education (Statistics South Africa 2003). Site C, is an urban area in a 
coastal suburb of Cape Town. It has a population of 21 843 (38% Black, 35% White 
and 27% Coloured). Seventy-two percent of the adult population have attained Grade 
















(Statistics South Africa 2003). Cervical cancer screening services are provided at the 
primary care clinics in all three sites. Only Site B has school health nurses. 
 
For the policy level of enquiry policy makers as well as individuals likely to have an 
effect on the policy making process were from the Western Cape Province or based at 
a national level. 
 
 5.1.3 Data collection 
For the community level of enquiry six focus group discussions were held; 2 in each 
of the three study sites. Providers in the six health care facilities assisted in 
purposively identifying and recruiting focus group participants (women with children 
aged 8 to 18 years). In total 43 female community members participated in the focus 
group discussion. On average, there were seven members per focus group (range 5 to 
10). The median age of the participants was 32.7 years (interquartile range 27-35 
years), 33 (77%) had completed some secondary school education, 26 (60.5%) were 
unemployed, and all had children eligible for HPV vaccination. Focus group 
discussions were conducted at either the health care facility or at a community venue 
(the church hall or public library).    
 
In-depth interviews with health care providers were undertaken in six public sector 
health care facilities (two in each of the three study sites) providing reproductive, 
maternal and child health and cervical screening services. Twenty four in-depth 
interviews were conducted with: 2 doctors, 17 primary care nurses (2 of whom were 
also clinic managers) and 5 school health nurses.  
 
A total of 26 in-depth interviews were held with policy makers and key policy 
informants. Study participants for the provider and policy level in-depth interviews 
were selected through purposive and snowball sampling (Bernard 1994). This enabled 
inclusion of individuals who had insights into the range of topics explored in the 
study.  
 
Interview guides for the focus-group discussions (Appendix D) and in-depth 
interviews (Appendix E and F) and were semi-structured, open-ended and probing. 
















views and experiences on current cervical screening policy and programmes; 
experience with vaccination programmes in general; views about primary prevention 
of cervical cancer through vaccination; knowledge of the HPV vaccine; issues related 
to HPV vaccine safety, efficacy and cost, target populations, possible opposition and 
optimal age for vaccination; service delivery issues and the role of the private sector. 
  
Interview guides and consent forms were piloted to check for language 
appropriateness and understanding. Experienced fieldworkers trained in qualitative 
research methods conducted the in-depth interviews and focus group discussions. 
Focus group discussions were conducted in the local language of participants. 
Interviews and focus group discussions were digitally-recorded and transcribed 
verbatim.  
 
All participants provided written informed consent. Participants were assured that 
individual data would be confidential and anonymity maintained. Ethical approval 
was granted by the University of Cape Town, Faculty of Health Sciences Research 
Ethics Committee and the Western Cape Province and City of Cape Town Health 
Departments granted permission to conduct the study at the selected research sites.  
 
 
5.1.4 Data analysis 
Data were analysed using a thematic analysis approach in which main themes and 
categories were identified and analysed within and across data (Boyatzis 1998; Braun, 
Clarke 2006).  Initial categories for analysing data were drawn from the interview 
guides. The transcripts were manually coded individually by members of the research 
team and then cross checked by another member of the research team for coder 
variation. Any coding discrepancies encountered were discussed and resolved by 


















Themes emerging from perceptions and insights expressed by respondents illustrate 
potential barriers to and facilitators for HPV vaccine introduction, and are highlighted 
below.  
 
5.2.1 Community level  
5.2.1.1 Knowledge and perceptions of cervical cancer 
All focus group participants had heard of cancer and the general view was that 
perceptions of cancer within communities had changed over time, making it easier to 
discuss cancer and to access help. 
 
Those years cancer was a sin.  One couldn’t just speak about their cancer then the 
other people gossiped.  It was almost like they had a big virus but today you can 
speak about it if there is a chance for you to be helped.  
(Focus group participant, Site C)  
 
The majority of focus group participants had heard of cervical cancer and some knew 
of relatives or friends that had cervical cancer. In discussions on the cause of cervical 
cancer some participants alluded to the association between sexual activity and 
cervical cancer, others suggested injectable contraceptives and sexual trauma as 
possible causes.  
 
Those people that have cervical cancer at a late age are sometimes people that where 
sexually active from a very early age and also if they have had many sexual partners 
and you don’t go for the pap smears it can happen that you at a later stage develop 
cancer and cancer is … and it can happen that the womb has to be removed. 
 (Focus group participant, Site A)   
 
Although some women had prior experience with having a Pap smear, in general the 
purpose and preventive nature of Pap smears was poorly understood. For some, Pap 
smears were associated with ―cleansing or scraping the womb‖, after exposure to a 
sexually transmitted infection or after being raped. Others viewed Pap smears as a 
















5.2.1.2 Views on vaccination as a means of primary prevention of cervical cancer  
All respondents were aware of the childhood immunisation programmes and had 
positive attitudes toward vaccination as a prevention tool. None of the focus group 
participants had heard of HPV or the HPV vaccine. Once basic information about 
both the link between HPV and cervical cancer and the HPV vaccine was provided by 
the interviewer, a positive attitude emerged from the groups towards this new product. 
Focus group participants reflected on the vaccine’s potential for a future generation of 
women and girls. 
 
If it can improve the future for all our daughters then it is a good thing.  In the past 
we never knew about things like this and a lot of women’s reproductive organs were 
removed because they contracted cancer.  So I think it is a good thing. 
 (Focus group participant, Site B) 
 
 I have one daughter and I have to go and tell her what I heard here and I must tell 
her the reason why she should have that injection.  It’s for her health and her own 
good.  If she is not going to do it now and at a later stage when she becomes sexually 
active and she gets the germ from another person or she transfers it then it is for their 
own health if they have it… (Focus group participant, Site A) 
 
Some participants did not understand that the currently available HPV vaccines are 
prophylactic, not therapeutic, and enquired about the vaccine as a means to protect 
themselves against cervical cancer. When it was explained by the interviewer that the 
current vaccines need to be given prior to the onset of sexual activity, respondents 
suggested vaccinating children from the age of 9 years. This was related to 
perceptions of early onset of sexual activity in the community. 
 
I will actually insist on it – the vaccine that you are speaking about especially for the 
children of the age 9 because I, as a mother, if I look at our community… the children 
in our community are very sexually active because they are already starting at the age 
of 10 and 11, they start with boyfriends and things like that. Prevention is better than 

















Most community respondents’ felt that boys and girls should be vaccinated as this 
would have a greater mutual benefit.   
 
Because men today have lots of women and maybe the girl is not as active as the man  
and now he comes from a lot of women and maybe he comes and gives that to his  
steady girlfriend.  I think it is something good to be given to them both for their 
protection. (Focus group participant, Site C) 
  
A few community respondents had questions around the quality of the vaccine that 
would be used and concerns were raised that a cheaper, inferior vaccine could have a 
negative impact on fertility as this interchange suggests:  
  
 Many a time we use vaccines that are not on the same standard as first world 
countries even private vaccines and government vaccines in South Africa are totally 
different.  Are they going to give us a cheaper vaccine with more side effects which we 
only see in 30 years and anything to do with the womb?  Is it going to affect fertility 
later on in the child’s life?  That is something I would be a bit conscious about, a bit 
scared. (Focus group participant, Site B)  
 
Yes, maybe the women can become sterilised because of that injection and they can 
perhaps never have children again.  These are things that will be discovered.  
(Focus group participant, Site B)  
 
Many community participants wanted the vaccine to be free like other childhood 
immunisations or available at low cost. 
 
It should be free.  Even if the government thinks about it - it is easier to give the three 
injections than to treat cancer later on because to treat cancer it is very expensive in 
the hospitals….The private hospitals are very expensive but it should be free.  It 
would be cheaper for the whole country if it was given for free.  

















5.2.1.3 Possible opposition to the HPV vaccine 
Focus group participants did not feel that that having the HPV vaccine would be 
perceived by adolescents as permission to engage in sexual activity. In discussion on 
possible opposition to the HPV vaccine, participants commented that some parents 
and church groups may object to HPV vaccination if it were associated with sexual 
activity and STIs. Community respondents suggested marketing the vaccine as a 
prevention method against cancer rather than against a STI. Respondents pointed to 
the role of women’s organisations and non-governmental organisations in preparing 
the way for the HPV vaccine.  
 
5.2.1.4 HPV vaccine delivery 
Community respondents mentioned both clinics and schools as possible routes for 
HPV vaccine delivery. Health care clinics were often named as the most suitable 
location for the distribution of the vaccine as ―most people come to the clinic with 
their children to receive other immunisations.‖ Other participants expressed support 
for delivery through schools to ensure coverage for all and to dovetail with the life 
skills school curriculum.  
 
5.2.2 Provider level 
5.2.2.1 Views on current cervical screening policy and programme 
Most health care providers interviewed were aware of the national cervical screening 
policy. However a number of providers did not understand the rationale for the 
current policy and commented that starting cervical screening at the age of 30 years 
and at 10 yearly intervals, as the national guidelines suggest, was not optimal to 
ensure cervical health.  
 
I’m concerned about the women younger than 30 years, that’s a concern for me,  
because sometimes you do, if they fall pregnant or some, some reason, maybe they  
have a VD, a vaginal discharge or some other reason and then the doctors investigate  
and then it ends up being cervical cancer.  We had one case like that a couple of  

















Providers felt that the current cervical cancer screening policy had not taken the 
HIV/AIDS epidemic into consideration and suggested that HIV positive women 
should be screened at a younger age and more frequently. A few providers were 
misinformed about the national policy, for example: 
 
What I heard of the original policy was that women had to be screened every 10 
years, and then they reduced it to every 5 years, and now I’ve heard that women are 
to be screened every year… in their reproductive years that would be between the 
ages of 14 and 45. (School nurse) 
 
Providers were asked about challenges to implementing the current cervical cancer 
screening policy. Clinic managers mentioned low staff morale and heavy workloads 
as barriers to implementation.  
 
You get a lot of resistance from the clinic staff, because they see it as extra work, so 
you had to work relatively hard on motivation, to motivate sisters as well about the 
policy… (Clinic manager)   
 
Some providers mentioned that more needs to be done to educate women about Pap 
smears. A comment by one provider confirmed the views expressed in the focus 
group discussions that many women consider Pap smears a means of preventing 
infection. Providers also mentioned difficulties with getting clients to return for 
management of abnormal Pap smears. 
 
A lot of women aren’t aware, and there’s an incorrect perception, women come here 
asking for a Pap smear because they have got an infection.  They don’t look at Pap 
smears as a cancer screening tool, they look at it as I’ve got a problem and I need a 
Pap smear, so I think a lot more needs to be done as far as educating people.(Primary 
health care nurse) 
  
5.2.2.2 HPV vaccine as a method of cervical cancer prevention 
A few providers working in reproductive health services had limited knowledge of the 
HPV vaccine, however the majority of providers interviewed had not heard of the 
















cervical cancer had been given by the interviewer, health service providers were in 
general supportive of the vaccine.  
 
A few health service providers raised questions about the HPV types in South Africa, 
and the likely impact of the vaccine on cervical cancer rates.  
 
Is it protecting against the strains that we have here… because you say it’s two and 
here are, I know that there are more than two, that are carcinogenic strains.  So I’m 
not so sure whether, I mean we’ve got the same strains, so whether it will be worth 
our while, you know, to give it (Family medicine doctor) 
 
Providers felt that the age at which to initiate vaccine should be determined by the 
median age of sexual activity, which was considered to be between 9 and 15 years.  
Providers had mixed views on whether boys should be included in a vaccination 
programme. Some felt that saw vaccinating boys as a means of complete eradication 
of the virus. Others pointed to difficulties with attracting males to the health services  
 
I don’t know how receptive they’re[boys] going to be to you know – reproductive 
health has always been focused on females more, then we have to have a whole mind 
set about, and reasons why, education as to why it is necessary, because it[HPV 
vaccine] can protect, you know, them. So I think it would be very difficult… (Clinic 
manager) 
  
Providers raised questions about side-effects, how the vaccine would have to be 
administered and efficacy of the vaccine. A few providers specifically mentioned that 
parents would want to know about the effect of the vaccine on fertility. 
  
The side-effects, nothing is 100%, the community they would worry that the vaccine 
will make their children barren…. will it? (Primary health care nurse) 
 
5.2.2.3 Possible opposition to the HPV vaccine 
The majority of the health care providers did not anticipate opposition to the 
introduction of the HPV vaccine from parents. Some providers thought that religious 
















promiscuity, but felt that this could be countered by providing information about the 
long term health benefits of the vaccine in preventing cervical cancer.  
 
5.2.2.4 HPV vaccine delivery 
Delivery through schools was considered by many providers to be appropriate in 
terms of accessing the target population. Respondents also pointed to the role of the 
school curricula (particularly life skills) in assisting with educating children about 
protection from HPV and other sexually transmitted infections. However, a lack of 
human resource capacity was considered a potential barrier to delivery through 
schools. Some respondents recommended that a programme be created through a joint 
effort of schools and clinics to ensure effective vaccine roll out. 
 
The school nurses are at the moment, to my knowledge, they’ve got a high case load 
 and I don’t think that they’re going to be very happy accepting an extra project like 
 this and  so human resources is going to be a very big issue (Clinic manager) 
 
Health service providers recounted the difficulties they had in reaching adolescents 
and most had reservations about HPV vaccine delivery through adolescent clinics. 
Providers also mentioned that in their experience adolescents who attended youth 
clinics were already sexually active, therefore youth clinics would not be suitable in 
reaching the appropriate target group. 
  
Teenagers don’t want to come to the clinic for those things. We are having a problem 
with family planning, we even tried another project to try to attract them, that we are 
having a special clinic for them you know, on Fridays, anything for family planning 
and voluntary counseling and testing services but, I’m telling you, that they don’t 
want to come (Primary health care nurse).  
 
5.2.3 Policy level 
5.2.3.1 Views on current cervical screening policy and programme 
Policy key informants expressed concern that the current cervical cancer screening 
policy had not considered the effect of HIV on cervical cancer. Many respondents 
















time interval. However, respondents were also mindful of the impact more frequent 
screening would have on the health system. 
 
But now with HIV and AIDS the compromised immune system can speed the 
progression of HIV and AIDS ...what would the effect of cervical cancer also have on 
a patient who’s already immune compromised.  So in that instance, it might 
necessitate reducing the period, the 10 year interval between the patients… (National 
Department of Health: Women’s Health Programme) 
 
Discussion on the current cervical screening policy and programmes led many policy 
makers to speak more generally about the structural constraints endemic to the 
healthcare system. Human resource shortages, patient education and lack of referral 
centers were mentioned as key barriers to implementation of the current cervical 
cancer screening programme.  
 
But practically it’s impossible, looking at the resources that you have,  go to one 
clinic where you have only one nurse, automatically that nurse wouldn’t be able to do 
it and they would give priority to the acutely ill patients as opposed to doing the 
screening, you know, and then you book the patient, they don’t turn, they don’t come 
back and you must understand, there’s a lot of education that it still needs to go into 
that, making people aware how important that is, because they do the bookings, but 
people don’t turn up.  So can you see, so there are many lost opportunities, we would 
be doing better than we do now. 
 (Provincial sexual and reproductive health programme manager)   
 
Half the screening programme is extremely flawed, it’s a policy, which if it were 
properly implemented and had 80% coverage of the target age group, would have an 
impact on cervical cancer prevention, but we’re nowhere near there, we haven’t got 
anywhere near the correct coverage, we’re using cytology as a screening test which is 
okay, but it’s got lots of problems and particularly in low resource settings… 
(Academic/Clinician) 
 
When you find an abnormal smear, there’s nowhere to send the lady, I mean there is 
















problem you see.  So if you can prevent it by vaccination, to me it’s much, much better 
than having a system where you have a health system that’s not working properly 
(Researcher)  
 
5.2.3.2 HPV vaccine as a method of cervical cancer prevention  
Policy key informants had heard of the HPV vaccine and expressed strong support, 
viewing it as an important adjunct to existing cervical cancer prevention strategies as 
shown below.   
 
I think it’s excellent, really, because we have an opportunity to prevent the majority, 
the majority of cervical cancer. I think there’s great opportunity in this vaccine.  The 
only draw-back is that South Africa has such a backlog of women who have already 
been exposed to human papillomovirus and the only way we can prevent it in those 
women, and I’m sure there’re loads of them out there is by doing Pap smears or 
screening and so that still needs to happen and so, if South Africa introduces the 
vaccine, we’ll have to have Pap smear programmes or screening programmes on-
going for quite a long time (Public health specialist) 
 
Similar to providers, many policy makers felt that the age at which to initiate vaccine 
should be determined by the median age of sexual activity. Researchers and 
academics highlighted that an additional consideration in deciding on the optimal 
target age group is immunological response. It was mentioned that pre-adolescents 
had a stronger immune response than adolescents and for this reason a vaccination 
programme should focus on pre-adolescents. 
 
Once you become sexually active, HPV enters the picture, is pretty much the take 
home message.  So you’ve got to do it before then for it to be effective, so probably 
younger than 15, towards 12 and that’s also probably where it’s going to have, from 
an immunological perspective, a  more robust response. That’s going to be required 
to sustain the population level impact and the individual benefit 
(Physician/Researcher)  
 
Respondents had mixed views on including boys in a vaccination programme. Some 
















stage Others pointed to the benefit of protection against anogenital warts if the 
quadrivalent vaccine is used, and the added benefit of herd immunity. 
 
So, yes it can protect boys against types 6 and 11, but they count probably for less 
than 75% I would guess, of the warts in men, so it’s not going to protect against all.  
You also have the second benefit you get, is that you reduce the transmittance to the 
women, of 18 and 16 as well, the men obviously if they were vaccinated, would not get 
those two common oncongenic ones, therefore if they have sex with someone who’s 
not been vaccinated, the woman hasn’t yet received her vaccine, then she may be 
protected through the vaccination of the man (Researcher/STI clinician)  
 
Some policy makers felt that they required more information on the vaccine efficacy 
and side-effects. Questions on the safety of the vaccine in HIV positive individuals 
were spontaneously raised. 
 
What we needed to know is their safety amongst HIV infected patients given the high 
prevalence of HIV in our country and we thought of, giving it okay from 9 it would be 
safe, but we could be having 9 year olds who are already HIV infected, maybe from 
mother to child transmission ((National Department of Health: Women’s Health 
Programme)  
 
When discussing the HPV vaccine as a method of cervical cancer prevention, most 
policy makers spontaneously raised concerns about cost.  Policy makers mentioned 
that the government was considering rolling out the pneuomococcal and rota-virus 
vaccines in the public sector, both expensive vaccines, and felt that introducing the 
HPV vaccine in the public sector would be unaffordable. Researchers and academics 
suggested that a reduced price be negotiated with the vaccine manufacturers.  
 
5.2.2.3 Possible opposition to the HPV vaccine 
Many policy informants anticipated some opposition from religious groups that 
generally oppose vaccines was to be expected. Some mentioned that the ―negative 
reaction of the Christian right in the USA to the HPV vaccine‖ could influence 
religious groups in South Africa. However, most respondents felt that parental and 
















suggested marketing the vaccine as a ―cancer vaccine‖ rather than a ―STI vaccine‖ as 
a means of minimizing opposition and referred to past experiences with the Hepatitis 
B and the introduction of the HPV vaccine elsewhere.  
 
Hepatitis B is also sexually transmitted, nobody ever talks about that side of it at all, 
they never talk about well let’s vaccinate our kids because they might get Hepatitis B 
when they become sexually active, but it’s a reality, especially in South Africa with 
the high carrier rates, so I think that’s a good thing to look at… (Researcher) 
 
To my understanding there’s been a lot of outreach by the various pharmaceutical 
companies to those groups to kind of alleviate any concerns and I think they’ve been 
relatively successful in saying this is a cancer vaccine. It’s not about STI’s, but 
protecting young girls from cervical malignancy that’s highly prevalent, it’s 
preventable now with this vaccine and I think that’s a tactic that can be successful 
(Clinician) 
 
The media and organisations such as LoveLife and Soul City were mentioned as 
potential sources of facilitating introduction of the HPV vaccine.  
 
5.2.3.4 HPV vaccine delivery 
Respondents had differing views in terms of who should manage the HPV vaccine 
programme. The Expanded Program on Immunization (EPI) was considered by some 
policy informants as a suitable location due to extensive experience with procuring, 
managing and monitoring vaccine delivery.  
 
I strongly feel it should be under the EPI where all vaccines are stored and looked 
after.  Because if you’re going to start, get a new lot of people looking after vaccines 
again, then it’s going to be another disaster, so rather with people who should be 
knowing about that – vaccine management and vaccine, the cold chain management is 
crucial (Provincial child health programme manager) 
 
However, some respondents were concerned that the EPI traditionally was targeted at 


















I would be concerned about just labeling it EPI, because I think EPI is, traditionally 
is a sort of baby, under 5’ , and I’d be worried that if we kick it to EPI and then wipe 
our hands and you know, feel like the job’s done, it won’t get done (Academic)  
 
A maternal and child health manager referred to the planned introduction of the 
combined diphtheria and tetanus vaccine at age 12 by the EPI and suggested that the 
HPV vaccine could be administered in tandem with this vaccine.     
 
For the most part policy informants felt that adolescent health had been neglected in 
South Africa, and that distributing the HPV vaccine at youth and adolescent clinics, 
which were few in number and located only in urban areas, would result in limited 
coverage.  However some policy informants felt that a HPV vaccine would help 
prioritise adolescent health in the country and argued for distribution via strengthened 
youth clinics. 
 
Most policy makers felt that the target population would be best accessed through a 
school delivery system. However many also pointed out that the school health system 
would need considerable strengthening to achieve adequate coverage. Department of 
Education respondents felt that the vaccine could be delivered through schools, but 
that this would require an increase in human resources, specifically school health 
nurses. Further it was suggested that the vaccine be accompanied by educational 
messages which could be delivered though the life-skills orientation curriculum.  
 
Respondents were asked to comment on the possible role of the private sector with 
regard to uptake of the HPV vaccine. Many policy informants mentioned that general 
practitioners (GPs) see a broad range of patients throughout the life cycle and could 
be an important source of access to the HPV vaccine. In addition it was mentioned 
that private health care providers generally form a rapport with their patients and this 
would be valuable in promoting a new product like the HPV vaccine. Others felt that 
the private sector would play a minimal role in promoting the vaccine as most medical 
insurances do not cover vaccines and that vaccination is traditionally the domain of 

















Some respondents pointed to the possible role of pharmacies in increasing access to 
the HPV vaccine, mentioning the increasing role pharmacies are playing in childhood 
immunisations and delivery of contraceptives. A policy informant reflected on the 
role of HPV manufacturing companies in driving the process and cautioned against 
being ―seduced‖ by drug companies at the expense of continued secondary prevention 
measures such as Pap smears.   
 
 
5.3 Discussion  
This is the first study undertaken in South Africa exploring key opinions about HPV 
vaccination and provides important insights into introduction and acceptability issues. 
Cervical cancer was perceived as a priority health condition and there was general 
support for the HPV vaccine at all three levels of enquiry. For many policy informants 
and providers an overriding concern was the overextended health care system with 
limited capacity to provide adequate public sector cervical screening services. The 
need for an adjunct product to prevent cervical cancer resonated strongly with all 
respondent categories.  
 
This study was conducted just prior to the licensing of the HPV vaccine in South 
Africa, and not surprisingly knowledge about the vaccine was limited, particularly at 
the provider and community level. Studies in developed countries have also reported 
poor levels of knowledge of HPV and the HPV vaccine among health providers, 
community members and policy makers (Sherris et al. 2006; Zimet et al. 2006). For 
the HPV vaccine to be effectively introduced in South Africa, a comprehensive 
education and training strategy will be required. Health service providers will need to 
understand: the natural history of HPV, how the vaccine works, the vaccine schedule, 
the vaccine’s limitations and the safety and side-effect profile. Providers will also 
need communication tools to facilitate effective discussions with clients, such as 
pamphlets and visual aids. This study also highlights the need for continued training 
and education of health service providers regarding the rationale for the current 

















An education and communication strategy will also need to provide clear information 
about the vaccine to the public, including information on the vaccine’s efficacy, side-
effects and recommended vaccine schedule. Rumors and misconceptions have done 
significant damage and have impeded the delivery of other vaccines elsewhere 
(Aylward, Heymann 2005; Kane et al. 2006). As was seen in our community level 
focus group discussions and in interviews with providers, a vaccine that targets 
adolescent females could be seen as a plot to sterilise females. A communication 
strategy with clear concise messaging that addresses this concern will be an important 
part of an HPV vaccine programme.  
 
In common with studies from other settings, our findings suggest that considerable 
health promotion efforts are also needed to improve community knowledge about 
cervical cancer and the need for regular cervical screening (Moreira et al. 2006; Zimet 
et al. 2006; Mosavel, El-Shaarawi 2007). The perception that Pap smears are 
important to clean the womb, treat STIs and ensure fertility, rather than to prevention 
cancer has been described previously in studies conducted in South Africa 
(Abrahams, Wood & Jewkes 1997; Wood, Jewkes & Abrahams 1997). This 
perception could have been fostered by the previous availability of Pap smears mostly 
at family planning clinics. Health education efforts need to emphasize the importance 
of Pap smears in preventing cervical cancer through early detection of pre-cancerous 
lesions.    
 
The ways in which a vaccine against genital HPV is promoted will be critical to its 
acceptance amongst young girls and parents. Community respondents advised on 
highlighting the vaccine’s cancer preventive properties, rather than focusing on the 
fact that the vaccine protects against an STI. The notion that vaccinating against an 
STI might encourage risky sexual behaviour has received media attention and interest 
in other settings (Zimet et al. 2006; Waller, Wardle 2008; Zimet, Shew & Kahn 
2008). Research on parental attitudes suggests that most parents in developed 
countries have positive attitudes toward HPV vaccination of adolescents (Constantine, 
Jerman 2007; Rosenthal et al. 2008). However the minority of parents who were not 
accepting of the HPV vaccine indicated concern about sexual disinhibition. An 
increase in risky sexual behaviour through use of vaccination, however, has yet to be 
















respondents did not feel that opposition to the vaccine would be a major obstacle, but 
felt that some religious groups might object to the vaccine because of a fear of 
increased risky sexual behaviour. As HPV vaccines are approved and become 
available it will be important to monitor community attitudes and beliefs, and provide 
accurate science-based information so that parents are able to make informed 
decisions.  
 
The target population for HPV vaccination is likely to vary from country to country 
because of differences in available resources. Most respondents felt that the age of 
immunisation should be at the lower end of the current recommended age range for 
the HPV vaccine (9 to 26 years), with an underlying concern by many that the high 
levels of sexual abuse and violence in South Africa had significantly decreased the 
age of sexual exposure. This is not surprising given the high levels of gender- based 
violence in South Africa and has been reported in other studies in similar settings 
(Dunkle et al. 2004; Orner et al. 2006).  
 
Although some countries have licensed the HPV vaccine for use in males, there is still 
debate as to whether males should be included in an HPV vaccination programme 
(Kane et al. 2006; Castle, Scarinci 2009; Cuschieri 2009; Hibbitts 2009). Some argue 
that vaccinating boys offers additional protection for females through herd immunity 
whilst also offering protection against anogenital warts and anal cancer for men and 
promotes equality between the sexes (Hibbitts 2009; Hull, Caplan 2009). Others argue 
that vaccinating boys is not cost-effective (Cuschieri 2009; Kim, Goldie 2009). A 
recent study that assessed the cost-effectiveness of including males in a HPV 
vaccination programme concluded that good coverage in females obviates the need to 
vaccinate males (Kim, Goldie 2009). Data on genital warts in South African men is 
lacking and would assist in assessing the potential benefit that could be derived by 
vaccinating boys. Further research on whether this benefit is likely to make HPV 
vaccination more appealing to young men is needed. However, current infrastructure 
limitations make inclusion of males in an HPV vaccination program in South Africa 
unlikely. In our study focus group participants felt that boys should be included 
suggesting that there should be equal social responsibility and mutual benefit. Most 
policy informants felt that although there were benefits vaccinating boys, cost would 
















   
Vaccinating pre-adolescents and adolescents is a relatively new phenomenon and one 
that poses challenges in both developed and developing countries (Brabin et al. 2008; 
Zimet, Shew & Kahn 2008). Immunisation service delivery through the EPI has been 
fairly successful in South Africa, and as stated by some respondents the country has a 
good infrastructure of trained staff, systems to maintain the cold chain and an 
information system. However although immunisation coverage nationally is high 
there are districts in the country with immunisation coverage rates of only 60% 
(Mhlanga 2008). Further in South Africa, a regular health care visit for immunisation 
at age 12 is currently not well established. This may well change with the planned 
introduction of the combined diphtheria and tetanus vaccine at age 12 and could be an 
ideal time for the HPV vaccine to be administered as part of the EPI.  
 
In South Africa 86% of school aged girls are enrolled in primary schools (UNICEF 
2010) and thus delivery of the vaccine through schools would be a good way to reach 
a large number of girls in the target age group. However South-Africa does not have a 
well established school-based health system and few districts have school health 
nurses. Experience with school-based delivery of the HPV vaccines in the UK and 
Australia have been promising, with high coverage rates and good vaccine 
acceptability (Brabin et al. 2008; Garland et al. 2008a; Shefer et al. 2008). Even in 
these countries with well established school-health systems there were challenges in 
integrating the 3-dose HPV vaccine schedule into the school academic calendar and 
arranging for alternate appointments for girls that missed their original scheduled 
appointments. Cognizant of these challenges, should South Africa decide on a school-
based delivery system, it would be advisable to pilot a school-based HPV vaccine 
delivery programme in advance of national roll-out. Strategies to reach the 
approximately 14 % of school girls that are out of school will also need to be 
explored.  
 
Young adolescents do not routinely interact with health systems in most countries 
including South Africa. An attempt has been made in South Africa to develop 
adolescent health programmes at primary care level through the National Adolescent 
Friendly Clinic Initiative (NAFCI) (Ashton, Dickson & Pleaner 2009). These clinics 
















clinics across the country and, unless the adolescent-friendly clinic initiative is 
expanded, HPV vaccine coverage will be low.  
 
While not likely to play a major role in achieving coverage goals in South Africa, the 
private sector could play an important role in generating knowledge and experience 
with the vaccine amongst health professionals and the community at large. 
 
Price is likely to be one of the most challenging obstacles to HPV vaccine 
introduction in the developing world. In our study, policy informants spontaneously 
raised concerns about the cost of the vaccine. Although a recent study in South Africa 
showed that adding the HPV vaccine to the current cervical cancer screening strategy 
in the country was cost-effective, the vaccine is unlikely to be affordable in the public 
sector at the current market price of US $120 per dose (Sinanovic et al. 2009). South 
Africa is not eligible for GAVI support for vaccine introduction and should a decision 
be made to introduce the HPV vaccine into the public sector, the South African 
government will need to negotiate a substantially reduced price with pharmaceutical 
companies manufacturing the vaccine. Competition between the two pharmaceutical 
companies producing the vaccines (GSK and Merck) could drive down the price of 
HPV vaccines, although the firms may prefer to compete on the basis of product 
characteristics. Other financing options such as international donor support for the 
vaccine might need to be explored. 
 
Our study was conducted in one province in South Africa for the community and 
service delivery levels of inquiry, and with provincial and national respondents for the 
policy level. As the focus groups were conducted during the day, it is not surprising 
that the unemployment rate among focus group participants was much higher than the 
demographics of the study population. Opinions expressed by focus group participants 
might not be generalisable to the study population. The results are therefore not 
necessarily representative of South Africa or beyond, but instead are meant to assist in 
framing the issues for HPV vaccine introduction strategies. Some issues will require 
further investigation and consideration in other socio- cultural settings, whilst others 
might be broadly applicable. Health-related decisions are often negotiated in broader 
social networks including religious and local community leaders (Kane et al. 2006). 
















gatekeepers (e.g. religious leaders), whose counsel is likely to be sought before 
important decisions are taken. Future studies should explore the perceptions of 
community gatekeepers and explore the possibility of using community leaders in 
building acceptance and disseminating information. 
  
The HPV vaccine offers a new primary preventive strategy for cervical cancer and our 
formative research indicated broad support for the introduction of the vaccine. 
Important challenges that need to be addressed include: procurement of the HPV 
vaccine at a reduced price, implementation of a comprehensive IEC strategy and 
















Chapter 6: HIV, cervical cancer precursor lesions and cervical 
cancer among South African women 
 
In the previous two chapters results of research on the challenges in implementing a 
cytology-based program in South Africa (secondary prevention) and the potential 
challenges to and opportunities for implementing a HPV vaccination program in 
South Africa (primary prevention) were presented.  South Africa has been severely 
affected by the HIV/AIDS epidemic - it has the world’s largest population of people 
living with HIV (UNAIDS/WHO 2009). In developing a comprehensive cervical 
cancer preventive strategy for South Africa, the implications of the HIV/AIDS 
epidemic will need to be considered. Two studies were undertaken to determine the 
role that HIV plays in the risk of cervical cancer and cervical precursor lesions. The 
first study was conducted to determine the association between HIV, cervical cancer 
precursor lesions and cervical cancer among South African women. Chapter 6 
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6.1.1 Study site and study population 
Data for this study were derived from a case-control study that examined the 
association between hormonal contraceptives and invasive cervical cancer (ICC). The 
case-control study was conducted in the Western Cape Province from January 1998 to 
December 2001 (Shapiro et al. 2003). In 2004 anonymous HIV testing was done on 
stored serum samples and the relationship between HIV, cervical cancer precursor 
lesions and cervical cancer was then explored.  
 
Women who utilised the public sector health services, were less than 60 years of age 
and lived within 150 kilometres of Cape Town were eligible for the case-control 
study. Cases were Coloured and Black women with first occurrences of histologically 
confirmed ICC, stages Ib to IV, diagnosed less than 6 months previously at two 
tertiary public sector gynaecologic oncology clinics in the Province. Women with 
stage Ia cervical cancer (non-invasive), a previous history of any cancer and those that 
had not resided in the study region for the preceding six months were excluded. Early 
Stage Ia cervical cancer cannot be clinically detected. Women with Stage Ia cervical 
cancer were excluded (in the original case-control) study to avoid selection bias due to 
more intensive screening in women using h rmonal contraceptivesIn total 526 cases 
of cervical cancer were identified, two of whom refused to be interviewed. The 
median age of the cases was 46 years. The stage of the cancer, based on clinical and 
pathological findings, was abstracted from oncology clinic records (Shapiro et al. 
2003). 
 
The controls were identified either at the two tertiary level hospitals, local public 
sector hospitals or the community health care centres and were frequency-matched to 
the cases in a ratio of approximately 3:1 for decade of age, ethnic group and area of 
residence. The women had a primary diagnosis of trauma or acute infections that were 
judged to be independent of contraceptive use or risk of cervical cancer. Women with 
a history of any cancer or those who had not resided in the study region for the 
preceding six months were excluded. In total 1654 controls were identified, 107 (6%) 
















cervical cancer and were excluded from the study. The median age of the remaining 
1541 controls was 44 years (Shapiro et al. 2003). 
 
6.1.2 Data collection 
Trained nurse interviewers collected data from the cases and controls using a 
structured questionnaire that was administered in the subjects’ preferred language 
(English, Afrikaans or Xhosa). Data was collected on socio-demographic status, 
sexual behaviour, contraceptive use, Pap smear history, obstetric and gynaecology 
history and risk factors for cervical cancer. The nurse interviewers performed Pap 
smears using a cytobrush and took endocervical samples for HPV testing. Pap smears 
were interpreted at the South African National Health Laboratory Service and were 
classified according to the Bethesda system (Solomon et al. 2002). Endocervical 
scrapings were taken from the controls only and were assayed for HPV infections 
using the Digene Hybrid Capture 2 HPV test (Digene Corporation, Gaithersburg, MD) 
which detects 13 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
and 68). The assay denaturing protocol was modified in that instead of denaturing the 
entire specimen, 70µl of specimen material was removed and mixed with 35µl of 
denaturing agent. Test results were classified as positive according to the 
manufacturer’s instructions.  
As part of the study protocol, and with a view to testing future hypotheses, blood 
samples were obtained and stored at -70°C. In 2004 anonymous HIV testing was done 
on stored serum samples, using the ELISA AXSYM screening (Abbott) followed by 
confirmatory ELISA (Vironastica) and latex agglutination (Capillus) if necessary. 
HIV data were available for 486 (93%) of the 524 cases of cervical cancer, and HIV 
and Pap results for 1365 (89%) of the controls.  
Serum samples were also screened for Herpes Simplex Virus type 2 (HSV2) and 
syphilis. Aliquots of sera were tested for HSV2 using ELISA screening and for 


















6.1.3 Data analysis 
Data analysis was conducted using the statistical programme STATA 10.1 (STATA 
Corporation, College Station, Texas). Socio-demographic and reproductive 
characteristics were compared between cases (n=486) and controls (n= 1365). Odds 
ratios and 95% confidence intervals were estimated for categorical variables using one 
of the levels of the variable as the referent category. The median ages of HIV positive 
and HIV negative cases were compared using the Wilcoxon rank-sum test. Adjusted 
HIV ORs and 95% CIs were calculated using multiple logistic regression. Variables 
entered in the model included those of a priori interest and were: age, number of 
sexual partners, herpes simplex virus type 2 (HSV2) infection, prior Pap smears, use 
of hormonal contraceptives and ethnicity. Cut-off values were guided by the literature 
and the distribution of the factor in the data. To avoid over adjustment age at sexual 
debut was excluded from the model. 
 
 
For the association between HIV and cervical cancer precursors the analysis was 
restricted to the control group which consisted of 103 women with ASC-US, 53 with 
LSIL, 50 with HSIL and 1159 with normal cytology.  Prevalence ratios and 95% CIs 
were estimated for categorical variables across each grade of cervical cytology 
abnormality, using women with normal cytology as the reference group.  Prevalence 
ratios were preferred to odds ratios as the latter would tend to overestimate the 
associations when the prevalence of variables are high (Thompson, Myers & Kriebel 
1998). The risk of SILs was compared for women infected with both HR-HPV and 
HIV, or neither HR-HPV and HIV. For this analysis women with SILs (both HSIL 
and LSIL) were compared to women without SILs (normal cytology and ASC-US). 
The outcome selected was the more clinically significant SIL. The clinical 
significance of ASC-US is not clear. ASC-US is an equivalent cytological diagnosis 
that was introduced by the Bethesda classification system and denotes cellular 
changes that are more marked than reactive inflammatory changes but are not 
diagnostic of neoplastic or pre-neoplastic conditions (Solomon et al. 2002). The 
majority of ASC-US lesions regress within 24 months (Melnikow et al. 1998; 
Schlecht et al. 2003). Adjusted PRs and 95% CIs were calculated for SILs in women 
with both HIV and HR-HPV (or either of these viruses) using log-binomial regression 
















included those of a priori interest and were: prior Pap smear, smoking, number of 
sexual partners, HSV2 infection, age, ethnicity and use of hormonal contraceptives. 
Cut-off values were guided by the literature and the distribution of the factor in the 
data. To avoid over adjustment age at sexual debut was excluded from the model. 
 
Ethical approval for the overall study and, later, for the anonymous HIV testing was 
granted by the University of Cape Town Faculty of Health Sciences Research Ethics 
Committee and the Boston University Ethics Review Board. Written informed 
consent for the overall study was obtained from all study participants.  
The work was supported by grants from Bristol-Myers Squibb HIV/AIDS Research 
Institute and the National Institutes of Health, USA (Grant number R01 CA 73985-




6.2.1 Socio-demographic and reproductive characteristics 
Table 6.1 provides socio-demographic and reproductive characteristics for the cases 
and controls. The cases and controls were similar with regard to age, ethnic group, 
educational level, residence and marital status. On univariate analysis there was a 
significant association between cervical cancer and sexual behaviour. Cases were 
more likely to have had four or more sexual partners (OR 1.57, 95% CI 1.23 - 2.01) 
and had their sexual debut before the age of 16 years (OR 0.65, 95% CI 0.52 - 0.82). 
Cigarette smoking was significantly associated with cervical cancer (OR 1.34, 95% CI 
1.11 - 1.71). Controls were significantly more likely to have used any hormonal 
contraceptive (OR 0.53 95% CI 0.41 - 0.69). There was no significant difference in 
oral or injectable contraceptive use among cases and controls. Cases were 
significantly less likely than controls to have had a prior Pap smear (OR 0.38, 95% CI 
0.30 - 0.46).There was no significant difference in STIs, including HIV, between the 
















Table 6.1: Socio-demographic and reproductive characteristics 
Characteristic Cases  
N = 486 
Controls  







  < 35 years 61 (12.5) 219 (16.0)  1  
  ≥ 35 years 425 (87.5) 1 146 (84.0) 0.061 1.33 0.98 - 1.81 
Education level 
< grade 8 397 (81.7) 1090 (80.0)  1  
≥ grade 8 89 (18.3) 275 (20.0) 0.3830 0.89 0.68 - 1.16 
Ethnic group 
  Coloured 367 (75.5) 1 030 (75.5)  1  
  Black 119 (24.5) 335 (24.4) 0.980 0.99 0.78 - 1.3 
Residence 
  Rural 208 (42.8) 632 (46.3)  1  
  Urban 278 (57.2) 733 (53.7) 0.182 1.15 0.93 - 1.42 
Marital status 
  Single 116 (23.9) 297 (21.8)  1  
  Married 223 (45.9) 704 (51.6) 0.117 0.81 0.62 - 1.06 
  Widowed 70 (14.4) 158 (11.6) 0.485 1.13 0.78 - 1.63 
  Divorced/separated 76 (15.6) 205 (15.0) 0.742 0.94 0.66 - 1.34 
Sexual partners 
  < 4 355 (73.1) 1 109 (81.2)  1  
  ≥ 4 127 (26.1) 252 (18.4) < 0.001 1.57 1.23- 2.01 
Sexual debut 
  < 16 years 156 (32.1) 323 (23.7)  1  
  ≥ 16 years 318 (67.1) 1 008 (75.7) < 0.001 0.65 0.52 -  0.82 
Parity  
   < 5 381 (78.6) 1 106 (81.5)  1  
   ≥ 5 104( 21.4) 251 (18.5) 0.162 1.20 0.93 - 1.55 
Hormonal contraceptive use 
   Never 117 (24.1) 197(14.4)  1  
   Ever 369 (75.9) 1 168 (85.6) < 0.001 0.53 0.41-0.69 
Tobacco use 
  Never 159 (32.9) 550 (40.3)  1  
  Ever 326 (67.1) 815 (59.7) 0.004 1.34 1.11- 1.71 
Prior Pap smear 
  No 242 (49.8) 370 (27.1)  1  
  Yes 244 (50.2) 994 (72.8) < 0.001 0.38 0.30 - 0.46 
Syphilis infection 
  No 464 (95.5) 1295 (94.9)  1  
  Yes 22 (4.5) 70 (5.1) 0.545 0.86 0.53 - 1.41 
Herpes simplex 2 infection 
  No 165 (34.0) 459 (34.3)  1  
  Yes 321 (66.0) 878 (65.7) 0.416 1.1 0.88 - 1.34 
HIV infection 
  Negative 457 (94.0) 1287(94.3)  1  
  Positive 29 (6.0) 78 (5.7) 0.838 1.05 0.67 - 1.62 
















6.2.2 HIV and invasive cervical cancer 
Overall 6.0% (29) of the cases (486) and 5.7% (78) of the controls (1365) were HIV 
positive. The adjusted odds ratios for variables of interest and cervical cancer are 
displayed in Table 6.2. There was no significant association between HIV and ICC 
(adjusted OR 1.05, 95% CI 0.65 - 1.70). On multivariate analysis history of a Pap 
smear was a strong protective factor for ICC (adjusted OR 0.36, 95% CI 0.29 - 0.46). 
Other factors associated with ICC were: number of sexual partners (adjusted OR 1.70, 
95% CI 1.30 - 2.23) and smoking (adjusted OR 1.33, 95% CI 1.02 – 1.74). 
  
Table 6.2:  Multivariate association of demographic factors, reproductive factors 
and HIV with invasive cervical cancer 
Variable Adjusted odds ratio
1 




(95% confidence interval) 
HIV infection 1.18 
(0.76 - 1.85) 
1.05 
(0.65 - 1.70) 
Prior Pap smear 0.38 
(0.31 - 0.47) 
0.36 
(0.29 - 0.46) 
Sexual partners ≥ 4  1.63 




(1.06 - 1.65) 
1.33 
(1.02 -1.74) 
Parity ≥ 5 1.07 
(0.82 - 1.40) 
1.18 
(0.89 - 1.57) 
Age * 1.02 
(1.01 - 1.03) 
1.01 
(0.99  - 1.02) 
Black 1.03 
(0.81 - 1.31) 
0.77 




(0.44 - 0.76) 
0.74 
(0.55 - 1.00) 
HSV2 infection 1.07 
(0.86 - 1.34) 
0.92 
(0.72 - 1.19) 
Adjusted odds ratio1 adjusted for age only 
Adjusted odds ratio2 adjusted for all other variables in the table 
* For an increment of 1 year 
HIV, human immunodeficiency virus; HSV2, herpes simplex virus type 2 
 
Among women with cervical cancer, those that were HIV positive were 6 years 
younger than those that were HIV negative [HIV positive cases median age 40 years 
(interquartile range 28 - 49 years), HIV negative case  median age 46 years 

















Overall the majority (71.4%) of women with cervical cancer presented with late stage 
disease (stages III and IV).  Analysis of HIV exposure by stage of cervical cancer at 
presentation showed that 4.9% of women with late stage cervical cancer were HIV 
positive compared to 8.6% of women with early stage cervical cancer (stages 1b and 
II). These differences were not significant (OR 0.54, 95% CI 0.24 - 1.29).  
 
 
6.2.3 HIV and cervical cancer precursor lesions 
Among the controls the prevalence of ASC-US, LSIL and HSIL was 7.5%, 3.9% and 
3.7% respectively. The socio-demographic and reproductive characteristics for the 
controls across Pap smear category are presented in Table 6.3. Women with a history 
of a Pap smear had a significantly lower prevalence of ASC-US, LSIL and HSILs. 
Black women compared to Coloured women had a significantly higher prevalence of 
ASC-US and HSIL. A history of four or more sexual partners was significantly 
associated with a higher prevalence of ASC-US, LSIL, but not HSIL. Parity was 
associated with a slightly elevated risk of HSIL, but not of ASC-US or LSIL. 
Early sexual debut and smoking were not associated with an abnormal Pap smear.  
 
The prevalence of HSV2 infection was significantly higher among women with all 
categories of abnormal Pap smear compared to women with normal cytology. HSV2 
infection was significantly associated with HIV infection (prevalence ratio 5.2 95% 
CI 2.4 – 11.1) 
 
Among the controls, 50% (39/78) of HIV positive women had an abnormal Pap smear 
(20.5% ASC-US, 17.9% LSIL and 11.5% HSIL), compared to 13% (167/1287) of the 
HIV negative women (6.8% ASC-US, 3.0% LSIL and 3.2% HSIL). Using women 
with normal cytology as the reference category, the prevalence ratios associated with 
HIV infection were: ASC-US 4.0 (95% CI 2.6 - 6.4), LSIL 7.9 (95% CI 4.6 - 13.5) 
















Table 6.3: Socio-demographic and reproductive characteristics according to cytology result 
Characteristic Normal 




n = 53 
HSIL 
n = 50 
 %  %   PR* 95% CI % PR* 95% CI % PR* 95% CI 
Age 
  < 35 years 15.4 14.6 1  30.2 1  18.0 1  
  ≥ 35 years 84.6 85.4 1.07 0.63-1.80 69.8 0.44 0.25-0.78 82.0 0.84 0.41-1.67 
Education attainment 
< grade 8 79.6 80.6 1  81.1 1  82.0 1  
≥ grade 8 20.4 19.4 0.95 0.59-1.51 18.9 0.91 0.47-1.79 18.0 0.86 0.43-1.75 
Ethnic group 
  Coloured 77.8 60.2 1  66.0 1  62.0 1  
  Black 22.2 39.8 2.14 1.47-3.10 34.0 1.8 1.00-3.04 38.0 2.07 1.19-3.61 
Residence 
  Rural 46.2 45.6 1  49.1 1  48.0 1  
  Urban 53.8 54.4 1.02 0.70- 1.48 50.9 0.89 0.53-1.51 52.0 0.93 0.54-1.60 
Smoked tobacco   
Never 39.7 46.6 1  45.3 1  36.0 1  
Ever 60.3 53.4 0.77 0.53-1.12 54.7 0.80 0.47-1.36 64.0 1.16 0.66-2.05 
Ever married 
  No 20.8 31.1 1  20.8 1  26.0 1  
  Yes 79.2 68.9 0.61 0.41-0.91 79.3 1.00 0.52-1.91 74.0 0.76 0.41-1.40 
Hormonal contraceptive use 
  Never 14.5 13.6 1  7.6 1  22.0 1  























n = 53 
HSIL 
n = 50 
 %  %   PR* 95% CI % PR* 95% CI % PR* 95% CI 
Sexual partners 
  < 4 83.7 66.0 1  64.2 1  81.6 1  
  ≥ 4 16.4 34.0 2.38 1.62-3.48 35.9 2.68 1.57-4.62 18.4 1.14 0.56-2.32 
Sexual debut 
  < 16 years 24.1 26.3 1  18.0 1  30.0 1  
  ≥ 16 years 75.6 73.7 0.90 0.59-1.38 82.0 1.43 0.70-2.90 70.0 0.75 0.42-1.36 
Parity 
< 5 81.7 83.3 1  84.6 1  70.0 1  
≥ 5 18.3 16.7 0.90 0.55-1.49 15.4 0.81 0.39-1.71 30.0 1.85 1.03-3.33 
Prior Pap smear 
  No 25.3 35.9 1  37.7 1  40.0 1  
  Yes 74.7 64.1 0.63 0.43-0.93 62.3 0.58 0.34-0.99 60.0 0.52 0.30-0.91 
Syphilis infection 
  No 95.2 94.2 1  88.5 1  91.7 1  
  Yes 4.8 5.8 1.2 0.55-2.62 11.5 2.42 1.08-5.44 8.3 1.74 0.64-4.68 
HSV2 infection 
  No 36.7 21.6 1  19.2 1  21.3 1  
  Yes 63.3 78.4 2.00 1.26-3.16 80.8 2.35 1.12-4.64 78.7 2.09 1.05-4.16 
HIV infection 
  HIV negative 96.6 84.5 1  75.6 1  82.0 1  
  HIV positive 3.4 15.5 4.04 2.55-6.39 26.4 7.85 4.55-13.54 18.0 5.31 2.74-10.29 
HR-HPV status 
  Negative 89.0 68.9 1  35.6 1  16.0 1  
  Positive 11.0 31.1 3.13 2.13-4.58 64.2 11.68 6.83-19.99 84.0 32.31 15.44-67.61 
* PR, unadjusted prevalence ratio reference category women with normal Pap smear.  
















Among women with abnormal Pap smears, HIV positive women tended to be younger, with 
the age differences only statistically significant for LSIL (see Table 6.4) 
 
























37 - 48 44 
 
39 - 51 1.025 0.305 
LSIL 32 
 
28 - 38 41 
 
37 - 44 2.412 0.016 
HSIL 42 
 
32 - 45 49 
 
40 - 55 1.820 0.069 
HIV, human immunodeficiency virus; ASC-US, atypical squamous cells of undetermined significance; LSIL, 
low grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions  
Z statistic and p-value from Wilcoxon rank-sum 
 
 
6.2.4 High-risk HPV, HIV and SILs  
Overall 17.2% of controls were positive for HR-HPV. The prevalence of HR-HPV increased 
significantly with increasing severity in cytological abnormality. With women with normal 
cytology as the reference group the prevalence ratios associated with HR-HPV were:  ASC-
US 3.1 (95% CI 2.1-4.6), LSIL 11.7 (95% CI 6.8-20.0) and HSIL 32.3 (95% CI 15.4-67.6).  
 
Fifty-one percent (40/78) of the HIV positive women were positive for HR-HPV, compared 
to 15% (195/1287) of the HIV negative women. HIV positive women were almost five times 
more likely to have HR-HPV present compared to HIV negative women (prevalence ratio 5.1 
95% CI 3.3-7.7). Women infected with both HIV and HR-HPV were at a higher risk of SILs 
than women infected with neither of these viruses (adjusted prevalence ratio 19.8, 95% CI 
















present is approximately equal to the sum of the increased risk when each virus is present on 
its own i.e. there is no additive interaction. 
 
 
Table 6.5: HIV, HR-HPV and risk of SIL 
 SIL absent 
N =1 262 
SIL present 
N = 103 
Adjusted  
PR* 
p-value 95% CI 
HIV negative 
HR-HPV negative 














































SIL, squamous intraepithelial lesions PR, prevalence ratio; CI, confidence interval; HC2, Hybrid Capture 2; HR-
HPV, high-risk human papillomavirus; HIV, human immunodeficiency virus;  
* PR prevalence ratio adjusted for prior Pap, smoking, number of sexual partners, smoking, parity, HSV2 




This study provides data on the risk of cervical SILs and ICC for HIV positive women in the 
Western Cape Province in South Africa. The extent to which HIV increases the risk for 
cervical cancer is especially important in South Africa given the size of the HIV epidemic.  
 
In our study HIV positive women did not have an excess risk of invasive cervical cancer 
(adjusted OR 1.05 95% CI 0.65 - 1.70).  However our study was conducted at an early stage 
of the HIV epidemic in the Western Cape Province. During the period of our study the 
estimated HIV prevalence in women attending public sector antenatal clinics in the Western 
Cape was 7.1% in 1999, 8.7% in 2000 and 8.6% in 2001 (Department of Health 2009). Our 
study was also conducted at a time when antiretroviral therapy was not available. The lack of 
















conditions associated with HIV. A case-control study conducted in Johannesburg, South 
Africa between 1992 and 1995 found no association between invasive cervical cancer and 
HIV (OR 0.6, 95% CI 0.2 - 1.9 (Sitas et al. 1997). However, the most recent data from 
another case-control study in the same setting reported an increased risk of cervical cancer 
(OR 1.6, 95% CI 1.3 – 2.0) among HIV positive women (Stein et al. 2008). The estimated 
HIV prevalence in women attending antenatal clinics in Johannesburg for the period of the 
latter study ranged from 12.0% in 1995 to 33.1% in 2004 (Department of Health 2009), 
which was much higher than the antenatal HIV prevalence in the Western Cape during our 
study. Studies elsewhere have produced inconsistent results on the association between HIV 
and invasive cervical cancer (La Ruche et al. 1998; Gichangi et al. 2003; Massad et al. 2004; 
Mbulaiteye et al. 2006; Adjorlolo-Johnson et al. 2010). These inconsistencies across studies 
are likely to be due to variations in the competing causes of mortality, stage of the HIV 
epidemic at the time a study is conducted and the efficacy of cervical cancer screening 
programmes in different settings.  
 
Studies have reported that HIV positive woman are more likely to present with advanced ICC 
compared to HIV negative women and that lesions progress more rapidly and recur more 
frequently in HIV positive women (Fruchter et al. 1996; Gichangi et al. 2003). In our study a 
very high proportion of women presented with advanced invasive cervical cancer and we 
observed no association between HIV and the stage of presentation of cervical cancer. Our 
findings are similar to other studies conducted in South Africa where the majority of women 
irrespective of HIV status present with late stage disease (Lomalisa, Smith & Guidozzi 2000; 
Moodley, Moodley & Kleinschmidt 2001). The high proportion of women presenting with 
advanced ICC is of particular concern as stage at diagnosis is an important determinant of 
prognosis (Sankaranarayanan et al. 1998; Wabinga et al. 2003).  
 
In the Gauteng Province HIV positive women with ICC were nine years younger than HIV 
negative women (Lomalisa, Smith & Guidozzi 2000). A study in KwaZulu –Natal Province 
reported that on average HIV positive women with ICC cancer were 15 years younger than 
HIV negative women with ICC (Moodley, Moodley & Kleinschmidt 2001). In our study the 
difference in median age between HIV positive and negative women with ICC was smaller 
than either of these studies (six years) and probably reflects the earlier stage of the HIV 

















A number of studies have reported on the high prevalence of cervical abnormalities in HIV 
positive women in Africa. Fifty percent of the HIV positive women in our study had a 
cytological abnormality, which is similar to that observed in 397 HIV-positive women from 
Cape Town (prevalence of  abnormal cytology 55%)  and a cross-sectional study of 1010 
HIV positive women in Johannesburg where 50% of women had cervical abnormalities 
(Denny et al. 2008; Firnhaber et al. 2010). Apart from a study in Zambia that reported a 
cervical abnormality prevalence of 93% in severely immunocompromised women attending a 
tertiary hospital (Parham et al. 2006), other studies in Africa have reported a lower 
prevalence of abnormal cytology among HIV positive women than has been reported in 
South Africa. Hawes et al. (2003) reported a cytological abnormality prevalence of 37% 
among women with HIV-1 infection attending an outpatient infectious-disease clinic in 
Senegal, Chirenje et al. (2002) reported a cervical abnormality prevalence of 26 % among 
family planning attendants in Zimbabwe, Laga et al. (1992) 27% in sex workers in Zaire, and 
Kreiss et al. (1992) 26% among sex workers in Kenya.   
 
Our study is the only study in South Africa that has reported on the association between HIV 
status and SILs, as other South African studies did not include a comparative HIV negative 
group. Our finding, that HIV infected women were at a significantly higher risk of LSIL and 
HSIL compared to HIV negative women confirm the findings of studies from both developed 
and developing countries (Massad et al. 1999; Duerr et al. 2001; Hawes et al. 2003). In our 
study HIV positive women were 7.9 times likely to have a LSIL than HIV negative women 
which is similar to that reported by the WIH study in the US (Massad et al. 1999). We 
observed a significantly increased risk of HSIL (PR 5.3 95% CI 2.7 – 10.3) among HIV 
positive women, which was in keeping with findings from other studies: the HER study based 
in the US, the WIHS, and a study in Senegal found that HIV positive women were at a 
significantly higher risk of HSILs compared to HIV negative women (ORs 4.0, 2.7 and 3.7 
respectively) (Massad et al. 1999; Duerr et al. 2001; Hawes et al. 2003).   
 
Internationally it has been shown that screening for cervical cancer precursors by means of 
Pap smears, reduces the incidence of cervical cancer (Sankaranarayanan, Budukh & 
Rajkumar 2001; IARC 2005). This was confirmed in our study where significantly more 
controls (73%) than cases (50%) reported having a previous Pap smear (adjusted OR 0.36 
95% CI 29 - 0.46). An important consideration in developing a cervical cancer screening 
















the age at which to initiate screening. This is influenced by the peak age at which SILs, 
particularly HSIL the immediate precursor to ICC, are observed.  In our study we observed a 
tendency for HIV positive women with SILs to be younger than HIV negative women with 
SILs (median age 32 vs.41 for LSIL, and 42 vs. 49 for HSIL respectively). This age 
difference between HIV positive and HIV negative women was significant for women with 
LSIL but not for those with HSIL.  These findings suggest that the current South African 
national cervical screening policy needs to be revised taking into account the impact of the 
HIV/AIDS epidemic on SILs. 
 
The high prevalence and risk of cervical abnormalities documented in our study underscores 
the importance of developing screening and management guidelines for HIV positive women. 
The HIV prevalence among adult women in the Western Cape in 2002 was 7.6% 
(Dorrington, Bradshaw & Budlender 2002). Based on our study results 50% of these women 
i.e. 49 076 HIV positive women in the province, had cervical lesions in 2002. As anti-
retroviral therapy becomes increasingly available in the public sector in South Africa, the life 
expectancy of HIV positive women will increase. It is important that this benefit is not offset 
by an excess risk in cervical cancer. In developed countries it is recommended that HIV 
positive women have two cytological assessments within the first year after HIV diagnosis 
and annually thereafter, with referral for colposcopy for any smear showing an ASC-US or 
more severe lesion (Centers for Disease Control 1997). These guidelines are not feasible in 
resource-poor settings. It is critical that a cervical cancer screening programme, informed by 
local research on the natural history of cervical abnormalities, is put in place for HIV positive 
women. 
 
South Africa has introduced a national cervical screening policy stating that all women 30 
years and older are entitled to three free Pap smears in their lifetime, at 10 year intervals 
(Department of Health 2000). If the policy is adequately implemented, over the next few 
years many women in South Africa will be screened for the first time and many abnormal 
cervical lesions will be detected. Based on our study findings that 1 in 4 women with LSIL, 
and 1 in 5 women with HSIL, were HIV positive, every effort should be made to ensure that 
women who are screened and found to have SILs should also be offered HIV voluntary 

















The HR-HPV prevalence was 17.2% among the controls in our study, with prevalence rising 
significantly with increasing severity of cytological abnormality. This prevalence is likely to 
be representative of the study population as controls were selected from the same 
neighbourhood as the cases. Our finding that HIV positive women were almost 5 times more 
likely to have HR-HPV present compared to HIV negative women, are in agreement with 
others that have shown an association between HIV, high-risk HPV and cervical 
abnormalities (Sun et al. 1997; La Ruche et al. 1998; Minkoff et al. 1998; Palefsky et al. 
1999; Ahdieh et al. 2001; Massad et al. 2001; Jamieson et al. 2002; Hawes et al. 2003). 
Mechanisms that explain the increased prevalence of HPV in HIV infected individuals 
include decreased immunity associated with HIV, chromosomal instability,  as well as a 
possible direct interaction between the 2 viruses, with HIV interacting with HPV at a 
molecular level, leading to an increased expression of the HPV E6 and E7 oncogenes 
(Palefsky 2006). The latter two mechanisms are not fully understood. For the combination of 
HIV and HR-HPV infection, we estimated a 20-fold increase in the risk of SILs, which was 
almost equal to the sum of the increased risk when each virus was present on its own 
suggesting no biological synergism between the viruses.  
 
In our study incident cases were used and controls were sampled at the time of the occurrence 
of a case i.e. we used incidence density sampling. In this design the incidence rate ratio can 
be directly estimated by the odds ratio (Pearce 1993; Knol et al. 2008). An advantage of this 
method is that it reduces bias from secular changes in the prevalence of exposure during the 
course of the study.  
 
A potential limitation of our study is that cytological abnormalities were not histologically 
confirmed. However, some studies have shown that the Pap smear sensitivity and specificity 
are similar among HIV negative and HIV positive women (Wright et al. 1994; Branca et al. 
2001). Further, the cytologists were blinded to HIV status and there is no reason to suspect 
differential misclassification according to HIV status. Non-differential misclassification 
would, if anything, dilute the estimated effect of HIV. An additional limitation of our study 
was that immune status was not recorded. A strong association between immune status (CD4 
counts and HIV viral load) and cervical abnormalities has been demonstrated in other studies 


















In summary South African HIV positive women are at a significantly increased risk of 
cervical HR-HPV infection and SILs. As the population of HIV-infected South African 
women survive longer through increased access to ARVs, invasive cervical cancer is likely 
increase and become an increasing public health burden, unless a functional cervical cancer 

















Chapter 7: HPV infection and cervical cancer precursor lesions among 
women initiating HAART 
 
This is the second study examining the role of HIV in cervical cancer among women in South 
Africa. The study was undertaken a later stage of the HIV epidemic in the Western Cape 
Province to determine the HPV prevalence, HPV types, HPV viral load and prevalence of 
cervical precursor lesions among women initiating HAART. Chapter 7 presents the methods, 
results and discussion for this study and is structured as follows: 
  
7.1. Methods 
7.1.1. Study design 
7.1.2. Study site and study population 
7.1.3. Data collection 
7.1.4. Data analysis 
7.2. Results 
7.2.1. Socio-demographic and reproductive characteristics 
7.2.2. HR-HPV prevalence 
7.2.3. HPV types  
7.2.4. HPV viral load 





7.1.1 Study design 
A cross sectional survey was conducted at a public sector ART clinic in Cape Town, South 
Africa, between January and May 2007.  
 
7.1.2 Study site and study population 
The ART clinic is based at a Community Health Centre in the Nyanga Health District of the 
Metro Region in Cape Town. Nyanga is a predominantly African township situated 26 
kilometres from Cape Town. It has a population of 58 723 and 48% of the population live in 
















seroprevalence was 29.1% (Department of Health, Western Cape 2006).  The ART clinic was 
started in 2004 by a non-governmental organisation, Absolute Return for Kids (ARK), and 
taken over by the Provincial Government of the Western Cape (PGWC) in 2006/ 2007.  
Patients are eligible for HAART if they have stage IV disease or a CD4 cell count below 200 
cells/µL. Patients undergo clinical and psycho-social assessment and three group treatment-
readiness sessions to ensure that they are ready to initiate and remain on long-term therapy. 
 
Women, eighteen years and older, who were being considered for initiation of HAART were 
eligible for inclusion in the study. Every second female client on the HAART eligible patient 
register was informed of the study by clinic staff and referred to the research nurse, who 
explained the details of the study and obtained informed consent. Women who had a 
hysterectomy, were menstruating or pregnant at the time of the study were excluded. A total 
of 120 women were referred by clinic staff to participate in the study. Nine women were 
excluded because they were menstruating and two declined to participate because of time 
constraints. 
 
7.1.3 Data collection 
 A structured questionnaire (Appendix G) was used to collected data on socio-demographic 
status, sexual behavior, history of a STI, obstetric and gynaecology history and risk factors 
for cervical cancer. The questionnaire was piloted prior to the study and the final 
questionnaire was administered by the research nurse in the client’s preferred language 
(Xhosa or English). The research nurse also conducted a pelvic examination; took a Pap 
smear using a cytobrush and collected cervical samples for HPV testing with Digene cervical 
samplers. The samples for HPV testing were stored in Digene transport medium at -80°C 
until required.  
 
Pap smears were interpreted at the South African National Health Laboratory Service and 
classified according to the Bethesda classification system (Solomon et al. 2002). Women with 
HSILs were referred to the regional colposcopy clinic and those with other cervical 
abnormalities asked to return for repeat Pap smears according to the clinic protocol.  
 
Cervical samples were assayed for HPV infection using the Digene Hybrid Capture 2 (HC2) 
assay (Digene Corporation, Gaithersburg, MD) which detects13 HR-HPV types (16, 18, 31, 
















which is the ratio of light emitted by the specimen to the light emitted from the mean RLU of 
triplicate positive control specimens containing 1 pg/ml of HPV DNA (5000 copies of HPV 
genome), was calculated. Specimens with a ratio of < 1.00 were considered negative, and 
those with a ratio of ≥ 1.00 were considered positive. Low, but positive RLU values were not 
retested and were considered positive for the purposes of the analysis. The RLU ratio reflects 
a semi-quantitative measure of the HPV viral load for one or more of the 13 HR-HPV types. 
The HC2 test does not provide type-specific HPV data. 
 
HPV types were determined using the Roche Linear Array HPV Genotyping test (Roche 
Molecular Systems Inc. California USA), and the results were validated utilizing the 
betaglobin according to the manufacturer’s instructions. The Linear Array assay detects a 
total of 37 HPV types. Individual HPV types were divided into 14 oncogenic (high risk) 
types: 16, 18, 31, 33, 35, 39, 45, 51,52, 56, 58, 59, 66, 68, and 73 non-oncogenic types (low 
risk): HPV 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69,70, 71, 72, 73, 81, 82, 83, 84, IS39 
and CP6108. 
 
All clients have blood taken for CD4 counts by the health service authority as part of their 
assessment for HAART eligibility. CD4 count data were extracted from clinical records. The 
cyto-technician and laboratory technician were blinded to the clinical profile of the clients.  
 
7.1.4 Data analysis 
Data analysis was conducted using the statistical programme STATA 10.1 (STATA 
Corporation, College Station, Texas). Descriptive statistics analyses were based on 
percentages for categorical variables and medians and interquartile (IQR) ranges for 
continuous variables. 
 
Continuous and categorical variables were compared between women with and without 
squamous intraepithelial lesions (SILs). Women with SILs included those with either HSIL 
or LSIL. Women without SILs included those with ASC-US or a normal Pap smear. ASC-US 
is an equivalent cytological diagnosis that was introduced by the Bethesda classification 
system and denotes cellular changes that are more marked than reactive inflammatory 
changes but are not diagnostic of neoplastic or pre-neoplastic conditions (Solomon et al. 
2002). The clinical significance of ASC-US is not clear and the majority of lesions regress 

















Continuous variables were assessed for skew and as all showed non-normality they were 
compared using the Wilcoxon rank-sum test. Proportions were compared using Chi-squared 
and, Fischer’s Exact test in the case of small numbers. Prevalence ratios and 95% confidence 
intervals were estimated using one of the levels of the variable as the reference category.  
Prevalence ratios were preferred to odds ratios which would tend to overestimate the 
associations when the prevalence of variables is high (Thompson, Myers & Kriebel 1998). 
Adjusted prevalence ratios and 95% confidence intervals for predictors of SILs were 
determined using Poisson regression with robust variance (Barros, Hirakata 2003). Log-
binomial regression was not used as the analysis could not converge (Barros, Hirakata 2003). 
Variables entered into the model were based on a priori considerations and were: HR-HPV 
infection, age, number of sexual partners, smoking, prior Pap smear, hormonal contraceptive 
use and CD4 cell count.  HR-HPV infection was categorized as: HR-HPV negative as the 
referent group and HR-HPV positive in categories according to the median HPV viral load. 
 
Ethical approval was granted by the University of Cape Town, Faculty of Health Sciences 
Research Ethics Committee. The PGWC health department granted permission to conduct the 
study at the ART clinic. Written informed consent for the study was obtained from all study 




7.2.1 Socio-demographic and reproductive characteristics  
A total of 109 women were included in the study. The socio-demographic and reproductive 
characteristics for the overall study population and according to cervical cytology results are 
presented in Table 7.1. Overall the median age of the participants was 31 years (interquartile 
range 27-36 years), the majority of women were unemployed (80.7%), just under half 
(47.7%) were either married or in a stable relationship and most participants had attended 
high school (55.1%). Fifty-five percent of the participants were currently on contraception 
(data not shown). Of these, 40% were using condoms only, 28% condoms and another 
















method. Most women reported having had an STI (84.4%). Of these 27.1% gave a history of 
having an STI in the preceding week.  
 
A total of 98 out of 109 women had an adequate Pap smear and of these 65 (66.3%) had an 
abnormal Pap smear. ASC-US was reported in 15 (15.3%), LSIL in 39 (40.0%), HSIL in 10 
(10.2%) and atypical squamous cells- cannot exclude HSIL (ASC-H) in 1 (1.0%) of women. 
None of the women had cervical cancer. The median age of women with SILs was 30 years 
(interquartile range 26 - 36 years) and that of women without SILs was 32 years (interquartile 
range 28 - 39). This difference was not significant (Wilcoxon test, p-value = 0.377).  A 
smaller proportion of women with SILs were employed compared to women without SILs, 
but this difference was not significant (PR 1.04, 95% CI 0.71-1.54).  Significantly more 
women with SILs compared to women without SILs had ever smoked (PR 1.73, 95% CI 
1.22-2.44). There were no other significant socio-demographic differences between women 
with and without SILs.  
 
Overall 42% of women had had a previous Pap smear. Although a greater proportion of 
women without SILs (48.9%) had had a Pap smear compared to women with SILs (34.0%) 
this difference was not significant (PR 0.73, 95% CI 0.48-1.12). There was no significant 
difference in hormonal contraceptive use between women with and without SILs. The median 
CD4 count among women with SILs [124 cells/µL (interquartile rang 62 - 168)] was not 
significantly different to that of women without SILs [126 cells/µL (interquartile range 64 -

















Table 7.1: Socio-demographic and reproductive characteristics for the overall study 
population and according to cervical cytology results    
Characteristic Overall 
N = 109 
SILs 
absent 
N = 48 
SILs 
present 
N = 50 
PR p- 
value* 
95 % CI 
Attended high school 
60 (55.1) 28 (58.3) 25 (50) 0.85 0.408 0.58-1.25 
Married or in stable 
relationship 
52 (47.7) 22 (45.8) 24 (48.0) 1.04 0.830 0.71-1.54 
Employed 
21 (19.3) 12 (25.0) 7 (14.0) 0.68 0.169 0.36-1.26 
Ever smoked 
21 (19.3) 5.0 (10.4) 16 (32.0) 1.73 0.009 1.22-2.44 
Sexual debut ≥ 17 years 
61 (55.6) 30 (62.5) 24 (48.0) 0.75 0.149 0.51-1.11 
Sexual partners ≥ 4 
63 (57.8) 26(54.2) 30 (60.0) 1.13 0.560 0.75-1.67 
Ever pregnant 
89 (81.7) 40 (83.3) 40 (80.0) 0.90 0.670 0.56-1.43 
Ever used injectable 
contraception 
97 (89.0) 43 (89.6) 43 (86.0) 0.86 0.589 0.51-1.45 
Ever used oral 
contraception 
29 (26.6) 11 (22.9) 13 (26.0) 1.08 0.723 0.70-1.67 
Ever used condoms 
55 (50.5) 21 (43.8) 30 (60.0) 1.38 0.107 0.92-2.07 
Ever had an STI 
92 (84.4) 41 (85.4) 43 (86.0) 1.02 0.934 0.58-1.80 
Past Pap smear 
46 (42.2) 23 (48.9) 17 (34.0) 0.73 0.135 0.48-1.12 
Data are N (%)   * p-values are from chi-squared tests for proportions or Fisher’s exact tests where numbers in 
the cells were < 5.  
PR, prevalence ratio; CI, confidence interval; STI, sexually transmitted infection; SILs squamous intraepithelial 
lesions  
 
7.2.2 HR-HPV prevalence 
The overall prevalence of HR-HPV using the Digene test was 78.9 % (95% CI 69.8% - 
85.9%). Women with SILs had a significantly higher prevalence of HR-HPV compared to 
those without SILs [96.0% vs. 58.3%, PR 6.95 (95% CI 1.93-26.33)]. Although the median 
CD4 count among women with HR-HPV [119.5 cells/µL (interquartile range 62 - 168)] was 
lower than that of women without HR-HPV [154 cells/µL (interquartile range 66 - 183)], this 

















7.2.3 HPV types 
Overall 89% (95% CI 81.20 - 93.93) of women had a positive Roche Linear Array HPV 
Genotyping test. A total of 35 HPV types were detected in the 109 women. The median 
number of HPV types per woman was 3 (interquartile range 1 - 5), with multiple types (≥ 2 
types) detected in 70.4% of all participants and in 78.4 % of participants with a positive 
Roche Linear Array HPV Genotyping test.  Women with SILs were significantly more likely 
than women without SILs to have multiple HPV types [92.0% vs. 47.9%, PR 4.83 (95% CI 
1.91 - 12.19)]. Sixty three percent of women with a CD4 count < 100 cells/µL had multiple 
HPV types present compared to 73% of women with a CD4 count≥ 100 cells. This difference 
was not significant (PR 1.16 95% CI 0.88 -1.54)   
 
The prevalence of the different HPV types detected is shown in Figure 7.1. Overall HPV 
types 61 and 66 were most commonly detected, with a prevalence of 23.9% and 18.5% 
respectively. The prevalence of HPV 16 and 18 was 13.8% and 15.6% respectively and the 
prevalence of types 6 and 11 was 2.75% and 4.6%, respectively.  
 
Figure 7.1: Prevalence of HPV types detected in 109 women initiating antiretroviral 
treatment 
          Oncogenic      Probable oncogenic  Non-oncogenic  
  
Among women with SILs the most prevalent HR-HPV/oncogenic types were HPV types 18 
(24.0%), 35 (22.0%) and types 16, 45 and 58 all with a prevalence of 20.0%. Among the 10 




























































































followed by HPV types 16, 35, 39, 58 and 51 all with a prevalence of 30.0% and HPV types 
18, 31, 33 and 66 all with a prevalence of 20.0%. 
 
7.2.4 HPV viral load 
The estimated median HPV viral load was 181.1 RLU among women that were HC2 positive.  
The median HPV viral load in women with SILs (404.8 RLU interquartile range 89.4 -
1394.8) was significantly higher than women without SILS (60.3 RLU interquartile range 8.6 
- 199.5) (Wilcoxon p-value = 0.0002). Table 7.2 provides information on the median HC2 
viral load and inter-quartile range by each category of cervical abnormality. The analysis 
showed an overlap in the range of viral loads for the cytology categories. There was a 
significant trend of increasing HPV viral load with increasing severity of cytological 
abnormality (p trend < 0.0001). 
 
 Table 7.2 HPV viral load and cervical cytology 
Cervical 
cytology 
N Median HPV viral load in RLU 
 
Interquartile range 
Normal 17 14.30 3.28 - 190.06 
ASC-US 11 90.27 33.59 - 232.08 
LSIL 37 365.49 82.06 - 1259.64 
HSIL 10 594.55 177.50 - 1504.88 
p trend  < 0.0001 
ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial 
lesions; HSIL, high-grade squamous intraepithelial lesions; HPV, human papillomavirus; RLU, relative light 
units  
 
The median HPV viral load among women with a CD4 count < 100 cells/µL (81.3 RLU 
interquartile range 11.0 - 464.9) was lower, but not significantly different compared to 
women with CD4 count ≥ 100 cells/µL (189.8 RLU interquartile range 49.1 - 915.9) 
(Wilcoxon p-value = 0.07). 
 
7.2.5 Risk factors for SILs 
Multivariate regression was carried out to determine independent risk factors for SILs. The 
model showed that HPV viral load and smoking were associated with an increased risk of 
SILs (Table 7.3). The risk of SILs was five times higher for those that were HC2 positive and 
had a viral load of ≤ 181.1 RLU (the median HPV viral load) compared to those that were 
















HPV viral load > 181.1 RLU the risk of SILs was 8.4 times higher  compared to those that 
were HC2 negative (PR 7.61, 95% CI 1.88- 30.75). Smokers were 1.5 times more likely to 
have SILs compared to non-smokers (PR 1.55, 95% CI 1.13 - 2.14). None of the other 
variables examined were significant risk factors for SILs.  
 
Table 7.3: Multivariate association of demographic factors, reproductive factors and 








(95% confidence interval) 
HC2 positive and low HPV viral 
load 
5.53 
(1.36 - 20.78) 
4.95 
(1.19 - 20.63) 
HC2 positive and high HPV viral 
load 
8.39 
(2.16 - 32.65) 
7.61 
(1.88 - 30.75) 
Smoking 1.73 
(1.22 - 2.45) 
1.55 
(1.13 - 2.14) 
Sexual partners  ≥  4  1.10 
(0.73 - 1.66) 
0.98 
(0.69 - 1.41) 
Prior Pap smear 0.73 
(0.48 - 1.12) 
1.05 
(0.71 - 1.56) 
Hormonal contraceptive use 0.81  
(0.47 - 1.40) 
0.95 
(0.61 - 1.50) 
Age 0.99 
(0.97 - 1.02) 
1.00 
(0.98 - 1.02) 
CD4 cell count 1.00 
(0.99 - 1.01) 
1.00 
(0.99 - 1.01) 
PR1 adjusted for age only; PR2 adjusted for all other variables in the table 
PR, Prevalence ratio; HC2, Hybrid Capture 2; HPV human papillomavirus 
Low HPV viral load < 181.1 RLU (median), compared to HC2 negative 




Our study of women initiating HAART recorded an exceptionally high prevalence of cervical 
abnormalities (66%). This is much higher than that recorded in studies conducted among HIV 
positive women in developed countries, where the prevalence of abnormal cytology reported 
ranged between 19% to 39% (Wright et al. 1994; Massad et al. 1999; Ahdieh et al. 2000; 
Delmas et al. 2000; Duerr et al. 2001; Schuman et al. 2003; Massad et al. 2008), and is one of 
the highest recorded in Africa (Hawes et al. 2003; Moodley et al. 2006; Parham et al. 2006; 
















cytological abnormalities than our study, was that conducted by Parham et al among women 
attending an HIV-care clinic at a tertiary centre in Zambia (abnormal Pap smear prevalence 
of 94%) (Parham et al. 2006). The latter study was conducted among women with a median 
CD4 count of < 200µ/L and of a similar age to our study population. Previous studies 
conducted among HIV positive women in South Africa have recorded abnormal Pap smear 
prevalence of between 50 and 55% (Moodley et al. 2006; Denny et al. 2008; Firnhaber et al. 
2010). These studies were conducted in women with either an unknown CD4 status (Moodley 
et al. 2006) or a higher median CD4 status (Denny et al. 2008; Firnhaber et al. 2010) than 
was observed in our study. The associations between low CD4 counts, HPV and cervical 
dysplasia have been previously documented (Delmas et al. 2000; Heard et al. 2000; Hawes et 
al. 2003; Schuman et al. 2003; Parham et al. 2006; Denny et al. 2008; Firnhaber et al. 2010). 
Hawes et al. (2003) found that among 433 HIV positive women, the presence of LSIL or 
worse was strongly correlated with decreased CD4 cell counts. HSIL was not present among 
women with CD4 > 500/mm
3
, however among women with CD4 cell c unts of < 500 
cells/µL, each 100 cells/µL  decrease in CD4 count was associated with a 1.7 fold increased 
risk of  HSIL diagnosis (Hawes et al. 2003). Similarly a study in Cape Town found that HIV-
infected women with a baseline CD4 count > 500 cells/µL had a lower risk of developing 
SILs over a 36 month period, compared to women with a baseline CD4 cell count < 200 
cells/µL (hazard ratio =0.43, 95% CI  0.20 – 0.93) (Denny et al. 2008). It has been suggested 
that severe immune-suppression might be associated with irreversible cellular damage 
(Palefsky 2006). Possibly because of the severe immune-suppression among women in our 
study population (median CD4 125 cells/µL), we found no association between CD4 count 
and the prevalence of cervical abnormalities. 
 
Women infected with HIV have a higher prevalence of HPV and are at a greater risk of 
developing cervical SILs  (Wright et al. 1994; Sun et al. 1997; La Ruche et al. 1998; Minkoff 
et al. 1998; Massad et al. 1999; Palefsky et al. 1999; Ellerbrock et al. 2000; Duerr et al. 2001; 
Jamieson et al. 2002; Hawes et al. 2003; Schuman et al. 2003; Harris et al. 2005; Rowhani-
Rahbar et al. 2007; Massad et al. 2008). Effective screening and early treatment of 
precancerous cervical lesions are key in preventing the progression to invasive cervical 
cancer in both HIV positive and negative women (IARC 2005). The majority of women in 
our study had not had a previous Pap smear (58%). Two other studies in South Africa have 
recorded even lower rates of Pap smear screening among HIV positive women attending HIV 
















positive women attending a HIV clinic had not had a previous Pap smear, whilst a study 
among three HIV clinics in the Western Cape found that 87% of women had not had a 
previous Pap smear (Batra, Kuhn & Denny 2010; Firnhaber et al. 2010).  The low Pap smear 
screening rates are of concern and highlight the urgent need for clear national guidelines for 
cervical screening for HIV positive women in South Africa. 
 
Studies have shown that HIV positive women have a high prevalence of HR-HPV, and this is 
associated with high HIV viral loads and low CD4 counts (Palefsky et al. 1999; Ahdieh et al. 
2000; Jamieson et al. 2002; Hawes et al. 2003; Sahasrabuddhe et al. 2007; Denny et al. 2008; 
Firnhaber et al. 2010). The prevalence of HR-HPV (79%) in our study is amongst the highest 
recorded in the literature. HR-HPV was significantly associated with SILs (PR 6.95 95% CI 
1.93 - 26.33). Although women in our study with HR-HPV tended to have a lower CD4 count 
than those without HR-HPV, these differences were not significant, but could be a result of 
our small sample size.  
 
The majority of our participants (70%) had multiple HPV types present. Studies elsewhere 
have also shown that a high proportion of HIV positive women are infected with multiple 
HPV types (31% - 87%) (Jamieson et al. 2002; Levi et al. 2004; Luque et al. 2006; Rowhani-
Rahbar et al. 2007; Sahasrabuddhe et al. 2007; Denny et al. 2008). The high prevalence of 
multiple HPV types is most likely a result of the decreased immunity in HIV positive women, 
which allows for more efficient replication of HPV and a greater likelihood of HPV 
persistence (Palefsky, Holly 2003). Most studies have reported an inverse association 
between the number of HPV types seen and CD4 levels (Palefsky 2006; Sahasrabuddhe et al. 
2007; Denny et al. 2008; Firnhaber et al. 2010). The women in our study were severely 
immune-compromised and we found no association between immune-suppression (CD4 
levels) and the number of HPV types detected. We did however find that the median number 
of HPV types and the proportion of women with multiple HPV types present, increased as the 
severity of the cervical abnormality increased.  
 
Information on HPV types present in HIV positive women is important as HPV type is a 
strong determinant of progression from persistent HPV infection to cancer (Khan et al. 2005; 
Schiffman, Castle 2005). Clifford et al have shown that there is considerable variation in 
regional HPV type distribution in HIV- positive women, with HPV types 31 and 35 being 
















among all women were HPV61 (23.9%), 66 (18.5%), 58 (17.4%), 18 (15.6%), 45 (15.6%) 
and 70 (15.6%); and the most common HR-HPV types among women with SILs were HPV 
types 18 (24.0%), 35 (22.0%) and types 16, 45 and 58 all with a prevalence of 20.0%. Among 
the ten women with HSIL in our study, HPV45 (40%) was the commonest HR-HPV type 
followed by types 16, 35, 39, 58 and 51 all with a prevalence of 30%. Two other studies have 
reported on HPV types among HIV positive women in South Africa, and although both also 
observed a high HPV16 prevalence, other HPV types reported were different from those in 
our study (Denny et al. 2008; Firnhaber et al. 2010). In a study in Cape Town the commonest 
HR-HPV types seen in HIV positive women with HSIL were HPV 16 (26%), 52 (22%), 35 
(18%) and 18 (35%) (Denny et al. 2008), whereas in a study in Johannesburg the commonest 
HR-HPV types in women with HSIL were HPV16 (42%), 56 (22%), 33(14%) and 59 (11%) 
(Firnhaber et al. 2010). Among 77 women with HSIL or cervical cancer in Zambia, HPV 52 
(42%) was the most common, followed by HPV 58 (32%), 16(22%), 45 (22%) and 63 (22%) 
(Sahasrabuddhe et al. 2007). As has been shown in other studies, we found that although 
HPV 16 was common among women with SILs it did not predominate over other types to the 
same extent as is usually seen in HIV negative women (Clifford et al. 2006; Luque et al. 
2006; Sahasrabuddhe et al. 2007; Denny et al. 2008; Firnhaber et al. 2010). Forty-four 
percent of the women with SILs in our study had HPV16 and/or HPV 18 present, thus a 
significant proportion of cervical abnormalities could potentially have been prevented by 
HPV vaccination before the onset of sexual activity. However a relatively high prevalence of 
HPV types not covered by the HPV vaccine was also seen. This has been documented by 
others (Clifford et al. 2006; Sahasrabuddhe et al. 2007; Denny et al. 2008; Firnhaber et al. 
2010) and has important implications for the potential impact of HPV vaccines currently 
available. It also highlights the fact that screening for cervical cancer remains essential for 
optimal cervical cancer prevention. In our setting maximum benefit would be obtained from a 
polyvalent HPV vaccine.  
 
Studies conducted in both HIV positive and negative women have documented an increase in 
HPV viral load with increasing severity of cervical lesions (Heard et al. 2000; Sun et al. 
2001; Sun et al. 2002; Dalstein et al. 2003; Levi et al. 2004; Wu et al. 2006). HPV viral load 
might therefore be useful in differentiating women at a higher risk of SIL, which would 
increase the specificity of HPV testing as a screening assay. This could be particularly useful 
in HIV positive women as a large proportion of HIV positive women have HPV present.  In 
















assessment of viral load.  It does not distinguish between single and multiple HPV infections, 
nor does it adjust for differences in the number of cells collected for viral quantification 
(specimen cellularity). Some studies have shown that HC2 results can be considered as 
reflective of HPV viral load (Pretet et al. 2004) while others have not (Gravitt et al. 2003).  
Gravitt et al (2003) found that although HPV viral load as measured by real time PCR 
increased linearly with increasing grade of SIL, HPV viral load measured by HC2 did not. In 
contrast Pretet et al. (2004) found that real time PCR and HC2 viral load measurements were 
significantly correlated and that adjustment for specimen cellularity was not necessary. Most 
HIV negative women will be infected with only one HPV type and therefore the RLU 
measured by HC2 will reflect the viral load of that HPV type.  HIV positive women are more 
likely to be infected with multiple HPV types compared to HIV negative women (Jamieson et 
al. 2002; Rowhani-Rahbar et al. 2007), but it is not known how many HPV types, in HIV 
positive women infected with multiple HPV types, contribute to cervical disease. It remains 
controversial if the HC2 test will give meaningful results in HIV positive women. In this 
study we investigated whether an increased HPV viral load, as measured by HC2, reflects 
increased risk of cervical disease if the result includes a combination of many HPV types and 
found an association between HPV viral load and SILs. The risk of SIL was 5 times higher 
(adjusted PR 4.95, 95% CI 1.19 - 20.63) for those that were HC2 positive and had a viral load 
of ≤ 181.1 RLU (the median HPV viral load), and 8 times higher for those that were HC2 
positive with a HPV viral load > 181.1 RLU (adjusted PR 7.61, 95% CI 1.88 - 30.75), 
compared to women with a negative HC2 test. We speculate that HPV viral load might be 
clinically useful in predicting SILs in HIV positive women if a higher cut-off point is used, 
but further studies are needed to test this hypothesis.  
 
In our study women who smoked were at a higher risk of SILs compared to women that had 
never smoked (adjusted PR 1.55, 95% CI 1.13 - 2.14). This finding is consistent with other 
studies that have reported an increased risk of developing HSIL and or cervical cancer, with 
odds ratios in the range of 2 to 5 among HPV-positive women (IARC 2005). Nicotine and 
tobacco-specific carcinogens have been detected in the cervical mucus of smokers 
(Prokopczyk et al. 1997) and it has been shown that cigarette smoke condensate can cause 
malignant transformation of HPV16 immortalized human endocervical cells (Yang et al. 
1996). Both of these findings strengthen the plausible role of cigarette smoking in cervical 
cancer. Strategies to decrease cigarette smoking among South African women could assist in 

















A strong association between HIV viral load and cervical abnormalities has been 
demonstrated in other studies (Delmas et al. 2000; Massad et al. 2001; Schuman et al. 2003). 
However, due to resource constraints we were unable to collect data on HIV viral load. 
Another limitation in our study was that cytological abnormalities could not be histologically 
confirmed in all women.  
  
In the past few years there has been a significant increase in access to HAART in the public 
sector health services in South Africa, with an estimated 40 fold increase in HAART 
coverage between 2001 and 2008 (Adam, Johnson 2009). Internationally since the 
introduction of HAART there has been a decline in certain malignancies in HIV infected 
individuals (Jacobson et al. 1999; Ledergerber, Telenti & Egger 1999). However the impact 
of HAART on SILs and cervical cancer remains modest at best (Heard et al. 1998; Orlando et 
al. 1999; Lillo et al. 2001; Minkoff et al. 2001; Heard et al. 2002; Moore et al. 2002; Ahdieh-
Grant et al. 2004; Heard, Palefsky & Kazatchkine 2004; Heard, Potard & Costagliola 2006). 
Recent results from a prospective cohort of HIV positive women in Soweto, South Africa, 
showed that HAART was associated with a decrease of 28% in risk of progression from a 
normal or LSIL to HSIL (adjusted hazards ratio 0.72, 95% CI 0.52 - 0.99). However HAART 
had no impact on regression (Omar et al. 2011). Thus HIV-infected women on HAART 
continue to have a substantial risk for cervical cancer. As HAART becomes increasingly 
available in the public sector in SA, the life expectancy of HIV positive women will increase.  
Women receiving HAART are assessed regularly, and the opportunity to prevent cervical 
cancer in these women through regular screening, should not be missed. In providing services 
for HIV positive individuals initiating HAART, health service managers need to include 
resources for cervical cancer screening and to be cognizant of the fact that more than 60% of 
the women initiating HAART are likely to have an abnormal Pap smear and will require 
further treatment.  
 
In summary, women initiating HAART in SA have an extremely high prevalence of HR-HPV 
and SILs. This has major health planning and resource implications. Long-term longitudinal 
studies of the natural history of cervical lesions in women initiating HAART will be critical 

















Chapter 8: Concluding discussion and recommendations 
Chapter 8 reflects on the main findings and discusses opportunities for and challenges to 
comprehensive prevention of cervical cancer in SA. The chapter is structured as follows: 
     8.1 Implications of main findings 
8.1.1. Policy environment 
8.1.2. Leadership 
8.1.3. Managerial capacity 
8.1.4. Human resource issues 
8.1.5. Public awareness 
8.1.6. The challenge of HIV 
8.1.7. Health system development and support 
8.2. Recommendations 
 
8.1 Implications of main findings 
As a result of considerable scientific advances in the past decade strategies for both primary 
and secondary prevention of cervical cancer are available. Regrettably, despite these 
advances, the disease continues to cause significant morbidity and mortality particularly in 
low and middle-income countries. No comprehensive cervical cancer prevention programme 
exists in sub-Saharan Africa. This thesis set out to examine the challenges to and 
opportunities for preventing cervical cancer in South Africa, a middle-income country with a 
relatively well-developed health infrastructure compared to most sub-Saharan countries. Four 
main questions were explored: a) can a cytology-based based screening programme be 
effectively implemented in South Africa? ; b) what are the potential challenges to and 
opportunities for implementing an HPV vaccination programme in South Africa? ; c) what is 
the association between HIV, HPV, cervical cancer precursors and cervical cancer in South 
Africa and d) what is the prevalence of HPV and cervical cancer precursors, and the HPV 
types and HPV viral load in women initiating ART?  These questions have local relevance in 
















Africa. In addition findings are of relevance to other middle-income countries contemplating 
implementing a cervical cancer prevention programme. Findings related to each of the study 
questions were discussed critically in the relevant chapter, and are briefly re-visited below 
before the more general issues that arise from the work as a whole are discussed. 
 
a)  Can a cytology-based based screening programme be effectively implemented in South 
Africa? 
To determine whether a cytology-based screening programme could be implemented in South 
Africa a study was conducted to design, implement and evaluate health system interventions 
for public sector cytology-based cervical screening services in South Africa (chapter 4). As a 
result of the health system interventions service related outputs increased. Health workers 
gained knowledge and changed their attitudes and practices. The number of Pap smears 
performed increased by 76%, with 90% of these smears done on women in the appropriate 
target age group. However the overall Pap smear coverage targets were not met and timely 
treatment for women with HSIL was a problem. Efforts to improve referral, feedback and 
health information systems proved challenging. Although there were some improvements in 
client’s knowledge of cervical cancer and Pap smears, this did not translate into an increase in 
the number of Pap smears among women interviewed post-intervention.  
 
b)  What are the potential challenges to and opportunities for implementing an HPV 
vaccination programme in South Africa? 
A qualitative study was conducted to explore key challenges to and opinions about HPV 
vaccination introduction in South Africa. Policy makers, providers and community members 
all indicated support for the introduction of the HPV vaccine. Respondents had limited 
knowledge of the HPV vaccine and requested more information about the vaccine side-
effects and efficacy. The high cost of the vaccine was perceived as a barrier by policy 
makers. Providers and policymakers noted that the DOH had sufficient experience with 
managing vaccines, but at the same time recognised that the HPV vaccine would need to 
reach a different target age group compared to that usually served by the EPI programme. 
The school based health system was suggested as the most appropriate form of delivery by 
















system to deliver the vaccine. Introduction of the HPV vaccine will need to be accompanied 
by a strong information, education and communication strategy that addresses issues of HPV 
vaccine safety, side-effects and efficacy as well as provides ongoing education on cervical 
cancer screening and cervical cancer. 
 
c) What is the association between HIV, HPV, cervical cancer precursors and cervical cancer 
in South Africa? 
A case-control study was conducted to determine the association between HIV and cervical 
cancer. The study was conducted at an early stage in the HIV epidemic and prior to the 
introduction of ART. At this early stage of the HIV epidemic HIV positive women did not 
demonstrate an excess risk of invasive cervical cancer (adjusted OR 1.05, 95% CI 0.65 - 
1.70).  A separate analysis of the controls was undertaken to determine the association 
between HIV and cervical cancer precursors and HPV. Among HIV positive women 50% had 
an abnormal Pap smear and 51% had HR-HPV present. HIV positive women were nearly five 
times more likely to have HR-HPV present compared to HIV negative women (prevalence 
ratio 5.1 95% CI 3.3 - 7.7). Women infected with both HIV and HR-HPV were at a higher 
risk of SILs (LSIL and HSIL) than women infected with neither of these viruses (adjusted 
prevalence ratio 19.8, 95% CI 11.0 - 35.7). 
 
d)  What is the prevalence of HPV and cervical cancer precursors, and the HPV types and 
HPV viral load in women initiating HAART? 
A cross-sectional survey was conducted at a public sector ART clinic in Cape Town, to 
determine the HPV prevalence, HPV types, HPV viral load and prevalence of cervical 
precursor lesions among women initiating HAART. Sixty six percent of women had an 
abnormal Pap smear, the HR-HPV prevalence was 78.9 % and the median HPV viral load 
was 181.1 RLU. Among women with SILs (LSIL and HSIL) the most prevalent HR-HPV 
types were HPV types 18 (24.0%), 35 (22.0%) and types 16, 45 and 58 all with a prevalence 
of 20.0%. Multivariate regression was carried out to determine independent risk factors for 
SILs (LSIL and HSIL).  HPV viral load and smoking were associated with an increased risk 
of SILs. The adjusted PR was 4.95 (95% CI 1.19 - 20.63) for those that were HC2 positive 
















HC2 negative. For those that were HC2 positive with a HPV viral load > 181.1 RLU the 
adjusted PR was 7.61 (95% CI 1.88- 30.75), compared to those that were HC2 negative. 
Smokers were 1.5 times more likely to have SILs compared to non-smokers (PR 1.55, 95% 
CI 1.13 - 2.14).  
 
The latter two studies (c and d) show that it is crucial to strengthen and expand cervical 
cancer prevention programmes in settings where HIV prevalence is high. 
 
8.1.1 Policy environment 
The advent of democracy in South Africa created an opportunity for hitherto neglected health 
conditions in the country to be addressed. The new government has demonstrated a 
commitment to reproductive rights and women’s health. Nationally, cervical cancer was 
finally recognised as a priority health condition in the country. In 2000 the South African 
NDOH signalled its commitment to addressing cervical cancer by formulating the national 
cervical screening policy (Department of Health 2000). This policy adopts a public health 
approach, focussing on the age group most at risk of developing HSILs, and if properly 
implemented has the potential to decrease the incidence of cervical cancer by more than sixty 
percent (IARC Working Group on Cervical Cancer Screening 1986; World Health 
Organization 2002). In our interviews with policymakers in 2007 (chapter 5), all indicated 
that cervical cancer was still a priority condition. Policymakers were supportive of the HPV 
vaccine as an important primary preventive strategy whilst still recognising the importance of 
an ongoing secondary preventive strategy viz. screening with Pap smears. The enabling 
policy environment and the supportive views toward comprehensive prevention are a 
constructive starting point; however there are many challenges that need to be addressed 
before the benefits of reduced cervical cancer morbidity and mortality will be seen.  
 
8.1.2 Leadership 
An important function of the National Department of Health is to provide effective 
leadership. It is important that leaders not only determine the content of policy, but also the 
mechanisms and resources to implement the policy. Leaders should bring together relevant 
















health programmes. Although the National Department of Health set up a Cervical Cancer 
Task Team, consisting of researchers, academics, clinicians and managers to discuss and 
advise on cervical cancer prevention efforts,  the team has had few meetings, and no plan of 
action has been developed. Further, sectors other than health for example the Department of 
Education that are critical to a comprehensive cervical cancer prevention programme are not 
part of this Task Team. The NDOH has failed to harness the considerable academic and 
research resource available in the country.  Although policy makers indicated their support 
for the HPV vaccine in interviews conducted in our research in 2007, and in a statement 
issued at the 3
rd
 Stop Cervical Cancer in Africa conference held in 2009 (Stop Cervical 
Cancer in Africa 2009), there has been little progress toward HPV vaccine introduction in 
South Africa. Policy makers have stated that the high price of the vaccine is a barrier to 
introduction. However the DOH has not negotiated a reduced public sector price with the 
HPV vaccine manufacturers nor has it identified alternate funding sources. Strong dynamic 
leadership that has oversight of the cervical cancer prevention programme and facilitates 
policy implementation is needed. 
 
8.1.3 Managerial capacity 
Managing a comprehensive cervical cancer prevention programme is complex and 
demanding. Secondary prevention using Pap smears as the screening test requires adequately 
trained staff to perform and interpret the smears, a good laboratory infrastructure with quality 
assurance mechanisms, transport systems to get smears to the laboratory, mechanisms for 
communicating the results to women and ensuring all women with abnormal smears are 
followed-up and treated, referral and feedback systems and a system to monitor and evaluate 
the performance of the programme. Primary prevention involves: reaching and vaccinating 
pre-adolescents with three doses of the HPV vaccine, mechanisms to educate and inform the 
public of the vaccine, trained personnel to deliver the vaccine, systems to maintain the cold 
chain and to monitor coverage and side-effects. Should a school-based delivery system be 
used to implement the HPV vaccine, the vaccine schedule will need to be integrated into the 
school’s academic calendar. Managing a comprehensive cervical cancer prevention entails 
synchronisation of various government and non-governmental departments; coordination of 
activities in communities and in health facilities (primary, secondary and tertiary), 
















system. In short skilled managers are needed to drive and co-ordinate a cervical cancer 
prevention programme. 
 
In our experience of setting up secondary cervical cancer screening services in three areas in 
South Africa (chapter 4), it was clear that the capacity of managers was variable and often 
limited. Although most managers were able to make facility level changes such as instituting 
fast-track queues for clients returning for Pap smear results, or increasing the times that 
cervical cancer screening was offered, most were unable to effect changes outside the facility 
level. This was either due to a lack of authority, a lack of skills or to bureaucratic inertia. For 
example in one of the study sites we found counter-intuitive referral patterns which meant 
that clients requiring a colposcopy assessment were making unnecessary visits to the regional 
hospital before being referred to the tertiary hospital. However the health manager did not 
have sufficient authority to change the existing referral pattern. We found that the health 
manager’s ability to secure equipment for Pap smears was variable across the three project 
sites with one site where the manager was able to secure provincial funds for equipment, yet 
in another site the manager was unable to acquire funds for basic equipment.  
 
Other programmes such as the ART and the tuberculosis control programme have found that 
lay counsellors can play an important role in stimulating demand for a service among the 
community, allaying fears and providing support for people once they are diagnosed with a 
particular illness (Schneider et al. 2006; Abdool Karim et al. 2009). As part of our research in 
setting up secondary screening services, community members were trained as peer-educators. 
Although these community members reported that they had delivered talks to various groups 
in the community, none of the managers actively engaged with the peer educators or included 
them in a cervical cancer preventative strategy. 
 
An important aspect of managing a programme is collecting, collating and using data to 
inform decision-making. Although data collation tools were developed as part of the research 
study on implementing cytology-based screening (chapter 4), managers did not use the tools 
or the available information to identify and correct problems. This failure to recognise the 
















national levels. It is now ten years since the DOH cervical screening policy was launched, 
however it is still not possible to get reliable cervical screening statistics. Some provinces are 
able to provide coverage data, but no information is available at a national or provincial level 
on the proportion of women with HSIL that are appropriately managed, a key aspect of a 
cervical screening programme. If clients with precursor lesions fail to be treated, screening 
efforts have been wasted. Further it is unethical to offer screening without ensuring follow-up 
and treatment services (Sackett 1975). To monitor the impact of a comprehensive cervical 
cancer prevention programme, a national population-based cancer registry is needed, yet this 
has still not been set-up in South Africa. The current national cancer registry provides data on 
the incidence of cervical cancer, however as a pathology-based registry it is prone to 
underreporting. Further there are serious backlogs with the registry reports on cancer 
incidence, with data currently only available for up to 2001. The lack of a culture of utilising 
data for planning, monitoring and evaluating services is not unique to cervical cancer 
programmes and has been recognised in other programmes in South Africa (Schneider, 
Barron & Fonn 2007; Harrison 2009). Strengthening of managerial capacity and systems is 
critical to the success of a comprehensive cervical cancer prevention programme. 
 
8.1.4 Human resource issues  
Attaining high coverage of either primary or secondary cervical cancer prevention efforts 
requires an adequate supply of trained, motivated health providers. In South Africa 
professional nurses, the backbone of the primary health care system, perform most of the Pap 
smears. Should the HPV vaccine be introduced in South Africa, professional nurses will most 
likely be responsible for administering the vaccine as currently they perform most of the 
childhood vaccinations. A number of studies have demonstrated the key role providers play 
in affecting health behaviour (Mandelblatt, Yabroff 2000; Miedema, Tatemichi 2003; 
Ogedegbe et al. 2005). In our research on implementing a cytology-based screening 
programme (chapter 4) we found that prior to the health care provider training intervention 
73% of professional nurses were aware of the national cervical cancer screening policy, 
however only 43% could correctly state the policy and only 23% agreed with the policy. 
When we interviewed health care providers in the HPV vaccine study in 2007 (chapter 5), it 
was apparent that some health providers were misinformed about the national cervical 
screening policy and that many did not understand the rationale for the policy. Poor health 
















cancer preventive strategy. Research has shown that barriers to change can be overcome with 
tailored interventions (Fox & Kahn 2010). Encouragingly we demonstrated that health 
worker knowledge and attitudes could be changed with a health worker training intervention. 
The government has articulated a commitment and orientation towards a PHC approach, 
however skills development and reorientation of curricula toward primary health care has 
lagged behind (Lehmann 2008).  Training curricula for primary health care nurses and in-
service training programmes across the country need to include training on the rationale for 
the cervical cancer screening policy and ensure that staff have the technical skills to perform 
their tasks. Manuals based on our experience of implementing a health worker intervention 
programme for cervical cancer screening are available to guide the content and process of 
health worker training (Cervical Health Implementation Project (CHIP) 2004a; Cervical 
Health Implementation Project (CHIP) 2004b).  
 
Linked to training are issues of ongoing supervision, feedback and support. Research has 
shown that supervision and feedback by senior staff is important in improving profession 
practise and health-care outcomes (Pattinson 2006). Despite an improvement in staff 
knowledge and attitudes, we found considerable missed opportunities for cervical cancer 
screening post-intervention (chapter 4). This highlights the important role health managers 
need to play in monitoring missed opportunities and supervising and motivating staff to be 
proactive in their screening efforts. 
 
An inadequate supply of health workers has been identified as a key constraint to 
implementing health programmes in South Africa (Schneider et al. 2006; Kawonga & Fonn 
2008; Coovadia et al. 2009). Issues of staff shortages and increased workload were raised by 
providers, during interviews regarding HPV vaccine introduction. In our research on 
implementing cytology-based screening in three sites in South Africa, we observed a 13 % 
staff attrition rate over an 18 month period, and staff shortages were cited as a barrier to 
performing Pap smears. In order to meet the national goal of screening 70% of women over 
the age of 30 years within 10 years, 550 000 new Pap smears will need to be done per year in 
the country (Fonn 2003). Although earlier estimates indicated that the country had sufficient 
nurses available to carry out this task, these require revision as the estimates failed to take 
















health services (Fonn 2003; Kawonga, Fonn 2008). Further the production of nurses has not 
kept up with population growth (Kawonga, Fonn 2008). Unless strategies to increase nurse 
production and retain existing staff are implemented, fewer nurses will be available for 
cervical cancer prevention efforts and motivation of the remaining staff is likely to become an 
increasing problem. The delegation of tasks to less specialized cadres, also referred to as task 
shifting, is increasingly being discussed as an option to address the human resource crisis 
facing many African countries hard hit by the HIV epidemic (Lehmann et al. 2009). Evidence 
suggests that task shifting can lead to improvements in health service access and coverage 
(Lehmann et al. 2009). Lower cadre nurses have been successfully used to perform Pap 
smears in a research study in South Africa and in a rural district in India (Fonn et al. 2002; 
Rao et al. 2007). Expanding the roles of other cadres could increase the number of staff that 
can provide Pap smears and should be explored. However for task shifting to be successful, 
lower cadre of staff must be properly trained, supervised and supported.   
 
A study conducted in South Africa in 2003 showed that should the cervical screening policy 
be implemented, more cyto-technicians will be required to process the increased number of 
Pap smears (Fonn 2003). In our research on implementing a secondary cervical screening 
programme in three sites, we noted that turnaround times for clinics to receive Pap smears 
were long and to a large extent this was a result of laboratory staff shortages. If the three 
study sites had actually reached their proposed coverage targets, many more Pap smears 
would have had to be processed and even longer delays could have been expected. The 
shortage of cyto-technicians must be addressed if Pap smears are to remain the secondary 
screening method for cervical cancer prevention in South Africa.  
 
8.1.5 Public awareness  
Our research showed that women’s awareness of cervical cancer, Pap smears and the HPV 
vaccine was low. We found, however that once women were informed about Pap smears by 
the research field workers, the vast majority indicated interest in being screened. Similarly 
once women were informed of HPV vaccines, they were supportive of its introduction in the 
public sector. These results suggest that once women are informed they are keen to be part of 
primary and secondary cervical cancer preventive strategies. Efforts to improve client 
















campaign proved to be expensive and time-consuming, and unless a district or province 
undertakes a long and sustained community IEC campaign, the results are likely to be dismal. 
It is probably better to spend those limited resources to create opportunities in health services 
to inform women about prevention of cervical cancer.  
 
8.1.6 The challenge of HIV   
We demonstrated that HIV positive women in South Africa are at a significantly increased 
risk of cervical HR-HPV infection and SILs compared to HIV negative women (chapter 6). 
These results are consistent with findings elsewhere (Sun et al. 1997; La Ruche et al. 1998; 
Minkoff et al. 1998; Massad et al. 1999; Palefsky et al. 1999; Ahdieh et al. 2001; Duerr et al. 
2001; Massad et al. 2001; Hawes et al. 2003). In our study HIV positive women were not at 
an increased risk of ICC, however this study was undertaken at an early stage of the HIV 
epidemic. Data from a case-control study conducted at a later period and in an area with a 
higher HIV prevalence than our study, have shown that HIV positive women in South Africa 
are at an increased risk of ICC (Stein et al. 2008). The only way to prevent development of 
ICC in these women is through screening and early treatment of precursor lesions. There is an 
urgent need for HIV positive women to be screened for cervical cancer, in particular the 
increasing numbers of women accessing HAART so that the benefits of HAART are not 
partially offset by an excess risk in cervical cancer. The NDOH cervical cancer screening 
guidelines (Department of Health 2000) does not make reference to screening HIV positive 
women. We found that in the absence of specific policy and guidelines the majority of HIV 
positive women in our studies had not had a previous Pap smear.  
 
In our study (chapter 6) we observed that HIV positive women with SILs had a tendency to 
be younger than HIV negative women with SILs, suggesting that HIV positive women should 
be screened at a younger age in South Africa. In 2010 the HIV/AIDs directorate of the 
National Department of Health released clinical guidelines for the management of HIV 
positive adults which advocate a  Pap smear on HIV diagnosis and then a repeat Pap smear  
every 3 years if the cytology results are normal (National Department of Health 2010). 
Women with LSIL or ASCUS are to have a repeat Pap smear in one year and women with 
HSIL, a second LSIL or a second ASCUS lesion are to be referred for colposcopy. This 
















countries. Two studies in South Africa have  also suggested screening intervals of two to 
three years in HIV positive women (Denny 2008, Omar 2010), however further longer-term 
studies are needed to assess whether this screening interval can be extended in resource 
constrained countries such as South Africa.   
 
The National Department of Health clinical guidelines for the management of HIV positive 
adults  has major resource implications as it is estimated that there are 3 000 000 women 
living with HIV in South Africa (UNAIDS/WHO 2008). If all HIV positive women are 
screened according to the new policy, approximately 1 000 000 Pap smears will need to be 
performed among HIV positive women per year over the next 3 years. Extrapolating from out 
study findings annually between 38.4% and 55.3% (based on results from chapters 6 and 7 
respectively) of the women screened will have a lesion that will require a repeat Pap smear 
(ASC-US/LSIL) i.e. annually between 384 000 and 553 000 women will need a repeat Pap 
smear. Between 10.2% (based on results from chapter 7) and 11.5% (based on results from 
chapter 6) will have HSIL and will require referral for colposcopy i.e. annually 10 200 to 11 
500 HSILs will be detected. There are limitations to these estimates:  they do not include the 
women with an inadequate Pap smear that will require a repeat smear and do not take into 
account women who will be entering and leaving the cohort of HIV positive women. 
However, they provide some idea of the likely impact of the HIV epidemic on the cervical 
cancer screening workload and can assist in planning appropriate screening and treatment 
services. 
 
The extent to which health managers and health care providers are aware of or are 
implementing the National Department of Health clinical guidelines for the management of 
HIV positive adults is unknown. Given that implementation of the 10-year screening policy 
has proved challenging in South Africa, the feasibility of screening HIV positive women 
more frequently in the current South African health care context is questionable. To 
implement the screening policy for HIV positive women, Pap smear screening will need to be 
integrated into HIV and ART clinics and staff at these clinics will need to be trained to 
perform Pap smears and manage women with abnormalities. Colposcopy and cytology 
services will need to be expanded to meet the anticipated increase in workload, additional 
financial resources will be required to implement the policy and systems set-up to monitor 
















leadership, management and commitment is required. However the scale-up of ART in South 
Africa could provide an opportunity to develop cervical cancer screening services for all 
women, provided that HIV care is integrated into existing service delivery, rather than 
delivered as a separate vertical programme. 
 
8.1.7 Health system development and support  
Given the complexity in implementing cytology-based screening, other technologies are 
being explored for secondary prevention of cervical cancer in low and middle-income 
countries (IARC 2005; Sankaranarayanan et al. 2005).These methods do offer some 
advantages over cytology-based screening, but also have constraints. VIA is less costly than 
Pap smears, reduces demands on laboratory facilities, and can be used in a one visit screen-
and-treat approach (Sankaranarayanan et al. 2005). However VIA has a low specificity and is 
associated with over-treatment. Similar to cytology-based screening, VIA is prone to 
subjectivity and provider training and ongoing quality assurance are important to support 
VIA based screening services (IARC 2005). Although VIA has been used to screen women in 
research settings in South Africa (Denny et al. 2002; Denny et al. 2005), no information is 
available on how VIA will perform as a routine screening test in real health service settings in 
the country. A rapid HPV test, careHPV, has been tested in a research setting in China with 
encouraging results (sensitivity (90%) and specificity (84%) to detect HSIL) (Qiao et al. 
2008). However this test is not yet commercially available.  
 
HPV triage followed by a Pap smear for HPV test positives has been suggested elsewhere as 
a rational approach because of the higher sensitivity of the HPV test and the higher 
specificity of cytology (Cuzick 2006). An alternative screening option for South Africa 
would be a screening algorithm with an initial rapid HPV test, followed by Pap smear 
screening of HPV test positive women. As rapid HPV test results are available within a few 
hours, clients with positive test could immediately go on to have a Pap smear. Further the 
rapid HPV test could be performed by technical staff. Using this as the primary screening test 
would have the advantage of decreasing the number of women that require a Pap smear - an 
advantage given the current shortage of professional nurses to perform Pap smears. Further 



















Replacing the Pap smear with an alternate test will however, not overcome the need for a 
functional health system. While research into new technologies has progressed, strengthening 
of the health system, which is required for any of these technologies to impact on morbidity 
and mortality rates, has received considerably less attention.  
 
Investment in overall health system strengthening is critical to prevention of cervical cancer 
in South Africa. The example of Chile, a middle-income country like South Africa, is worth 
considering, as it has faced similar challenges to SouthAfrica in terms of re-organizing the 
cervical cancer screening program. Until 1985 Chile had an opportunistic screening 
programme in which women attending family planning services were screened on an ad hoc 
basis, with poor supervision of screening activities and little monitoring and evaluation of 
services (Sepulveda, Prado 2005; Salas 2006). In 1986 Chile re-oriented its cervical screening 
programme using a health systems development approach. The Chilean programme focussed 
on improving technical skills, managerial capacity and strengthening the health system. The 
result has been an improvement in organisation of the cervical cancer screening services with 
a 39% reduction in age-adjusted cervical cancer mortality rates between 1986 and 2001 (11.1 
per 100 000 women to 6.8 per 100 000 women) (Sepulveda, Prado 2005; Salas 2006).   
 
Without strong leadership, improved management capacity and a strengthened health system, 




The following recommendations are made for a comprehensive cervical cancer prevention 
programme in South Africa: 
 To reduce the high incidence of cervical cancer in South Africa, a secondary 
prevention programme needs to focus on recruiting large numbers of women, 
providing good-quality-screening services and ensuring that those with precursor 
lesions are treated.  Locally relevant health system interventions have been developed. 
















must be developed. The following recommendations are made for strengthening the 
health system: 
 Ensure that a system to monitor and evaluate the cervical cancer screening 
programme is set up and that managers at all levels are able to utilise health 
information in decision making 
 Develop the capacity of health managers to plan, implement, monitor and 
evaluate health programmes through management training programmes 
 Explore mechanisms to improve the supervision skills of health managers 
 Incorporate supervisory duties into staff contracts and performance appraisals 
of staff at various levels  
 Allocate resources so that all primary health care clinics are equipped to 
perform Pap smears 
 Investigate the use of lower nursing cadres to conduct Pap smears 
 Integrate skills required to implement the cervical screening into the nursing 
curriculum and continuing professional development programme 
 Ensure that cytology quality assurance programmes are in place 
 Increase the production of cyto-technicians 
 Ensure that an efficient referral system is in place for clients with cervical 
abnormalities 
 
 Local research should be conducted to explore the efficacy, cost-effectiveness and 
feasibility of a screening algorithm with an initial rapid HPV test, followed by Pap 
smear screening of HPV test positive women.  
 The HPV vaccine offers potential for primary prevention of cervical cancer in South 
Africa. However the high price of the vaccine is a major barrier. The National 
Department of Health must negotiate a price reduction with the pharmaceutical 
industry. In addition accessing international funding mechanisms, such as the United 

















 Recognizing that introducing the HPV vaccine will present some unique challenges 
(pre-adolescent target age, dose schedule, delivery mechanism through schools etc.) a 
pilot demonstration project should be set-up. This will provide an opportunity to test 
field logistics, develop appropriate training programme and materials for providers, 
develop appropriate educational materials for the community, monitor potential 
opposition and evaluate factors that may impact on coverage and uptake.  
 
 There is worldwide variation in HPV prevalence and types. Further studies on the 
HPV types present among women in South Africa are needed to evaluate the potential 
impact of HPV vaccines. 
 
 A national population-based cancer registry should be set up to assess the impact of 
primary and secondary cervical cancer preventive strategies. 
 
 Current knowledge on the impact of HIV on cervical disease is limited. South Africa 
has a high prevalence of both HIV and cervical cancer and is well placed to conduct a 
cohort study that would increase our understanding of cervical disease in HIV positive 
women. A long term cohort study will also inform screening policies for HIV positive 
women in resource constrained studies as it will provide information on regression 
and progression rates of cervical cancer precursor lesions.  
 
 Our current understanding of the impact of HAART on the natural history of cervical 
lesions is limited. As HAART programmes are scaled up in South Africa, an ideal 
opportunity exists to conduct a longitudinal study of the natural history of cervical 
lesions in women initiating HAART. This research will inform cervical screening 
practices for HIV positive women on HAART. 
 
Ultimately successful prevention of cervical cancer is South Africa requires renewed political 
commitment, adequate resource allocation and an investment in health systems development. 
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Appendix A: Health facility audit 
 
PART A: KEY INFORMANT INTERVIEW 
Clinic name:       
 
District:       Province: 
 
 




ORGANISATION OF SERVICES 
1. Does this health facility provide Pap smear services?    
1. Yes 
2. No  
 
2. What is the total number of consulting rooms at your clinic?  ___________________________ 
 
3.  In how many rooms are Pap smears performed?   ___________________________ 
 
4. Do women require an appointment to have a Pap smear? 
1. No 
 2. Yes: (describe how the appointment system works)  ___________________________ 
5. Do women have to wait in a separate queue for a Pap smear? 
1. Yes 
2. No 
6. Does this health facility have mobile services? 
1. Yes 
2. No 
7. Do the mobile services provide Pap smears? 
1. Yes 
2. No 
3. Not applicable 
STAFF 
8. How many staff are assigned to work at this facility, and how many of these are trained to take Pap smears? 
 Number working at facility. Number trained in taking Paps 
1. Staff nurses    
2. Professional nurses    























9. How many staff actually perform Pap smears (i.e. those doing at least one Pap smear per month)? 
1. Staff nurses    
2. Professional nurses    
3. Doctors     
 
2. CYTOLOGY REPORTING 
10. To which cytology lab(s) do you send your Pap smear specimens? 
Lab 1 ____________________________________________ 
Lab 2 ____________________________________________ 
Lab 3 ____________________________________________ 
 
11. On average, how long does it take for cytology results to return to your clinic from the cytology lab? 
(indicate turnaround time for each lab they utilise)  
Lab 1 _________________________________________________________________ 
Lab 2 _________________________________________________________________ 
Lab 3 _________________________________________________________________ 
 
3. FOLLOW-UP 
12. If a client has an abnormal Pap smear, who notifies her of the results?  
(i) The person who receives the result 
(ii) The person who did the smear 
(iii) One person is in charge of the follow-up 
(iv) The lab notifies her 
(v) Other (please specify) _____________________________________________________________ 
 
13. How are clients with abnormal Pap smear results contacted and followed-up (ask for description of follow-
up system) ___________________________________________________________________________ 
 
14. Is there a system in place by which records are kept and reviewed to ensure that results were received and 




15. If yes to Q 14, describe the system and how it works: ________________________________________ 
 
16. If yes to Q 15, In your opinion, does the current system for follow-up work? 






















4. PATIENT MANAGEMENT AND REFERRAL  




18. If yes to Q 17, what is the source of these guidelines (who developed them?)______________________ 
 
19. Where do you refer patients who need colposcopy and treatment?  
 
20. Do you get feedback on the outcome of the referral for clients you refer to hospital for further management? 
1. Yes, frequently 




21. Describe how records of Pap smears are kept in this facility: __________________________________ 
 
22. Do you have any suggestions for how you feel the system for record keeping can be improved? 
__________________________________________________________________________________________

































PART B: FACILITY CHECKLIST 
1. ACCESSIBILITY 
ORGANISATION OF SERVICES 
1. Official opening time for this health facility:   ____________________________ 
2. Official closing time for this health facility:   ____________________________ 
3. Days of the week that health facility offers Pap smears: 
 Day        Time 
Monday  To  
Tuesday  To  
Wednesday  To  
Thursday  To  
Friday  To  
Other (specify)  To  
Other (specify)  To  
 
IEC  
4. Information for patients about Pap smear service availability Yes No 
(i) Poster(s) displayed announcing Pap smears are available at this health facility?   
(ii) Poster indicates clearly the times/days that Pap smear service is available?   
 
5. IEC methods used to educate and inform patients about Pap smears:  Yes No 
(i) Educational videos   
(ii) Posters   
(iii) Health talks   
(iv) Pamphlets to take home   
(v) Other (specify)     _______________________________________   
 
 CYTOLOGY REPORTING 
6. Cytology request forms available for each lab they use? (obtain copy) Yes No  
(i) Lab 1 ___________________________________________   
(ii) Lab 2   ________________________________________________   

















7. Do cytology report forms have the following information (tick appropriate box)? 
(request copy of cytology report for each lab they use)  Lab 1  Lab2  Lab 3 
(i) Clinic name      
(ii) Clinic code      
(iii) Patient name      
(iv) Patient number      
(v) Date of smear      
(vi) Date of smear report      
(vii) Result of smear - Bethesda      
(viii) Result of smear - other      
(ix) Recommended management included      
 
3. FOLLOW-UP 
8. System for patient follow-up:  Yes No  
(i) Use standard notes/letters for follow-up of clients    
(ii) Records kept of clients that need follow-up   
(iii) From records are able to determine those that did & did not come for follow-up?   
 
4. PATIENT MANAGEMENT AND REFERRAL  
9. Guidelines for management of patients with abnormal Pap smear results  Yes No 
(i) Each consulting room has a copy of the guidelines   
(ii) Guidelines available in one or some consulting rooms only   
(specify which room(s) ________________________________________ 
 
5. RECORD-KEEPING 
10. Method for maintaining Pap smears patient records    
  Yes    No 
(i) Pap smear log book    
(ii) General clinic register   
(iii) Use minimum Data Set format   

























11. Pap smear patient records include the following information 
(ask to see records and indicate which of the following data are recorded)    
   Yes    No 
(i) Patient name    
(ii) Patient age / date of birth    
(iii) Patient contact details (physical address, telephone etc)   
(iv) Date smear taken   
(v) Date result of smear received   
(vi) Any past history of abnormal smear   
(vii) Whether first time or repeat smear   
(viii) If follow-up is needed   
(ix) If follow-up has been done   
(x) If referral is needed   
(xi) If has been referred   
(xii) Outcome of referral   
(xiii) Log book / recording book could not be located   
(xiv) No records kept by facility   
(xv) Other (please specify) ______________________________   
 
12. Monthly/quarterly statistics and data collation reports for screening service (observe walls, and ask to see 
reports)                           Yes     No 
(i) Statistics displayed on the walls   
(ii) Appropriate statistics displayed   
(iii) No statistics displayed on walls   


















Appendix B: Staff KAP survey 
DATE:   (DD/MM/YY) 
 
GENERAL/ BACKGROUND 
1. Gender  
1. Female  
2. Male  
 
2. Age in years _________  
 
3. What is your position at your clinic? (circle one only)     
1. Sister in Charge 
2. Professional Nurse- Clinical Nurse Practitioner (CNP) 
3. Professional nurse 
4. Other (specify) 
 
4. How long have you been qualified? (circle one only )  
1.  Less than 2 years 
2.  2 to 5 years 
3.  More than 5 years 
 
STAFF TRAINING 








3. Was your training in taking Paps linked to other training (such as family planning training or training for STD 
treatment)? 
1. Yes (specify which) ______________________________________________ 
2. No 
3. Not applicable 
 
4.1. When did your training in taking Pap smears occur?   
1. In the last month 
2. In the last year 
3. In the last five years 
4. More than five years ago 




5.1. Have you performed a Pap smear since your training in taking Paps?  
1. Yes 
2. No 
5.2. If yes, when was the last time you did a Pap smear? 
1. In the last one month 
2. In the last three months 
3. More than three months ago 
 






















STAFF PRACTICES AND POLICY 
1.  If women come in for non-gynaecologic problems, do you talk to them about having a Pap smear? (please 
circle one only)  
1. Yes 
2. No 
3. Sometimes (please specify when you talk to them)______________________ 
 
2. What criteria do you use to decide if a woman should have a Pap smear? (circle all the criteria that you 
use) 
1. Time duration since her last Pap smear 
2. Her age  
3. If she has had a Pap smear before 
4. If she is sexually active 
5. If she has multiple sex partners 
6. If she is pregnant 
7. If she has a vaginal discharge 
8. If she has abnormal bleeding 
9. If her cervix appears abnormal 
10. If she has had an abnormal Pap smear in the past 
11. If she requests one 
12. Other (please specify)__________________________________ 
 
3. If a woman comes to you and asks why Pap smears are important, what do you tell her? (may circle more 
than one response if wish to) 
1. Pap smears will protect her from getting cancer 
2. Paps will help diagnose infections 
3. Cervical cancer is very common 
4. Other (please specify)______________________________________ 
 
4.1   Do you know the National Policy regarding when women should have Pap smears? 
1. Yes 
2. No 
4.2. If yes, what is the policy? (circle correct one only)  
1. Every ten years if the first one is normal 
2. Starting at age 30 
3. 1 and 2 (Every ten years starting at age 30 ) 
4. At least every ten years but preferably every two or three 




INPUT ON SCREENING PROGRAM 
1.  Do you think that more Pap smears could be done in your clinic? 
1. Yes 
2. No  
2. If more Pap smears were to be done at your clinic, when do you think they should be done? (circle one 
response only)  
1. Every day (at any time) 
2. Every day (only at certain times) 
3. Only on certain days 
4. Other (please specify) ________________________________________ 
 
3. What are the obstacles to performing Pap smears / more Pap smears at your service? (circle all those that 
you feel are obstacles at your clinic) 
1. Lack of equipment (speculum, spatula, slide, fixative ) 
2. Not enough adequate lighting  
3. No room/space in which to do the exam 
4. Not enough staff 
















6. Clients will be made to wait even longer to see staff  
7. It is difficult to follow up with every woman after she has a Pap 
8. Women are not interested in coming in for Pap smears 
9. Women do not know that they should come in for a Pap smear  
10. Language barriers 
11. Staff do not like performing Paps 
12. Often run out of equipment (speculum, slides, fixative, spatulas) 
13. Not been able to access equipment 
14. Other (please specify)_____________________________________ 
 




5.  The majority of Pap smears are currently done on younger women. How can older women be reached to 
come in for Pap smears? (circle the method(s) you agree with) 
1. Media 
2. Community discussions/education 
3. Posters 
4. Pamphlets 
5. Other (please specify _______________________________________ 
 
6. Currently many women do not request Pap smears. Why do you think this is so? (circle those you think are 
the reasons) 
1. Lack of education 
2. Fear 
3. Lack of concern over their own health 
4. Pap smears are uncomfortable 
5. It is difficult for them to get to the clinic 
6. Long wait to see staff 
7. They are shy 
8. They do not feel comfortable around the staff 
9. Other (please specify)________________________________________________ 
 
FOR STAFF THAT HAVE PERFORMED PAP SMEARS WITHIN THE LAST 3 MONTHS: 
1. Do you get the results for the Pap smears that you perform? (circle one answer only)  
1. Yes, often 
2. Yes, rarely 
3. No 
 
2.. Indicate the action required for each of the following Pap smear results.  
 
Result Action required 
 
Do not know 
High grade SIL 














3. In your opinion, how much time does performing a Pap smear add to a client visit? 
1. Less than 10 minutes 
2. 10 to 15 minutes 

















4.. After a Pap smear is done, how does a woman learn of the results? (circle response for what is practised at 
your clinic) 
1. She is informed of the results when she next comes to the clinic 
2. She has a follow-up appointment 
3. She receives a letter 
4. She is visited at home 
5. Other (please specify)_______________________________________ 
 
 
ATTITUDES TOWARD POLICY AND SCREENING 
1. For each of the following statements, please indicate whether you strongly agree, agree, disagree, or strongly 
disagree (please respond to all 6 statements 17.1. to 17.6.). 
(Strongly agree=1, agree=2, disagree=3, strongly disagree=4) 
1. 17.1. Women over 60 should have Paps  
2. 17.2. Nurses should tell all women over 30 to have Paps  
3. 17.3. Women should be able to have Paps in public health facilities whenever they want  
4. 17.4. My other responsibilities are more important than performing Paps  
5. 17.5. Sharing information with women about Pap smears will encourage women to have a Pap  
6. 17.6. Nurses are too busy to share information with women about Pap smears   
 
2.1 The National Policy states that women should have a Pap smear every ten years starting at age 30. Do you 
agree with this policy? 
1. Yes 
2. No 
2.2. If no, why not? (circle all the reasons you don’t agree with policy) 
1. Every ten years is not often enough - every three to five years is ideal 
2. Every ten years is not often enough - should have a Pap smear annually 
3. It is difficult for women to remember to come back after ten years 
4. Should have a Pap smear when pregnant 
5. Should start even when under 30 years old 
6. Should start when over 30 
7. Should start when they become sexually active  
8. Other (please specify) ___________________________________________ 
________________________________________________________________ 
 
3.1.   Have you ever had a Pap smear yourself? 
1. Yes 
2. No 
3.2. If no, why not? (you may circle all that apply to you) 
1. Forgot 
2. Was too busy 
3. Paps are uncomfortable 
4. Was embarrassed 
5. Was afraid something bad would be discovered 
6. Did not think I needed one 
7. Other (please specify)_______________________________________ 
 
























Hello, my name is ............................... I do not work at this health center, but I work at the  ……….. We are doing a 
health survey and would really appreciate it if I could ask you a few questions about your health.  It will take about 
10-15 minutes.  You will not lose your place in the queue. 
 
I am not going to write your name on the form, therefore anything you tell me will remain anonymous and be treated 
confidentially. You may stop the interview at any time you wish to. Your answers will help us to improve services. 
You do not have to participate if you do not want to. 
 
 Thank you. 
 
 
Personal information  






2 Why did you come here today? 
 












3a  What standard did you complete in school? 











4 What is your marital status ?  Married (incl. common law) 
Widowed 
Divorced/Separated 





5 Are you living with your husband or any male 





2 Skip to q 8 
8 Skip to q 8 






2 Skip to q8 
9 Skip to q8 











2 Skip to q 9 






Skip to q 10 







Unemployed – looking for work? 
Unemployed - not looking for 
work? 
Disabled (physically or mentally) 
A pensioner (government or private 


































2 Skip to q12  
9 skip to q12 
11. What radio stations do you listen to? 













Yes            No 
1                  2 
1                  2 
1                  2 
1                  2 
1                  2 
1                  2 
1                  2 
 



























Knowledge of Pap Smears and cancer of the cervix 
14 
 
Have you ever heard of a Pap Smear test? 
 
 
Yes        
No         
Unsure 
1 
2 skip to q27 
9 skip to q27 
15 
 
 If Yes, what part of the body is examined during a 
Pap smear test?   
Interviewer do not prompt. Code yes if any of the 
following words are mentioned spontaneously: 
Cervix/womb/vagina/private parts (or local word 




Yes      No 
1          2 
16 What do you think a Pap Smear test is testing for? 
 
(Note here………………………………...)  
 
Interviewer: open-ended, do not prompt).  Code yes 
if the following words are mentioned 
                                          
Cancer 






Yes        No 
1             2 
1             2 
1             2 
1             2 
1             2 
1             2 
9 
17 At what age does the Department of Health (DOH) 
say that a woman should have her first Pap Smear 
test?  Before the age of 30 or after the age of 30 
years? 
 
Less than 30 years old 
More than 30 years old 






Actually, the  DOH says a woman should have her 
first Pap smear at the age of 30 years or older.  Do 







9 skip to q19 
18 
(b) 






















19 How often or how many years apart, does the DOH 
say that a woman should have a Pap Smear test 
during her life? 




Once a year                              
Every 2-5 years                        
Every 6-9 years                      
Every 10 years                         
With each pregnancy               
Other................................……… 










Actually, the DOH says that a woman should have a 







9 skip to q 21 
20 
(b) 
Why do you say this (agree/disagree)? 





21a Do you think women who have stopped having sex 








9 skip to q 22 
21b Why do you say that (yes or no)? 






22a Do you think women who have stopped having 








9 skip to q 23 
22b Why do you say that? 






23 What does it mean if the Pap test is abnormal/shows 
that there is a problem? 


















25 Have you ever discussed Pap smears with a 
 









Anybody else (specify……... 
…………………………….. 
 Yes        No 
1                2 
1                2 
1                2 
 
 








INTERVIEWER say to ALL respondents: A Pap smear is a test for cancer of the cervix. 
 
27 Have you ever heard of cancer of the 







2 skip to q33 
9 skip to q 33  







29 At what age are women most likely to get cancer 
of the cervix?   
As teenagers 



















(Interviewer, read the list and ask respondent to 
select which age group) 



































33a Interviewer: ask all respondents 
In the last 6 months, have you ever seen or heard 
about Pap smears or cancer of the cervix such as 
on:  
 







a. a poster 
b. a leaflet/pamphlet 
c. a talk by health workers 
d. personal discussion with a health 
worker 
e. an organised talk in the 
community 
f. a radio programme 
g. an article in the newspaper 
h. anything else? (specify) 
…………………………………… 
Yes  No   DK 
1         2       9 
1         2       9 
1         2       9 
1         2       9 
 
1         2       9 
 
1         2       9 
1         2       9 
1         2       9 
33b What did you learn from these about pap smears 
and/or cervical cancer? 








Pap Smear History 
 
This section for ALL respondents 
 
First, explain what a Pap smear is: ………… 
A Pap smear is a simple test done on women to check if the mouth of the womb (cervix) is healthy.  The client 
lies on a couch, on her back with knees bent and apart, and feet apart. The nurse/doctor places an instrument 
into the vagina to see the mouth of the womb. The mouth of the womb is gently wiped; a sample is taken and 
sent to the laboratory for testing. The results of this test will be sent to your clinic so you have to remember to 
go back for your results. 
 






1 skip to q 36 
2 
9 skip to q 44 
35 If No, is there any reason why you have not 
had a Pap smear?) 









Now skip to Q 
44 
 
36 If yes, how many times have you had a Pap 
Smear (in your life time)? 
 
Actual if able to estimate (………) 
Once 
2-5 times 






37 Have you ever had a Pap smear without it 











































2 skip to q 41 
9 skip to q 41 
40 How did you get the results? 
 
 
Client contacted the clinic 
Clinic contacted client 


















DK / unsure 
 
1 
2 skip to 44 
9 skip to 44 
42 If yes, when will that be?   
 
Years from now……………. Skip to q 46 
43 For those not planning another pap smear 










Never heard of a Pap smear, or never had a Pap smear? 
 
This section is for those women who have never heard of a Pap smear, or they have heard of them, but never 
had one (women who answered no or DK to question 34/35)  
 
 
44. Do you think you would be interested in 




1 Skip to 46 
2 
9 Skip to 46 


























Appendix D: Focus group interview guide 
INTRODUCTION 
We are going to be talking to you today about a way to prevent cervical cancer. 
  
1. Could you discuss what you know or have heard about cancer? 
 
2. Could you discuss what you know or have heard about cervical cancer? 
If participants are not familiar with cervical cancer, what kind of sicknesses do you know of that can affect a 
woman’s reproductive system?  
 
2. How do you think a woman gets cervical cancer?  
 
3. How can a woman prevent cervical cancer? 
Have you heard about any tests that prevent women from getting cervical cancer?  
If so, have you gone for these services or do you know anyone who has gone for these services?  
What was your experience like or what did they tell you about their experiences?  
Where could a woman get these cervical cancer prevention services in your area?  
 
4. Could you describe anything you might have heard about the HPV virus and/or the HPV vaccine? If 
participants have, could you describe what you have heard?  
 
Interviewer: Then explain 
 
The HPV virus is a sexually transmitted virus and is the virus most responsible for cervical cancer. A small 
number of women who are infected with the HPV virus may develop cancer of the cervix.  A new HPV vaccine 
is now available in some countries but not yet in South Africa. This vaccine can be given to prevent cervical 
cancer. 
 Will prevent cervical cancer (approximately 70 % of cases).  
 Should be before one starts having sex that is before they are exposed to the HPV virus 
 Will be given in 3 injections over 6 months 
 
5. What are your thoughts or feelings about vaccination in general? 
 
6. Do you think people in your community would be interested in receiving the HPV vaccine? 
 What would then decide to have the vaccine?  
 What would them decide not to have the vaccine? 
 
7. How would you feel about young girls or your child receiving the vaccine?  
 
8. Who do you think would NOT want to use this vaccine?  
 Why would they not want to use it?  
 
9. Would you have any concerns about your child receiving the HPV vaccine? If yes, what would they be? If no, 
why not? 
Probes: 
 Would you have any concerns around safety, if yes what would they be  
 Would you have any concerns around the effectiveness of the vaccine? 
 Concerns around side effects 
 Have you had any other experiences with vaccines – if yes, what were they? 
 
10. Do you think you would be prepared to pay for the vaccine? If yes, how much would you be willing to pay 
for the vaccine? If no, why not?  
 
 
11. What kinds of information would you like to receive about the vaccine before making decisions whether to 

















12. Where do you think people in your community would like to get information about the vaccine? 
 
13. Where do you think the vaccine should be made available? 
Probes: 
 Should it be available at clinics such as youth clinics or public health care clinics? Why? Why not? 
 Should it be available at schools? Why? Why not? 
 What other places do you think it should be available? Why? 
 
14. Are they any individuals or people who you think could influence who would influence decisions to use it or 
not to use the HPV vaccine?  
Probes: 
 Would family or parents influence the decision? 
 Would friends or peers influence the decision? 
 Would healthcare providers influence the decision? 
 Are there other people or organisations that may influence the decision to use or not use the vaccine? If 
yes, who are they?  
 
15. Do you have any other thoughts, concerns or questions? 
 


















Appendix E:  Health care provider interview guide 
Introduction 
I would like to discuss some issues related to prevention of cervical cancer. 
1. Are you aware of the South African cervical cancer screening policy? 
If yes, could you discuss what you know? 
If no, explain below. 
Note to interviewer: Even if responded yes explain below starting with ―Just to re cap‖. 
 
In an effort to reduce cervical cancer the National Department of Health introduced a cervical screening policy 
in 2000. According to this policy all women over the age of 30 years attending public sector services are entitled 
to three free Pap smears in their lifetime at 10-year intervals.  
 
2. What are your views on this policy? 
 
3. What has your experience been with regards to cervical cancer screening programs and cervical cancer 
treatment? 
Probe:  If not mentioned, what have your experiences been with doing Pap smears, getting and interpreting 
results from the lab and with women returning for their Pap smear results? 
 
We now know that cervical cancer is caused by the human papillomavirus (HPV). HPV is a common, 
asymptomatic sexually transmitted infection. There are many types of HPV and certain high risk types of HPV 
cause cervical cancer. However, not all women who have HPV infection go on to get cervical cancer. 
 
4. Had you heard of the HPV vaccine? 
If yes, could you describe what you had heard? 
 
There is now an HPV vaccine which is available in some countries but not yet in South Africa. This vaccine 
provides protection against 2 strains of HPV which are responsible for most, not all, of cervical cancer cases. 
The HPV vaccine is effective if it is given before one is sexually active and thus before exposure to the HPV 
virus. The vaccine must be given as 3 injections over 6 months. As with any new product, there are many 
questions about how best to deliver the vaccine and how to integrate the HPV vaccine into existing cervical 
cancer prevention programs. 
 
5. What are your views about preventing cervical cancer by using a vaccine? 
 
6. Who do you think is likely to use the HPV vaccine? Are there certain clients or groups that you think it 
would be most appropriate to offer the vaccine to? If so, who?  
 
7. Currently the HPV vaccine has been licensed for girls and women elsewhere, what do you think about 
boys and young men receiving the vaccine?  
 
8. Who should manage and be responsible for this program?  
 
9. What would be the most suitable places for distributing the HPV vaccine?  
Probe: Expanded programme on immunization (EPI) and Child Health, Sexual and Reproductive Health 
How would you feel about administering the vaccine at youth/adolescent clinics or within the school health 
services? 
 
10. Information/counseling:  
What information/resources do you think providers would need to have to effectively introduce the 
HPV vaccine? 
What do you think would be the most suitable means for providing information and counseling on 
the HPV vaccine? 
 
11. Assuming the HPV vaccine is approved for use in South Africa, how would you feel about introducing 
it at the facility that you work at? What issues do you think would facilitate or hinder offering the 

















12. Do you have any concerns that the introduction of the HPV vaccine could impact on existing cervical 
cancer screening programs and strategies?  
If yes, what would they be? 
 
13. How do you think the HPV vaccine should be integrated into existing screening programs? 
 
14. Do you foresee any problems or opposition from health care providers, parents, community or religious 
organizations that could oppose the introduction of HPV vaccines?  
If yes, what would be the best approach to handle any opposition or concerns? 
 
15. What has been your experience in the introduction of other similar methods or new technologies? How 
can these experiences be applied to the introduction of the HPV vaccine?   
 
16. Do you have any other comments, suggestions or questions that you would like to ask? 
 

















Appendix F: Policy-makers interview guide 
 
Introduction 
I would like to discuss some issues related to prevention of cervical cancer. 
 
1. Are you aware of the South African cervical cancer screening policy? 
If yes, could you discuss what you know? 
If no, explain below. 
Note to interviewer: Even if responded yes explain below starting with ―Just to re-cap‖. 
In an effort to reduce cervical cancer the National Department of Health introduced a cervical screening policy 
in 2000. According to this policy all women over the age of 30 years attending public sector services are entitled 
to three free Pap smears in their lifetime at 10-year intervals.  
 
2. What are your views on this policy? 
 
3. What has your experience been with regards to cervical cancer screening programs and cervical cancer 
treatment? 
 
4. What sorts of priorities do you think cervical cancer prevention programs have in relation to other 
health programs. 
 
5. Had you heard of the HPV vaccine? If yes, could you describe what you had heard?  
 
Note to interviewer: discuss below even if have heard of HPV vaccine 
 
There is now an HPV vaccine which is available in some countries but not yet in South Africa. This vaccine 
provides protection against 2 strains of HPV which are responsible for most, not all, of cervical cancer cases. 
The HPV vaccine is effective if it is given before one is sexually active and thus before exposure to the HPV 
virus. The vaccine must be given as 3 injections over 6 months. As with any new product, there are many 
questions about how best to deliver the vaccine and how to integrate the HPV vaccine into existing cervical 
cancer prevention programs. 
 
 
6. What are thoughts around the HPV vaccine as a particular method of cervical cancer prevention? 
      Probes: Ask these questions if not discussed 
Issues related to safety and efficacy: How effective would it have to be for you to consider recommending 
it? Could you comment? 
Cost: Do you have concerns about cost? If yes, what are they? 
Training and service needs: Do you have concerns about training and other service related needs such as 
procuring the drugs and delivery of a vaccine. 
Target age: What do you think the target age should be for the vaccine? Why do you think it should be 
targeted at this age? 
Who would use: Elsewhere the HPV vaccine has only been licensed for girls and women what do you 
think about boys and young men receiving the vaccine? 
Information/counseling What do you think would be the optimal channels for providing information and 
counseling? 
Distribution channels What do you think would be the optimal channels for HPV vaccine delivery? 
 
7. The HPV vaccine has the possibility of being positioned in various programs, where do you think 
management of the HPV vaccine program should be best positioned? Why? 
 
8. How would you feel about placing the vaccine at youth/adolescent clinics or within the school health 
services?  
 
9. Is there anything else that you would need to consider in recommending or not recommending the HPV 

















10. Do you have any concerns that the introduction of the HPV vaccine could impact on existing cervical 
cancer screening programs and strategies? If yes, what would they be? If no, why not?  
 
11. Do you foresee any problems or opposition from parents, community, health care providers, religious 
organizations or anyone else? Probe why, why not?  
 
12. Are there any groups or individuals that you believe could facilitate or hinder the introduction of the 
HPV vaccine?  
 If yes, who are they? 
 If yes, how could or would they facilitate or hinder introduction?  
 
13. What has been your experience in the introduction of other similar methods or new technologies? How 
can these experiences be applied to the introduction of the HPV vaccine?   
 
14. What role do you think the private sector could play in the introduction or uptake of the HPV vaccine? 
 
15. Do you have any other comments, suggestions or questions that you would like to ask? 
 
















Appendix G: Questionnaire cervical intraepithelial lesions in HIV positive women 
initiating highly active antiretroviral therapy 
1. Date of Interview      dd/mm/yy   / /  
 
I would like to ask you a few questions to see if you are eligible to be in the study. 
 
2. Age                     
 
3. Date of Birth                     dd/mm/yy   / /   
 
If younger than 18 years thank the respondent and discontinue the interview 
 
 
4.  Are you currently pregnant ? ________                                                  
 
5. Have you had your uterus/womb removed?                                                  
6. Are you menstruating at present (bleeding or spotting).                                  
 
If YES to questions 4, 5 or 6 thank the respondent and discontinue 
If NO to question 4 and 5 and 6 then explain to the client that she is eligible and proceed with the 
interview 
 
A SOCIO-DEMOGRAPHIC CHARACTERISTICS 
Interviewer to transcribe Age and Date of Birth from page 1 
1. Age                   
  
2. Date of Birth                    dd/mm/yy   / /   
 
 
I would like to ask you a few questions about your education, marital status etc. 
3. What is the highest level of education that you have completed?                                                            
0.  Did not attend school at all                              7    Std 5    Grade 7                                     
1.  Sub A    Grade 1                                                   8    Std 6    Grade 8                                      
2.  Sub B    Grade 2                                       9    Std 7    Grade 9                                     
3.    Std 1    Grade 3                                       10  Std 8    Grade 10                                      
4.    Std 2    Grade 4                                       11  Std 9    Grade 11                                      
5     Std 3    Grade 5                                     12  Std 10   Grade 12                                      
6     Std 4    Grade 6                                     13  Tertiary (University/technikon/college)                                  
 
4. Do you do work that you are paid for?__________       
 
If NO skip to Q 6 
5. If Yes: What is your job?           Specify:  ___________________________          
                        
1. Professional (teacher, nurse, doctor, researcher) 
2. Skilled (saleswork, hairdresser erc) 
3. un/semiskilled manual (labourer, domestic worker) 
4. Other    
6. If NO, are you:          
  
1. Unemployed-looking for work 
2. Unemployed-not looking for work 
















4. Full-time student 
5. Disabled (physically or mentally) or a pensioner (government or  
private civil pension/not working due to old age) 
 
7. What is your current relationship status?           
  Are you now                                                                             
1. Married (including common –law)                 
2. Single: in a stable relationship                                            
3. Single: in a casual/short term relationship                             
4. Single: no relationship now 
 
B.  SMOKING HISTORY 
1. Do you now or have you ever smoked cigarettes?                              
1. Never  
2. Ex-smoker  (stopped more than one year previously)   
3. Current smoker (smoking sometime during the past year) 
 
If never smoked go to next Section on Pregnancy History    
If current smoker go to question 5 
If Ex-smoker go to question 2  
 
2. How many cigarettes did you smoke a day?               
          
3. For how long did you smoke?          
1.  1 year  
2. 1-5 years 
3.  5 years 
4. Don’t remember 
4. How long has it been since you stopped smoking?         
            
1. 1-5 years 
2.  5 years 
3. Not sure/don’t remember 
                                    
5. How many cigarettes do you smoke a day?            
            
6. For how long have you been smoking?            
   
1.   1 year  
2. 1-5 years 
3.  5 years 
4. Not sure/don’t remember 
                                          
 
C.  PREGNANCY HISTORY  
 
I am now going to ask you about pregnancies. 
1. Have you ever been pregnant?                                                                
 
If NO go to next section on Contraceptive History 
 
2. IF YES:  How many live children do you have?____________________________________              
 
3. Have any of your children died      _______________________________________________      
 
IF YES: 
a.    How many___________________________________________________________________   
 

















IF YES:  
a.     How many____________________________________________________________________   
 
5. Were any of these babies born by Caesarian section? 
________________________________________  
 
IF YES:    
a. How many______________________________________________________________________  
6. Have you had any miscarriages? ________________________________________________________ 
  
                 (abortions/ectopic pregnancies) 
 
 IF YES:   
a.   How many_____________________________________________________________________   
 
D. CONTRACEPTIVE HISTORY 
I am now going to ask you  about contraceptive methods 
 
Have you ever used any of the following methods (Past use):  
 
Interviewer to read each option 
1.Birth control Pills (Oral contraceptive/"The Pill")      
2. Injectable contraception          
3.  Foam/Jelly/Cream          
4. Condom Male ________         
5. Condom Female ________         
6. Sterilization (Tubes Tied)         
7. Partner's vasectomy           
8. Other (e.g. Withdrawal)  Specify        
                                                          
9.  Are you currently using any contraception?______________________________________________  
a.   If YES which method are you using? ___________________________________________________  
 
1. Birth control Pills (Oral contraceptive/"The Pill") 
2. Intrauterine Device (IUCD/ Loop/ Coil) 
3. Injectable contracpetion 
4. Condom Male 
5. Condom  Female  
6. Other  
 
E.  Pap/CERVICAL SMEAR HISTORY 
I am now going to talk about Pap smears 
Do you know what a Pap smear is? Could you describe this for me.  If the person fully understands don’t give 
an explanation again, otherwise say, let me go over it again and then give explanation: It is a test to detect 
abnormal cells in the mouth of the womb that could lead to cancer. When performing this test the doctor or 
nurse places an instrument called a speculum (spoon) in the woman’s vagina so that he/she can see the mouth of 
the womb and the test is done.  
Then interviewer to ask:  
1. Did, you ever have this test done?            
        
If NO go to next section on STIs 
If YES,  


















3. How long ago did you have your last Pap smear?________________________      
     1.    1 year ago (within the last year) 
     2.   > 1 year ago but  5 years ago 
     3.  > 5 years ago 
 
4. Did you ever get the result of any of your Pap smears/tests?                   
  
a. If yes what were you told:  _________________________________________   
 
5. Have you ever been told that there was something wrong with the mouth of your womb?    
a. If yes what were you told:  ________________________________________________  
 
F.  SEXUALLY TRANSMITTED INFECTIONS (STI) 
I would like to talk about diseases or conditions that women often complain about. These include: a 
discharge from the vagina - sometimes this discharge causes itching or may be foul smelling or may cause 
you some worry; a sore, warts or blisters on the women’s private parts  
 
1. Have you had a vaginal discharge that has caused you some worry.     
 If No go to Q 3  
 
2. If YES, When was the last time it occurred:         
1. In the last week      
2. More than 1 week but less than a month ago   
3. More than 1 month but less than 6 months   
3. Have you ever had ulcers/blisters/warts on the genitals       
 
If No go to next section on Sexual Activity 
4. If YES, When was the last time it occurred:         
1. In the last week      
2. More than 1 week but less than a month ago   
3. More than 1 month but less than 6 months   
   
G. SEXUAL ACTIVITY 
The following questions are about private aspec s of your life. I understand that these are sensitive questions 
about your personal sexual history. Please let me know if there is any question you do not wish to answer. 
 
1. If you think back to the past, how old were you when you first had sex with a partner  (even if 
unwilling)  
      years 
2. Up until now, how many sexual partners have you had?____________________________  
 
3. How man y sexual partners have you had in the past year? ____________________________  
 




1. Are you taking ARVs at present? _________________________________________________  
If No go to question 4 
2. If Yes  how long have you been on treatment? _______________________________________  
 
3. What treatment are you currently on______________________________________________  
 
4. If No – when do you think  you will start ARV treatment? 
 
 ______________________________________________________________________ 





























If the lesion is a wart or ulcer please record the site of lesion (vulva, vagina or cervix) 
 
Symptoms Present/ Absent Comment Code 











    






Specimens for TESTS - tick when completed 
    
WOMEN 
Cytobrush for Pap smear                                                                           




J. DATA TO BE EXTRACTED FROM CLINIC RECORDS 
 
Clinic record number ________________________________ 
 
MOST RECENT CD4  COUNT 
Date done dd/mm/yy         / /  
Count________________         
 
 
 
 
